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Antibodies used for cancer treatment and immune therapy have, to date, been of the IgG
class. Efficacy might be improved by using the IgE class of antibodies as these have higher affinity
for their Fc-receptors. IgE has a greater tissue penetration and longer half-life in tissue and IgE
bound to IgE-receptor-expressing effector cells is thought to actively infiltrate tumours. IgE has
not been subject of in vivo imaging studies to date.
Objectives: The aim was to radiolabel both anti-CSPG4-IgE and MOV18-IgE, and their IgG
counterparts targeted to the same antigen, while maintaining the functionality of the antibodies;
and subsequently, to compare IgE with IgG in in vivo imaging and biodistribution studies in a
disease model.
Methods: IgE’s and their antigen-matched IgG counterparts were engineered against two
different tumour antigens. Tumour models were developed to assess targeting in vivo and imaging
and biodistribution studies using radiolabelled IgE were carried out. Six antibodies were engineered
for comparison: MOv18-IgE and -IgG antibody targeted against the folate receptor alpha (FRα)
expressed on ovarian cancer cells; A MOv18-IgE and -IgG chimeric rat/mouse were engineered
for evaluation in a new syngeneic immunocompetent rat model to mimic the immunotherapeutic
antibody (human/mouse chimeric MOv18-IgE and -IgG) planned for a clinical study; and a sec-
ond antibody, anti-CSPG4-IgE, targeted against the chondroitin sulfate proteoglycan 4 (CSPG4),
expressed in melanoma cancer was compared to its IgG counterpart. The antibodies were anal-
ysed in a NOD/SCID xenograft mouse model with splenic engraftment of human peripheral blood
lymphocytes. All antibodies were labelled with 111In using the same bifunctional chelator and
labelling conditions (p-SCN-CHX-A"-DTPA) and radiolabelled with 111In at room temperature.
Functional assays using FACS were carried out to assure binding to the target and high- and
low-affinity Fc-binding to FcεR expressing immune effector cells. NanoSPECT/CT imaging and
biodistribution studies were used to determine targeting and clearance of IgE in vivo.
Results: 111In-CHX-A"-DTPA-IgE and -IgG antibodies were labelled with high efficiency
(>98%). Binding of the conjugated antibody to the target antigen and FcεR expressing immune
effector cells was identical to that of the native antibody. IgE showed a higher liver uptake in
biodistribution (up to 75% ID IgE vs 5% ID IgG 8 h post injection) compared with the IgG
counterpart as well as more than 10 times faster blood clearance where as IgG showed prolonged
half-life (2.5 days) in blood. Tumour-to-blood and tumour-to-muscle ratios of IgE and IgG showed
significant (tbr: P<0.05; tmr: P<0.0005) differences. Conclusion: Similar conjugation and radi-
olabelling of all antibodies as well as the in vivo assessment allowed the evaluation of targeting,
biodistribution and clearance of IgE compared with its IgG counterpart. Observed characteristics
of IgE like the rapid blood clearance and the higher liver uptake were found to be fundamentally
different compared to its IgG counterpart and suggest a different and mostly unknown mode of
action.
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1.1 Immune system and structure and function of antibodies
1.1.1 Adaptive immune system
The human immune system is a complicated set of pathways that allows a network of cells, tissues,
and organs to work together to respond to antigens. Antigens are any of the various substances
that when recognised as non-self by the immune system trigger an immune response. The human
immune system has innate and adaptive components, and is divided into two main parts: humoral
immunity, which deals with infectious agents in the blood and tissues, and cell-mediated immunity,
which deals with cells that have been infected, e.g. with a virus. The adaptive immune system
consists of different types of cells, each of which have a specific task assigned to them in the defence
of the body. It uses the principles of selection and selective agents as it prepares its response to
various foreign invasions.
1.1.2 Cellular immune system
In general, the cell-mediated immune response involves the activation of phagocytes, antigen-
specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen.
The T-lymphocytes have an important role in managing the cell-mediated system. Cells that have
been infected by a pathogen (e.g. virus), present fragments of antigens on specialised receptors on
the cell surface. The display of such foreign peptides by major histocompatibility complex (MHC)
proteins makes the infected cell recognisable for T-lymphocytes, which in response are activated
and destroy the infected cell. Cytotoxic T-lymphocytes recognise these displays and respond
by releasing their cytotoxic granules (e.g. granzymes and perforins) or otherwise destroying the
infected cell.
1.1.3 Humoral immune response
The extracellular spaces are protected by the humoral immune response, in which antibodies
produced by B cells cause the destruction of extracellular microorganisms and prevent the spread
of intracellular infections. The activation of B cells and their differentiation into antibody-secreting
plasma cells is triggered by antigen and usually requires helper T cells.
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Figure 1.1: Origin and differentiation of cells of the immune system [1].
Humoral immunity is based on the production and secretion of pathogen-specific antibody
molecules by B-lymphocytes. The first step of defence in the humoral pathway is phagocytosis
of foreign matter by specialised antigen presenting cells (APCs). These cells digest the infectious
agent and subsequently display some of its components on their surfaces. Cells called helper-T cells
recognise this presentation of antigen fragments and activate an immune response. In the following
immune response helper-T cells and B-cells communicate. This communication leads among other
immune activities to the maturation of B-cell progenitors to plasma cells. The matured and
proliferated plasma cells begin to produce large quantities of antibodies.
1.1.4 B-cells clonal selection
B-cells can make antibodies against almost any pathogen invading the body and the underlying
concept is called clonal selection and expansion. During immune responses, B lymphocytes clonally
expand and undergo secondary diversification of their immunoglobulin genes in germinal centres
(GCs). Large receptor diversity is achieved by gene re-arrangement in the binding region of the an-
tibody. During this process B-cells undergo a rearrangement of genes at the antibody loci, through
different stages from early pro-B cell to mature B-cell. This random recombination of various gene
loci for every segment of the antigen binding part of the antibody produces a huge quantity of
B-cell receptors with a wide range of specificities. The clonal selection hypothesis postulates four
important principles; the first one is that each lymphocyte has a single type of receptor with a
unique specificity. Second, the interaction between an antigen and the unique specific lymphocyte
receptor that can bind the antigen with high affinity leads to the activation of this lymphocyte.
Further, the differentiated effector cells derived from this activated lymphocyte will express recep-
tors with the identical specificity. The fourth principle is that lymphocytes expressing receptors
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specific for ubiquitous self-molecules are deleted at an early stage of development and are not part
of the mature lymphocyte population. After binding to the specific antigen the B-cell becomes
activated if a second signal is mediated by a helper T-cell and the process of maturation is initiated.
Once activated as described above, it differentiates into a plasma cell secreting large amounts of
a specific antibody. The production of antibodies is the main function of the humoral immune
system.
Figure 1.2: The structure of IgG. The site of interactions between IgG
and an antigen (epitope) is shown, as are the binding sites for
the complement components C1q and activated C3b and C4b,
and the sites of interaction between heavy chains of IgG and
FcγR. CDR, complementarity-determining regions; CH, con-
stant heavy domain; CL, constant light domain; Fab, fragment
antigen binding; Fc, fragment crystallisable; FcγR, Fcγ recep-
tors; VH, variable heavy domain; VL, variable light domain
[2]
1.1.5 Antibodies
Antibodies (Ab), part of the immunoglobulin superfamily (Ig), are one of three classes of specific
antigen-recognition molecules in the immune system, the others being the T-cell receptor and the
major histocompatibility complex (MHC) with its class I and II molecules. Antibodies are large
proteins of a Y-shape produced by B-cells. Immunoglobulins are either bound to the membrane
and are then referred to as B-cell receptor (BCR) or secreted by terminally differentiated B-
cells (called plasma cells). Soluble antibodies are released into blood and tissue fluids and help
immune cells to identify and neutralise foreign objects such as bacteria and viruses. Antibodies
are bifunctional molecules. They specifically bind to an epitope on an antigen and at the same
time can elicit responses of the host immune system that can lead to removal or destruction of the
bound antigen. The effector functions and the nature of the recruited host response are determined
by the constant region, also historically called Fc region (Fragment crystallisable) of the antibody
(Figure 1.2). Each distinct type of constant region defines an antibody isotype with different
biological functions depending on which receptors they bind to and the cellular distribution of
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those receptors.
1.1.6 Antibody specificity
Antibodies bind their antigen targets with high specificity and consist of two identical light chains
and two identical heavy chains, interconnected by disulfide bonds as depicted in figure 1.2. De-
pending on the isotype, the heavy chain consists of 4-5 immunoglobulin domains of ∼110 amino
acids each. The light chain consists of 2 domains. The domains are organised in two opposing
β-pleated sheets stabilised by a disulfide bond. (This structure is also called a β barrel). The
N-terminal domains of the heavy and light chain are highly variable in their amino acid sequence
and are referred to as variable regions VL+VH or Fv (fragment variable), respectively. Within
these variable regions three short hypervariable loops, also known as complementarity determining
regions (CDR) are enclosed by less variable framework regions (FR). The unique three-dimensional
structure of the CDRs in concert with the framework regions determines the specificity and affinity
of the antibody for a given antigen. The combination of the CDRs of the light and heavy chain
forms the antigen binding site or paratope. The antigen binding site is highly specific for the three-
dimensional conformation of the epitope. The principles of clonal selection ensure that antibodies
are produced against an extremely high diversity of epitopes. To reach such variability antibody
genes undergo a complex rearrangement of small gene segments called VDJ-recombination. This
results in a unique combination of gene segments across the heavy and light chain variable region in
a given B-cell. Further diversity is introduced upon joining the segments and after B-cell activation
by an antigen in a process called directed somatic hypermutation.
1.1.7 Antibody isotypes
Antibodies come in different isotypes (the class switch occurs during the course of an immune
response). Five classes of antibody molecules, namely, IgG, IgA, IgM, IgD and IgE are known
in humans, including four subclasses of IgG (IgG1, IgG2, IgG3, IgG4) and two subclasses of IgA
(IgA1, IgA2). Each class (or subclass) differs in size and number of immunoglobulin domains,
amino acid (aa) sequence, isoelectric charge, carbohydrate side chains and most importantly its
effector function. The class, subclass and isotype are determined by the heavy chain constant
region (CH). Each antibody has a characteristic type of heavy chain (IgG: γ chains; IgM: µ chains;
IgA: α chains; IgD: δ chains; IgE: ε chains). The C-terminal regions of the CH form the constant
region and determine the effector functions mediated by binding to different cellular receptors for
antibody.
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Figure 1.3: Immunoglobulins are composed of two identical heavy chains
and two identical light chains, linked by disulfide bridges. The
class of antibody is determined by its heavy chain, with all
classes sharing the same light chains. Light chains fold into a
variable domain (VL) and a constant domain (CL), whereas
heavy chains are composed of one variable domain (VH) and
either three (in IgG and IgA) or four (in IgE) constant do-
mains. The antigen-binding sites at the tip of the Fab regions
are formed from the variable domains of both the heavy and
light chains. The Fc region mediates interaction with effector
molecules, such as complement and Fc receptors. In IgG and
IgA, the Fab and Fc regions are separated by a flexible hinge
region, which varies in length and sequence between different
immmunoglobulin classes and subclasses. In IgE, the classical
hinge is replaced by an extra pair of constant domains. For
each antibody, one heavy chain is shown in red, the other in
orange, with light chains in yellow. N-linked oligosaccharides
are shown in blue and O-linked oligosaccharides on the IgA1
hinge region in green [3].
1.1.8 Fc-receptor
The function of the antibody is determined by its Fc-region. Each subclass has different functions
and characteristics transmitted through the Fc-region (Table 1.1). Fc-receptors are found on a
variety of immune cells. Depending on cell type or isotype of the antibody, the binding of an
antibody to an Fc-receptor can trigger different effector functions within the cell. In order to elicit
specific host responses, antibodies need to bind to isotype specific Fc-receptors displayed on the
cell surface of a variety of immune effector cells. The interaction of antibodies and Fc-receptors on
immune effector cells presents a link between the humoral and the cell mediated immunity. Studies
have shown the role of Fc-receptors in triggering effector responses such as phagocytosis, natural
killer cell (NK cell) driven ADCC, neutrophil activation, or the inhibition of B cell activation
[4]. Generally, effector cells are activated by cross-linking with and aggregation of two or more
Fc-receptors by specific antibody-antigen immune complexes [5]. Each isotype may have more
than one isotype specific Fc-receptors expressed by effector cells. For IgE antibodies, for example,
two receptors can be found, FcεRI and FcεRII. The pathway of immune response depends on the
specific Fc-receptor.
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Table 1.1: Overview of FcR, binding antibodies and effector functions.
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1.1.9 IgE and Fc-receptor
FcεRI is expressed as an αβγ2 tetramer on human mast cells and basophils, and as an αγ2 trimer
on human antigen-presenting cells (APCs), monocytes, eosinophils, platelets and smooth-muscle
cells. The low-affinity receptor CD23 is also known as FcεRII. CD23 is distinguished structurally
from almost all other immunoglobulin receptors as it belongs to the C-type (calcium dependent)
lectin superfamily. Both membrane bound as well as soluble CD23 can be found as well as two
different size versions CD23a and CD23b. CD23 is also expressed by different cells: CD23a is
expressed by antigen-activated B cells before differentiation into antibody-secreting plasma cells,
whereas CD23b expression is induced by interleukin-4 (IL-4) on a variety of inflammatory cells, B
cells and epithelial cells.
1.1.10 IgE-Fc crosslinking and IgE functions
IgE can crosslink with both its high affinity receptor FcεRI and its low affinity receptor FcεRII or
CD23. The crosslink of IgE in the mucosal tissues leads to recruitment of mast-cell and APC’s
and IgE production in the mucosal tissues. This is a central function of IgE, and occurs within the
first hour of crosslinking complexes of IgE with FcεRI at the surface of mast cells or basophils by
allergens. Mast-cell precursors are generated in the bone marrow and migrate to mucosal tissue
before expressing FcεRI (∼500,000 copies per cell) [6, 7].
IgE binds to FcεRI on the surface of Langerhans cells and to epithelial dendritic cells (APCs).
Antigen-presenting cells (APCs) can internalise and process antigen, and then display antigenic
peptide fragments on their surface, together with molecules required to activate the cognate lym-
phocytes. Langerhans cells are professional antigen presenting dendritic cells localised in the skin
epidermis. Following the capture of allergens they either migrate to local lymph nodes or remain
in the tissues where they present the processed allergens to helper T cells [8]. Helper T (TH)
cells are critical to coordinating the activity of the immune response. The chemical messages they
secrete (cytokines) stimulate the non-specific immune response to continue, and strengthen and
boost specific responses. Allergen-IgE complexes can also crosslink in the mucosa to CD23 that is
expressed by activated B cells. They then can facilitate antigen presentation to the T cells [9]. The
process of antigen presentation by way of CD23 is termed facilitated antigen presentation (FAP).
The interaction between CD23 and HLA-DR in the cell membrane is involved in the trafficking of
allergen-IgE-CD23 complexes to endosomes, where the allergen-derived peptides are loaded onto
the HLA-DR molecules for presentation at the B-cell surface [10]. HLA-DR plays a central role in
the immune system by presenting peptides derived from extracellular proteins. Class II molecules
are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages).
Antigen presentation through the membrane bound B-cell receptor (BCR) involves the interaction
of B cells that are bound to a specific antigen with TH cells.
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An antigen activated B cell expressing CD23 can in effect behave as a ‘professional’ APC
such as a dendritic cell. This can simultaneously process unrelated antigens through FcγRs and
cause epitope spreading to other antigens, a process by which an antibody response to one epitope
on an antigen leads to the production of antibodies specific for other epitopes on the same antigen
or for epitopes on entirely unrelated antigens. Research showed that CD23-mediated FAP is as
efficient as FcγR-mediated antigen presentation by dendritic cells [11]. Monocytes and eosinophils
are also bound by IgE. Crosslinking of these cells with IgE upregulates the expression of FcεRI, or
in combination with IL-4 and IL-13 stimulates the expression of CD23 by these cells. Monocytes
and eosinophils are recruited by these interactions for different functions, such as the clearance of
antigen-IgE complexes, and killing and phagocytosis of pathogens [12] and tumour cells that bear
‘foreign’ antigens [13]. The ability of FcεRI and CD23 to mediate IgE-dependent monocyte- and
eosinophil-mediated lysis of target cells and phagocytosis of the resulting cell fragments was shown
by experiments with an IgE antibody against tumour cells [13]. The upregulation of CD23 was
also observed to release soluble fragments that interacted in IgE-independent monocyte-mediated
cytotoxicity. In addition to IgE, CD23 binds a second ligand in a carbohydrate-dependent manner
called CD21. CD21 is expressed by B cells, follicular dendritic cells (FDCs), activated T cells
and basophils. Crosslinking between these two molecules shows the ability of CD23 to bind both
IgE and CD21 and links the IgE antibody and complement systems. The complement system is
a heat-labile component of normal plasma that entails many proteins acting together to augment
opsonisation of targets by antibodies and promote antibody-mediated target destruction by forming
membrane-attack complexes that form pores in target cell membranes, and also leads to clearance
of immune complexes.
1.1.11 Antibody-dependent cellular cytotoxicity and phagocytosis
Antibody-dependent cellular (e.g. monocyte-mediated) cytotoxicity or phagocytosis described
above (ADCC and ADCP) is one of the central functions of antibodies. ADCC and ADCP, while
important in antitumour activity, may also have an important role in antibody dependent antitu-
mour mechanism of tumour-antigen specific antibodies, but evidence supporting its relevance to
efficacy of antibody-based immunotherapy is scarce [14]. Antibody-dependent cellular cytotoxicity
might directly induce a variable degree of immediate tumour destruction. This leads to an anti-
gen presentation of the lysed cell debris and the induction of cross-primed tumour-antigen-specific
T-cell responses [15].
Tumour cells are ineffective at initiating host-protective immunity, and the activation of
tumour specific cytotoxic T-cells depends on uptake of tumour antigens by dendritic cells and
their subsequent presentation to both helper and cytotoxic T cells [16]. Cytotoxic T cells kill
their targets by programming them to undergo apoptosis. Specific recognition of MHC class I
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complexes on a target cell by a cytotoxic T cell (CTL) leads to the death of the target cell by
apoptosis. Killing requires a series of steps, including receptor binding and directed release of
cytotoxic proteins stored in lytic granules [17, 15]. The membrane-bound MHC I protein displays
the antigen for recognition by special immune cells known as cytotoxic T cell lymphocytes. MHC
I proteins work to present the types of proteins being synthesised within a cell, which can then
be monitored by killer T cells as part of a surveillance system that identifies and destroys any cell
with over-abundant or unfamiliar peptide antigens, such as malignant cells or those harbouring
viruses.
If not cited otherwise all information about the immune system development and the struc-
ture and function of antibodies originates from Chapter 3 of Immunology by David Male et al.,
8th Edition and Chapter 9 of Janeway’s Immunobiology by Janeway et al., 7th Edition [18].
1.1.12 Monoclonal and recombinant antibodies
The development of hybridoma technology by Köhler and Milstein in 1975 (continuous cultures of
fused cells secreting antibody of predefined specificity [19]) has led to sophisticated methods for
the generation and production of antibody molecules with predefined specificity and against any
protein of interest [19]. The first generation of recombinant antibodies was polyclonal and gener-
ated from various species. These antibodies predated the hybridoma technology, which marked the
second generation. Hybridoma technology enabled the production of murine monoclonal antibod-
ies, and the new generation of antibodies showed first promising clinical results, although, these
were outweighed by disappointing outcomes. The third and current generation of antibodies is
characterised by the development, testing and use of antibodies with essentially human properties
and broad clinical applicability [20]. The current generation of clinically effective unconjugated
antibodies emerged from fundamental advances in antibody engineering. Advances like the replace-
ment or avoidance of rodent immunoglobulin sequences permitted the development of antibodies
with human properties. The replacement of rodent sequences improved the pharmacology and
reduced the immunogenicity of antibodies, thus allowing repeated therapy for prolonged periods of
time [21]. Chimeric monoclonal antibodies contain human constant domains and rodent variable
domains [22, 23]. Humanised antibodies, such as trastuzumab and alemtuzumab, represented a
further evolution of antibody engineering technology, with human sequences replacing all rodent
sequences except for the complementarity determining regions (CDRs) that are responsible for
antibody specificity [24].
1.1.13 Antibodies in targeted therapy
Various definitions of targeted therapy can be found in literature. Hait and Hambley [25] defined
targeted therapy as ‘drugs developed against a specific target based on its important biological
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function in cancer. In contrast, non-targeted therapies are drugs identified by phenotypic screening
of natural products or chemical libraries against established cancer cell lines or preclinical animal
models without a priori knowledge of the target. Targeted therapies are designed to selectively
inhibit a target that is abnormal in malignant compared with normal tissues. While therapeutic
antibodies have changed and expanded the therapeutic landscape, most have limited efficacy in
cancer when used alone and, therefore, they are most often combined with more conventional
chemotherapeutic agents [26].
Much of the progress in targeted therapy came from the identification of cell surface anti-
gens that are central to the tumour cell signal transduction pathways. These pathways control
proliferation and differentiation of cells and the mutations in these pathways often lead to the
development of tumours. Antibodies targeting and disrupting these pathways result in the death
of the tumour cells. Small molecules, such as imatinib and antibodies, such as trastuzumab, are
early examples of successful targeted therapy [26].
Cell surface antigens that are expressed by human cancers and are suitable targets are
overexpressed, mutated or selectively expressed compared with normal tissues [28]. One of the
key challenges in targeted antibody therapy has been, and still is today, to identify antigens that
are suitable for antibody-based therapeutics. Ideally, the target antigen should be abundant and
accessible with a homogeneous expression, consistently and exclusively on the surface of cancer
cells. Antigen secretion and shedding should be minimal because secreted antigens can bind the
antibody in the circulation and could prevent sufficient antibody from binding to the tumour. If
the desired mechanism of action is ADCC or complement-dependent cytotoxicity (CDC), then
the antigen-antibody complex should not be rapidly internalised to maximise the availability of
the Fc region to immune effector cells and complement proteins, respectively. However, rapid
internalisation is desirable for antibodies that deliver drugs or toxins to the tumour cell and for
antibodies targeting the downregulation of cell surface receptors [27]. Aside from targeting antigens
that are involved in cancer cell proliferation and survival, antibodies can also function to either
activate or induce apoptotic-signalling events, by binding and subsequently blocking growth factors
(e.g., VEGF), thereby depriving tumour cells of the necessary components to survive [26].
Antibody therapeutics can also function through various pathways. For example, antibodies
can mediate modifications of the antigen or can activate the immune system and recruit immune
responses or deliver a specific drug or toxin conjugated to an antibody with a specific target [29–
31]. Antibody therapeutics might also have a role in the generation of de novo immune responses
to the antigen targeted by the antibody through promoting antigen presentation to Fc receptor-
bearing cells [32], thus allowing the effects of therapeutic antibodies to persist after the treatment
is completed. While this ability of antibodies to promote anti-tumour effects through tumour-
antigen-specific immune responses has been almost ignored [15] in recent years researchers are
now more and more trying to engineer antibodies to improve these functions. Antigen-specific
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Table 1.2: FDA approved antibody-based therapeutics. ADCC, antibody-dependent cellular
cytotoxicity; CDC, complement-dependent cytotoxicity; CLL, chronic lymphocytic
leukaemia; CTLA4, cytotoxic T lymphocyte-associated antigen 4; EGFR, epidermal
growth factor receptor; FDA, US Food and Drug Administration; IgG, immunoglobulin
G; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small-cell lung cancer; SCCHN, squa-
mous cell carcinoma of the head and neck; VEGF, vascular endothelial growth factor.
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Figure 1.4: Mechanisms of tumour cell killing by antibodies. a) Direct tu-
mour cell killing can be elicited by receptor agonist activity,
such as an antibody binding to a tumour cell surface receptor
and activating it, leading to apoptosis (represented by the mi-
tochondrion). It can also be mediated by receptor antagonist
activity, such as an antibody binding to a cell surface receptor
and blocking dimerization, kinase activation and downstream
signalling, leading to reduced proliferation and apoptosis. An
antibody binding to an enzyme can lead to neutralisation, sig-
nalling abrogation and cell death, and conjugated antibod-
ies can be used to deliver a payload (such as a drug, toxin,
small interfering RNA or radioisotope) to a tumour cell. b)
Immune-mediated tumour cell killing can be carried out by the
induction of phagocytosis; complement activation; antibody-
dependent cellular cytotoxicity (ADCC); genetically modified
T cells being targeted to the tumour by single-chain variable
fragment (scFv); T cells being activated by antibody-mediated
cross-presentation of antigen to dendritic cells; and inhibition
of T cell inhibitory receptors, such as cytotoxic T lymphocyte-
associated antigen 4 (CTLA4). c) Vascular and stromal cell
ablation can be induced by vasculature receptor antagonism
or ligand trapping (not shown); stromal cell inhibition; deliv-
ery of a toxin to stromal cells; and delivery of a toxin to the
vasculature. MAC, membrane attack complex; MHC, major
histocompatibility complex; NK, natural killer. Figure original
from Nature Cancer Reviews [27]
immune responses are the result of a complex interaction between antigen-presenting cells (APC),
T lymphocytes and tumour cells. A large proportion, as much as 50%, of tumour lesions are made
up of infiltrating immune cells that are also found in higher concentrations around the tumours
[33, 4, 34]. Some of these infiltrates are known powerful FcεR- and FcγR-expressing effector cells
such as monocytes/macrophages, mast cells, dendritic cells and eosinophils [35–37].
The mechanism triggered and the quality of its reaction depends on specificity and isotype
of the antibody and its ability to interact with the FcR. ADCC has been demonstrated to have
a major role in antibody efficacy, and there is evidence that in IgG class antibodies FcγRIIa-
131H polymorphisms have a favourable effect on response rates for cetuximab in colorectal cancer,
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trastuzumab in breast cancer and rituximab in follicular lymphoma [38–40].
To address the difficulties in engineering new antibody-based therapies molecular techniques
that can alter antibody pharmacokinetics, effector function, size and immunogenicity have emerged
as key elements in the development. In general, changes to the Fc domain structure can affect an-
tibody clearance and the interaction of Fc domains with cellular FcR of effector cells. Activation
of FcR helps the recruitment of adaptor proteins that mostly function as molecular mediators
and interact with signal transduction pathways. They regulate cell signalling and can amplify a
receptor-mediated signal to facilitate coupling of the signal to different signal transduction path-
ways for the activation of immune effector cells. Strategies to improve ADCC activity, such as
fucosylation modification (a process in which fucose sugar residues are added to a antibody to
increase its affinity to the FcR), have become introduced into the clinic. However, FcγR genotypes
are not completely predictive of response, indicating that other factors are also highly relevant to
tumour response to antibody therapy. Different strategies have emerged, like the use of targeted
IgE antibodies to exploit the naturally high affinity to its FcεRI [41, 42, 13]. Furthermore, the
ability of antibodies to generate T cell responses to tumour antigens may be affected by a broad
range of factors, including cross-presentation of antigen by dendritic cells, the efficiency of antigen
processing and immune escape through regulatory T cells [43].
1.1.14 The role of antibodies of the IgE isotype and their potential use in
targeted therapy
IgE has unique properties that could overcome some of the limitations of antibody treatment. IgE
is commonly known as a powerful trigger of immune responses in allergic reactions. These strong
reactions are based on strong interaction of the allergy antigen-IgE complex with the high affinity
IgE Fc-receptor and its ability to recruit and bind effector cells efficiently. Another factor might
be the ability of IgE to reside in tissue for extended periods of time.
Figure 1.5: Domain structures of IgE and IgG. Schematic representations
of the polypeptide and domain structures of human IgE and
IgG1, showing the intra- and inter-domain disulfide bridges
and the sites of N-linked glycosylation [44].
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While very few data are available on the elimination pathways of therapeutic IgG and IgE
type monoclonal antibodies, there are some data on IgE serum and tissue half-life in general. The
half-life of IgE in human serum is found in literature with variations ranging from 1.5 to 3 days and
everything in between. Most publications seem to publish a compromise of 2 or 2.5 days as IgE
serum half-life for humans [45–47, 42, 48, 49]. The half-life of IgE in tissue or cell-bound was found
in literature with 14 days or weeks. This data was based on measurement of IgE in skin of rats
[48] and based on the affinity calculations for the interactions of the FcεRI with its corresponding
receptors [45, 49]. For comparison, the IgG half-life in serum is ∼20 days and ∼2-3 days in tissues.
The neonatal Fc receptor (FcRn) expressed on endothelial cells might provide an explanation for
the extended half-life of IgG in serum and the regulations of IgG levels in rodents and in humans
[50]. An FcRN knock-out study has been shown to reduce the plasma half-life of IgG in mice
from 9 days to 1.4 days [47]. Thus, indicating that the main reason for the difference in half-life
between IgG and IgE is this stabilising interaction between IgG and FcRn. The FcRn receptor
possesses two main functions: the transport of IgG known as transcytosis and the control of IgG
catabolism [51, 50]. The IgG in excess (not bound to the saturable FcRn) undergoes degradation
in lysosomes [52, 50]. The behaviour of monoclonal antibodies bound to target cells is unknown.
Kennedy et al. [53] suggested that circulating B lymphoma cells bound to rituximab via the CD20
antigen could be sequestered by phagocytic cells where the complex antigen/antibody is removed
[54]. However, the FcRn receptor binding domain is not present in IgE antibodies. But the factors
influencing the half-life of IgG can give further evidence to support that the turnover of IgE may
be much faster than that of IgG and a substantially higher amount of IgE may be produced than
is reflected in its plasma levels. Further, it has to be considered that the majority of IgE is bound
to high-affinity FcεRI on the surface of basophils and mast cells or the low affinity receptor FcεRII
on B-cells [44, 55, 35]. This is in marked contrast to IgG that instead is primarily found in free
circulating form. The IgE-FcεRI interaction has a potentially stabilising effect on IgE half-life [47].
The half-life of receptor bound IgE has been estimated to approximately 14 days, which indicates
that the majority of IgE may have a half-life similar to IgG, despite its much lower plasma half-life,
once bound to FcεRI immune effector cells [47, 56].
With a serum half-life of 21-24 days, compared to a half-life of 2-3 days in tissues, IgG
antibodies may be the most effective antibody class to target blood-resident tumours and circu-
lating tumour cells, while their ability to exert tumour surveillance in tissues may be less potent
[47, 42, 35, 4].
In vivo research performed by Kershaw et al., showed a syngeneic animal model used to
examine the anti-cancer effects of a rat/human chimeric IgE specific for murine Ly-2 [57].
Syngeneic mouse models have also been used to evaluate the ability of murine IgE to act
as an adjuvant for cancer immunotherapy [58]. Reali et al,. postulated that IgE on the surface
of tumour cells would affect tumour immunogenicity by the activation of innate immunity within
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the tumour microenvironment and that these changes might affect tumour growth. The study
showed that the treatment of tumour bearing mice with IgE significantly reduced tumour growth
and prolonged survival compared to IgG treatment. These studies were later confirmed in a more
immunogenic tumour model using the syngeneic murine lymphoma RMA-Thy1.1 cell line under
comparable conditions [58]. Karagiannis and colleagues demonstrated the potency of IgE to mount
superior immune responses against tumours in disease-relevant models [35].
FcεRI-receptor expressing effector cells, such as monocytes-/macrophages and eosinophils,
were found to kill tumour cells by activation by tumour specific IgE antibodies. They describe
the engineering of a humanised IgE counterpart of commercially available trastuzumab IgG, an
antibody against HER2/neu. Remarkably, the IgE retained all proliferation restricting functions in
HER2/neu-expressing tumour cells but also showed activation of effector cells and tumour killing
by different mechanisms like ADCC and ADCP [42].
The receptors for IgE expressed on immune effector cells are the high-affinity receptor,
FcεRI, and the low-affinity receptor, FcεRII (CD23), which they bind to with affinities of 10-9 -
10-11 and 10-6 - 10-8 M-1, respectively [44, 45]. The structures of these receptors differ hugely: The
high affinity receptor is a critical component of IgE-mediated allergic reactions. It is expressed as
a tetramer, with subunits ac2, on eosinophils and monocytes. FcεRI exists also as a tetramer, with
subunits abc2, on mast cells and basophils, A trimeric form is expressed on antigen presenting cells
where it acts to facilitate antigen presentation via IgE.
Both the expression and the signalling capacity of the trimer are lower than those of the
tetramer and in both of these receptors the IgE binding domain is on the extracellular α-chain [59–
61].IgE binding to FcεRI and FcεRII receptor has a significantly different signalling response in each
case. IgE bound to the high affinity receptor FcεRI and cross-linking with a specific antigen will
result in aggregation and downstream signalling through a Syk-dependent pathway. The spleen
tyrosine kinase (Syk) is associated with Fcγ receptors (FcγRs) and transmits activation signals
through FcγRs in myeloid cells. The consequences are the degranulation of mast cells and release
of inflammatory mediators like histamine, leukotriene and proteases as well as cytokines attracting
T cells, monocytes, basophils, eosinophils and APCs to the site of inflammation [44, 45, 62].
In vivo experiments showed IgE mediated anti-tumour efficacy in immunosupressed rodents to
utilise human T cell receptors expressed on murine T cells and human tumour cells [63]. The
same mediators also activate infiltrating cells in situ to induce ADCC through release of pro-
inflammatory cytokines, enzymes and other cytotoxic mediators (e.g., TNF-α, lysozyme, nitric
oxide (NO), H2O2 and other reactive oxygen species) [64–66].
IgE that is bound via the low affinity receptor FcεRII to CD23 leads to an ADCP immune
response through activation of macrophages/monocytes. In a Th2 introduced immune response
and particularly through IL-4 and IL-13 CD23 is tremendously up regulated [67–72]. So, it can be
seen that differential methods of cell killing are promoted by the binding of IgE to the receptors
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FcεRI and CD23: degranulation with release of pro-inflammatory mediators and cytokines by
mast cells and basophils, ADCC, mediated by the release of mediators such as NO, enzymes and
cytokines resulting in target cell lysis, and ADCP, mediated by the activation of macrophages and
monocytes.
Figure 1.6: IgE is synthesized and secreted by B cells that have undergone
heavy-chain class switching from IgM to IgE. The IgE binds
to FcεRI on mast cells and antigen-presenting cells (APCs) (a)
and sensitizes these cells to the antigen. Omalizumab inhibits
the binding of IgE to FcεRI on mast cells and APCs (b). Aller-
gen binding to IgE triggers mast-cell degranulation to elicit an
ADCC/ADCP response(c). Antigen binding to the APC leads
to the presentation of antigen peptides to T helper 2 (TH2)
cells (d). The allergen-activated TH2 cells secrete interleukin-
4 (IL-4) (e) to maintain the TH2-cell lineage and recruit more
TH cells into this lineage (e). The TH2 cells also secrete IL-13,
which together with IL-4 stimulates heavy-chain class switch-
ing to IgE (f). The allergen-activated mast cells contribute to
the production of IL-4 and IL-13 [44].
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1.1.15 Human chondroitin sulfate proteoglycan 4 (CSPG4) and folate
receptor (FRα) as target receptors for antibody therapy
Human chondroitin sulfate proteoglycan 4 (CSPG4)
The CSPG4 receptor is also known as ‘Human high molecular weight-melanoma-associated
antigen’ (HMW-MAA) [73] or melanoma chondroitin sulfate proteoglycan (MCSP) [74]. It consists
of an N-linked glycoprotein of 280 kDa and a proteoglycan component of about 450 kDa [75] and
plays an important role in melanoma cell proliferation, migration, and metastasis [76]. CSPG4 has
a restricted expression in normal tissues, although it is expressed at high levels on both activated
pericytes and pericytes in tumour angiogenic vasculature, which are associated with neovascular-
ization in vivo [77–80]. CSPG4 is overexpressed on over 90% of the surgically removed benign nevi
and melanoma lesions [73]. It has also been found to be overexpressed on triple negative breast
cancer cells and expressed by basal cell carcinoma, tumours of neural crest origin (astrocytomas,
gliomas, neuroblastomas and sarcomas); some forms of childhood leukemias and lobular breast
carcinoma lesions. In vitro experimental data have shown that CSPG4 is involved in the adhesion,
spreading and migration of melanoma cells and may play a role in cell invasion and metastasis
[81, 73, 76]. CSPG4-specific mAbs have been shown to disrupt melanoma cell adhesion to collagen
type I (CI), CVI, and fibronectin [82, 83].
Folate receptor alpha
Folate receptor (FRα), also known as the high affinity membrane folate-binding protein,
is a glycosylphosphatidylinositol (GPI)-linked glycoprotein with an apparent molecular weight of
38-40 kDa [84, 85]. FR appears in two known membrane-bound isoforms in humans, designated α
and β. FRs bind folic acid with high affinity. Folic acid is needed by all eukaryotic cells for DNA
synthesis and one-carbon metabolism and an essential dietary vitamin [86, 85].
FR driven molecule uptake follows the endocytosis mechanism by which cells transport
essential molecules, such as vitamins and hormones, across the cell membrane and into the cell
interior [87–90]. This process is dependent on a specific binding of a ligand to a membrane-bound
receptor, with subsequent formation and release of an intracellular vesicle termed an endosome.
Inside the cell the endosome can experience different fates depending on the uptake pathway,
including ligand release into the cytoplasm [91, 92]. The role of FR in cellular folate transport is
not well understood, although a ‘potocytosis’ model has been proposed [87]. The recycling rate
for the folate receptor is relatively slow. FRα recycling reportedly occurs in the range of 0.5 to 5
hours [93–95]. Folate receptor expression can be very high in cultured KB human oral carcinoma
cells (up to 30x106 receptors/cell), with moderately high expression in IGROV-I ovarian carcinoma
cells (1x106 receptors/cell) [96].
Elevated expression levels of FR have also been evaluated in various types of cancers. [97–
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101]. Additionally, FRs were found to be clustered in non-coated membrane regions called caveolae
[85]. The receptor has been found on epithelial originated tumors such as ovarian carcinomas.
Studies show that over 90% of ovarian carcinomas overexpress the FR [102, 103]. High frequencies
of receptor overexpression were found in many types of tumors, including ovarian, endometrial,
colorectal, breast, lung, renal cell, brain metastases derived from epithelial cancers, and neuroen-
docrine carcinomas [102, 85].
The overexpression in tumour cells makes FR a potential molecular target for tumour-
selective drug delivery, including radiolabelled conjugates for diagnostic imaging. Tumour over-
expression of the folate receptor has been exploited in vitro as a marker to localise and visualise
tumour cells [104, 105, 93, 106, 100], with FRα ultimately being recognised to be the antigen target
of many tumour-specific monoclonal antibodies (e.g., MOv18, MOv19) [107, 102, 108, 106, 99, 100].
The folate receptor has been targeted for tumour imaging using radiolabelled antibodies to the
folate receptor [109–113]. However, the kinetics of tracer uptake in tumour tend to be unsatis-
factory and limited presumably by the rate of antibody extravasation, resulting in relatively poor
target-to-background tissue contrast at short times after administration [86].
1.2 Imaging
SPECT and PET are radionuclide molecular imaging techniques that enable evaluation of bio-
chemical changes and levels of molecular targets within a living subject. Both techniques have
deep penetration and enable whole body imaging of molecular targets and processes with high
sensitivity [114]. To image a certain molecular target using SPECT a target has to be identified
and a radiolabelled imaging agent that is specific and selective for the target of interest has to be
available. A suitable radionuclide in terms of half-life has to be chemically bound to the imaging
vector and finally, a nanomolar amount of the chosen radiolabelled agent is administered to the pa-
tient/subject, typically via an intravenous injection. The radioactivity is then traced through the
body and its distribution determined from scans obtained with a SPECT camera [115, 116, 114].
1.2.1 Basic principles of SPECT
The basic principles and instrumentation of SPECT, assume an accumulation of the radiophar-
maceutical at a targeted specific area (e.g. tumour) [117]. SPECT uses nuclides such as 99mTc
(t1/2=6 h), 123I (t1/2=13.3 h), and 111In (t1/2=2.8 days), which decay via the emission of single
gamma rays with differing energies (Table 1.3). During the decay of the radionuclides γ-rays are
emitted in all directions and some of the γ-rays are attenuated and scattered in the body due to
the photoelectric interaction and the Compton scattering. The photoelectric effect is described as
emitted electrons from solids, liquids or gases after the absorption of energy from electromagnetic
radiation and the Compton scattering is the decrease of energy of an X-ray or γ-ray photon, when
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it interacts with matter.
a 
b 
Figure 1.7: a) PET scans are acquired following administration of a radiotracer.
The radiotracer accumulates in the target of interest, and its ra-
dionuclide decays by emission of a positron. A positron will collide
with an electron, simultaneously releasing two gamma rays with
energy of 511 keV into opposite directions. These two photons are
detected by the PET camera and simultaneously localised within
a fixed period of time by a series of opposing detectors, which cor-
respond to multiple rings of scintillation crystals. By collecting a
statistically significant number of radioactive events, mathemati-
cal algorithms reconstruct a three-dimensional image that shows
the distribution of the positron-emitting molecules in the brain. b)
Gamma-ray photons emitted from the internal distributed radio-
pharmaceutical penetrate through the animals or patient’s body
and are detected by a single or a set of collimated radiation de-
tectors. Most of the detectors used in current SPECT systems are
based on a single or multiple NaI(TI) scintillation detectors. In
SPECT, projection data are acquired from different views around
the animal/patient.
SPECT employs the use of a gamma camera that rotates around the subject to capture data
on the emitting γ-rays from numerous positions to obtain a tomographic reconstruction. However,
the position detection of the photons in SPECT does not deliver specific information about its
origin or the direction it was travelling (Figure 1.7b).
The direction of the travelling photon is determined by adding a lead collimator that acts
as a γ-ray lens between the source and the detector. This collimator rejects most of the photons
not travelling along certain directions. As a result the direction can be determined but typical
sensitivity of SPECT is several orders of magnitude lower than for PET systems described below
[118, 114] depending on the collimator diameter. The collimator selects only those γ-rays that
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Table 1.3: Common gamma-emitting radionuclides for SPECT imaging
Common	  gamma-­‐emi+ng	  radionuclides	  for	  SPECT	  studies	  
Radionuclide	   Physical	  half-­‐life	   Energy	  (keV)	  
99mTc	   6.02	  h	   140	  
111In	   2.8	  days	   171;	  245	  
131I	   8.02	  days	   364	  
123I	   13.2	  h	   159	  
67Ga	   78.2	  h	   93	  
have an angle of 90°±α to the detector plane, the cone angle α being defined by diameter and
length of the collimator. γ-rays with other angles are blocked; typically 1 out of 10000 emitted
γ-rays is transmitted through the collimator. By modifying α, the resolution and sharpness can
be increased or decreased. If the collimator is built of a narrow diameter it rejects most rays and
if built with a larger diameter the origin of the γ-rays can only be determined imprecisely. New
systems use up to nine distinguishing pinholes with different α and reconstruct an image resulting
in increased signal and resolution.
Two-dimensional distribution of the activity is measured, where the intensity in each pixel
represents the total number of emitted γ-rays that have passed the collimator stage. Three-
dimensional imaging is performed, by rotating the γ-ray detector/camera around the body. The γ-
rays that pass through the collimator are converted into a detectable signal using a photomultiplier.
When the γ-ray hits the scintillation crystal, it loses energy through photoelectric and Compton
interactions with the crystal. This photoelectric interactions result in the emission of light, the
intensity of which is proportional to the energy of the γ-rays [119, 115]. The camera acquires several
planar images from different view angles in a stop-and-go mode. Up to 120 pictures are acquired
and a filtered back-projection algorithm is then applied to reconstruct a three-dimensional image
of activity distribution within the body. Modern SPECT systems have an integrated X-ray CT,
which provides anatomical information. The basic design of a γ-camera was described by [120] and
there are three components: the collimator, the scintillation crystal and several photomultiplier
tubes.
1.2.2 Basic principles of PET
Noninvasive positron emission tomography (PET) is another important nuclear imaging technique
that is very similar in some aspects, but uses positron-emitting isotopes instead of single photon
emitters. To image a certain molecular target using PET the radioactivity is traced through the
body and its distribution determined from scans obtained with a PET camera. Radionuclides
frequently used in PET include 18F (t1/2= 109.8 min), 64Cu (t1/2= 12.7 h), or ultra-short-lived
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radionuclides such as 11C (t1/2= 20.3 min) [121, 122]. These radioactive isotopes decay via positron
emission, otherwise known as beta-plus decay. Nuclei that decay in this manner have an excess
of protons, making them unstable. This instability is rectified by transforming a proton into
a neutron, a positron, and a neutrino. PET measures the coordinates of the annihilation of
positrons emitted from the radioisotope injected into the body. Due to the conservation laws of
energy and momentum, the combined mass of the positron and electron is converted into two
photons, each with energy of 511 keV, travelling at opposite directions to one another, 180°apart
[114, 123, 124]. The positron range effect poses a lower limit to the spatial resolution with PET,
achievable without the use of sophisticated mathematical models [118, 125]. The average distance
that a positron travels from its origin is small (∼0.5 mm or more depending on its energy) and has
bi-exponential shape (Figure 1.7a) [126, 127].
PET detectors take the form of a closed ring, or set of rings, surrounding the subject to
be imaged. These rings are designed to detect annihilation events (gamma-rays) and convert
the resulting electrical signals into sinograms that are ultimately reconstructed into tomographic
images, following dead time correction, detector normalisation, subtraction of random coincidences,
attenuation correction, and scatter correction [128, 129]. The detector signals are processed by
specialised coincidence circuitry and, if the difference in the time of arrival of these photons is
smaller than a pre-determined value, then the two detectors define a line of response. This is
the geometric region between the two detectors in which the annihilation photons were detected
[118, 130, 114].
1.2.3 Alternative imaging modalities
Like SPECT, PET imaging instrumentation was originally developed for clinical applications and
translated into small animal SPECT/CT and PET/CT, specifically designed for imaging small
animals [118, 130–132].
Since biochemical changes generally occur before anatomical changes in disease, PET and
SPECT have a clear diagnostic advantage over anatomical techniques such as classical CT and
MRI. The initial lack of an anatomical reference frame in PET and SPECT was addressed by
combining the systems with a CT (X-ray computed tomography) or recently introduced with MRI
(Magnetic resonance imaging) [133, 134].
Pre-clinical MRI is generally performed using high-field systems, due to the signal-to-noise
gains that can be achieved with larger magnetic fields. Such imaging systems are able to charac-
terise both anatomical and functional information across the whole body. MRI is a highly versatile
imaging modality [135] that uses a powerful magnet and radiofrequency (RF) energy to visualize
the internal structure and soft tissue morphology of the body. The underlying principles of MRI
allow imaging of atomic nuclei within the body. Nuclear particles (protons and neutrons) are in
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constant motion and spin about their axes, which gives rise to angular momentum. Atoms with
an equal number of protons and neutrons have a net angular momentum of zero, whereas atoms
with an unequal number possess a specific spin angular momentum. Along with angular momen-
tum, certain nuclei can also produce a small magnetic field (due to the mass, spin, and charge of
protons). This magnetic field is termed magnetic moment and, like angular momentum, is a vector
quantity. The ratio of angular momentum to magnetic moment is known as the gyromagnetic ratio
and is unique for each magnetically active nucleus [136]. In general, an MRI scanner is comprised
of a set of embedded coils: one coil that generates the main relatively homogeneous magnetic
field; gradient coils that produce variations in the magnetic field in the X, Y, and Z directions
that are used to localize the source of the MR signal; and finally RF coils that generate an RF
pulse responsible for altering the alignment of the magnetic dipoles. After every RF pulse, the
magnetic dipoles in the subject are tipped away from equilibrium and subsequently undergo two
forms of relaxation back towards equilibrium. The contrast between different tissues in MR images
is generated due to the different relaxation times of each tissue [longitudinal (T1) and transverse
(T2) relaxation times]. For instance, proton nuclei in fat and hydrocarbon-rich environments have
relatively short relaxation times compared with those in aqueous environments [137]. MRI has a
number of important advantages compared with other imaging modalities including no need for ion-
izing radiation; unlimited depth of penetration; high spatial resolution (clinical: 1 mm compared
with 5-7 mm for PET, preclinical: micrometers, as opposed to millimeter resolution achievable
via optical and radionuclide imaging; unparalleled soft tissue contrast, superior to that attainable
with CT; concurrent collection of physiological or metabolic data with high-resolution anatomical
images, and even molecular information when used in conjunction with targeted MRI-compatible
imaging agents. A major limitation of MRI is its extremely poor sensitivity compared with other
molecular imaging modalities. This low sensitivity can lead to relatively long acquisition times,
and in the case of physiological/molecular MRI, is the reason why large amounts of imaging agents
are often required to obtain an adequate signal. These large amounts of imaging agents (i.e., many
log orders higher compared with that needed for PET or SPECT) can be problematic due to the
likelihood of altering the biological system of interest through pharmacological effects (generally
proportional to the mass of agent administered). Toxicity issues associated with administrating
large doses of MR imaging agents are also an important consideration. For this reason, MRI molec-
ular imaging is sometimes thought to be more suited for targets within the vasculature, as then
the imaging agent does not have to reach an extravascular target which would require a greater
injected mass of imaging agent [138].
Clinical diagnostic ultrasound (US) scanners typically use sound frequencies between 1 and
20 MHz [139]. During a US study, a transducer (also called a probe) sends and receives sound
waves. In simple terms, the transducer converts electrical signals to US waves, the US waves enter
the body, and some sound waves are reflected back to the transducer where they are detected and
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converted into electrical signals. These signals are then processed by a computer and displayed
as an image. Resolution of US improves significantly with higher frequencies, but at the cost of
depth of penetration. This decrease in depth of penetration is due to the fact that high- frequency
sound waves possess shorter wavelengths, meaning they are more likely to interact with matter and
slow down, thus reducing their travelling distance. Depending on the subject and on the required
data, the imager needs to consider resolution versus depth. The main strengths of US include
its relative cost effectiveness, wide availability, good temporal resolution, good safety profile (no
ionizing radiation), and excellent sensitivity (picogram level) when microbubbles are used. On the
other hand, US is limited by its difficulty in imaging structures that contain bone or air, due to the
tendency of air and bone not to transmit sound waves and also by its limited depth of penetration.
Optical fluorescence and bioluminescence (BLI) imaging. The required infrastructure for
optical fluorescence and bioluminescence imaging, namely, a charge-coupled device (CCD) camera
and a source of filtered light, is relatively inexpensive and easy to setup. Imaging sensitivities
achievable with these techniques are typically very good and since they involve the detection of
low-energy photons, as opposed to high-energy gamma rays detected by PET and SPECT, they
are considered relatively safe. However, the use of low-energy photons means that the depth of
penetration is limited to only a few centimeters, which makes it virtually impossible to study deep
tissues in large animals or human subjects, unless one uses endoscopes or their equivalent to get
closer to the tissue(s) of interest. This limitation cannot be overcome by using a higher intensity
laser due to the risk of overheating the tissue/system being studied [140]. Depth of penetration is
not so much of a problem in mice and small animals (no bigger than a rabbit) due to their size.
In fact, many of the commonly used fluorescent and bioluminescent imaging agents can be visual-
ized in internal organ structures of small animals [140], making these optical imaging techniques
suitable for preclinical research. BLI is one of the most extensively used technologies for assess-
ing biological function in preclinical models of disease. The underlying mechanism of BLI is the
enzymatic conversion of luciferins, in the presence of ATP and oxygen, resulting in the emission
of light. The introduction of luciferase genes into non-expressing cells allows various biological
functions to be assessed by the administration of a luciferin substrate. Different luciferase enzymes
can be introduced into a biological system as a molecular reporting device. These enzymes are
usually introduced into cells via transfection with the gene that encodes them. Unlike fluorescence
imaging, bioluminescence does not need an external light source. Due to this, and because tissues
do not exhibit endogenous bioluminescence, greater sensitivities and higher signal to background
ratios can be achieved compared with fluorescence techniques. One of the main advantages of bio-
luminescence imaging compared with fluorescence imaging is its higher sensitivity due to enzymatic
amplification of signal and low background signal due to the lack of natural bioluminescence from
tissues (however, it should be noted that substrates themselves also lead to background signals).
Although bioluminescence imaging has limited depth of penetration like fluorescence imaging, its
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primary limitation is getting light out of the subject, whereas fluorescence imaging is limited by
both the ability to pass light into and out of a subject. Its multiplexing capabilities, by combin-
ing different luciferases/substrates, make it a flexible and highly useful modality. The substrate
requirements of bioluminescence may limit its clinical translatability [138].
1.2.4 Advantages and limitations of SPECT and PET
The combination of two or more different imaging modalities is called ‘multimodality imaging’
to compensate for weaknesses of each imaging system whilst exploiting their individual strengths
[114]. Another limitation of radionuclide imaging techniques is the exposure of radiation workers
and patients to ionising radiation. Consequently, there is a limit to how many scans a subject can
have per year which needs to be considered when planning clinical and pre-clinical studies.
The key strengths of SPECT and PET include its excellent sensitivity (10-10 to 10-11 M for
SPECT and 10-11 to 10-12 M for PET), good depth of penetration, and quantitation capabilities.
Although, the spatial resolution is limited compared with MRI, it is extremely flexible in terms
of the types of imaging agents that can be used to bind specific molecular targets. SPECT has,
additionally, some multiplexing capabilities due to different nuclides giving rise to gamma rays
with differing energies. While SPECT is less expensive and more widely available than PET, it is
generally less sensitive and has a lower spatial resolution (8-10 mm, compared with 5-7 mm seen
with clinical PET) [141]. PET has up to a 10-fold advantage over SPECT in terms of sensitivity
[142, 143], SPECT on the other hand has the advantage of being capable of imaging two or more
radionuclides of different energies simultaneously and has a wider range of radionuclides and linking
chemistry available. In small animal models, SPECT has greater resolution [144, 145].
Unlike MRI and optical imaging techniques, both PET and SPECT only require small mass
amounts of imaging agent (nanogram to milligram range). They are, therefore, used in tracer
studies. A tracer study is performed using a sub-therapeutic amount of the proposed therapeutic
biological attached with radiopharmaceutical, with subsequent serial imaging assessing uptake in
tumour and critical normal organs such as liver, kidneys, bone marrow, and lung [146].
Overall, PET and SPECT are extremely valuable imaging modalities for investigating molec-
ular processes in living intact subjects/patients [141, 114, 123].
1.2.5 Imaging in therapy and diagnosis of cancer
Imaging occupies a central position in the development and application of targeted cancer therapy.
Very early on in the history of antibody-targeted therapy radioimmunoconjugates were field-tested.
Starting in the 1950’s radioiodinated polyclonal antibodies were used. However, it was not before
the 1970’s that scientists were able to locate human tumour with the help of radiolabelled antibodies
used a in process called external scintigraphy or radioimmundetection (RAID). In the 1980’s the
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therapeutic activity of 131I-labelled polyclonal anti-CEA IgG against human tumour xenografts
was another milestone marking the introduction of radioimmunotherapy (RAIT) [26]. Since then a
variety of antibody-based formats have been explored based around the IgG antibody and including
different proteins based on single-chain variable fragment (scFV), the minimal component required
for antigen binding. Today, imaging is used for a variety of tasks from patient selection, dosimetry
and assessment response to imaging distribution of antibody targeted therapeutics.
When a targeting moiety delivers a therapeutic payload, imaging can potentially be used to
identify deposits of tumour, decide on the most appropriate treatment strategy, confirm delivery of
the therapeutic, measure the dose and function of the therapeutic delivered and to assess tumour
response. In clinical drug development the advantage of imaging as a tool in drug development and
first-in-man studies is the injection of a sub-therapeutic dose into patients. This dose is too small
to have any effect, good or bad in the patient, but enables the researcher to validate targeting and
initial therapeutic dosing.
The antibodies initially developed for imaging and therapy were intact IgG molecules with
a molecular weight of 150 kDa. Mach et al. showed that in some cases only 0.0001-0.01% of the
injected dose of full size antibody localises to a gram of tumour [142].
Dancey and colleagues suggested in their paper from 2009 that the standard approach in
drug development until now was to establish a new capable mechanism of action with evidence
of efficacy and lack of toxicity in a pre-clinical model [142, 147]. The starting dose for a clinical
trial was then calculated or estimated taking the toxicity data into account at a ‘no observed
adverse effects level’ (NOAEL) [148] with the addition of a safety factor. This procedure has been
proven reasonably safe for small molecule ‘off target’ drugs. With the newer biological agents
especially antibodies the toxicity comes from an ‘on target’ effect as was tragically illustrated by
the TGN1412 trial of an agonist antibody to CD28 T-cell antigen [149, 150]. The message was
that there is a need to study mechanism of action more thoroughly in animal model systems and
in phase 0 clinical trials. Imaging studies are likely to play a crucial part in this process.
1.2.6 Imaging in pre-clinical drug development
Imaging in a pre-clinical setting has become a valuable tool in diagnostic and therapeutic drug
development. In particular, the development and validation of biomarkers has the potential to
accelerate research and transfer it into clinical exploitation in the future. Where imaging in first-in-
man or phase 0 studies gives crucial information it comes short in biodistribution data because the
injected quantity is usually in trace amounts. Information to predict efficacy and pharmacokinetics
and biodistribution can be acquired in pre-clinical in vivo imaging studies using appropriate animal
models. In vivo testing is a critical part of preclinical development because it offers the first evidence
that the new agent has a superior anti-tumour effect in a whole animal, thus accounting for other
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mechanisms impacting on cancer growth such as the stromal environment. It provides valuable
animal pharmacokinetic and pharmacodynamics information that can be used to plan the starting
dose and schedule of subsequent phase I studies [147].
Animal models have been an integral part of biomedical research in the study of drug
development and disease processes [151]. In pre-clinical nuclear imaging radioactive tracers that
rely on the application of a conjugated target specific molecule in very small concentrations were
traditionally used, in combination with organ dissection and tissue counting, which still are a
crucial part of pre-clinical evaluation [152]. Alternatively, whole-body cryosection followed by
digital autoradiography [153] can provide anatomic images with good spatial resolution (∼50 µm)
correlated with quantitative measures of the tracer concentration. The disadvantage of these
ex vivo methodologies is that only a single time point per animal can be sampled during an
investigation. The lack of a method to study repeatedly the same animal model before, during,
and after an intervention has been a significant limitation of these traditional investigative methods.
Small animal PET and SPECT imaging instrumentation can achieve exactly these desired types
of studies and results in one animal. Furthermore, pre-clinical PET and SPECT are able to give
an answer to questions at a very early stage in regards to biological drug development in suitable
projects with validation of biomarkers and quantification of response to therapy and proof of
principle studies. It can also help to predict the clinical outcome or predict the efficacy ahead
of time. For example, Dancey et al. reported a study in 2009 in which the maximum tolerated
dose (MTD) was determined on the basis of imaging data [142]. While the ultimate goal is the
clinical application, the advantage of pre-clinical animal experiments that include in vivo imaging
techniques is aiding validation and the reduction of animals used in research [154].
1.2.7 Molecular imaging and imaging probes
Radionuclides used for imaging need to fulfil certain properties and are selected for every target
and target environment individually to match appropriate therapeutic or diagnostic assignments.
While some radionuclides such as iodine-131 emit both β and γ radiation and are therefore suitable
for both imaging and therapy, others are more suited to imaging or therapy alone. For example,
based on similar chemistry and distribution pre-clinical imaging for iodine-131 and yttrium-90,
with half-lives of 8.02 days and 2.67 days respectively, can be performed with iodine-123 (half-
life, 13.3 h) and indium-111 (half-life, 2.8 days). Other combinations include imaging with 99mTc
and therapy with rhenium-186 [142]. Radiometals like indium-111 or technetium-99m are coupled
with antibodies through a chelating agent. There are various chelating agents at hand with often
differing affinities for various metals. This results in a vast possible combination of chelators and
radiometals, in which the in vivo stability of one radiometal bound to a particular antibody-
chelate conjugate might not be the same as another radiometal bound to the same conjugate. A
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number of techniques have been developed for radiolabelling biomolecules, including antibodies,
peptides and non-peptide receptor ligands. They are often classified into three main categories:
direct labelling approach [155, 156], pre-labelling or preformed chelate approach, and post-labelling
approach [157, 158]. Every labelling procedure has to be critically assessed to determine how much
impact of the procedure and the isotope is made on the biological activity and functionality.
In direct labelling of an antibody, a radiometal is attached to a disulfide bond or a functional
group of the antibody, such as tyrosine, lysine without any use of intervening spacer.
Radioiodination was one of the first methods to label antibodies with iodine-131 and iodine-
125 [159, 160]. Iodine anions in aqueous solutions undergo an equilibrium reaction process in the
presence of an oxidising agent to form reactive H2OI+ species that is capable of modifying the
tyrosine side chains and imidazole groups of histidine. This reacts with chemically reactivated
iodine [161, 155, 156].
The pre-labelling or pre-formed chelate approach involves as a first step the formation of a
radio isotope-chelate complex, before in a second step this complex is conjugated to the biomolecule
[162, 163]. Advantages are the better defined chemistry and the protection of the biomolecule from
often harsh chemistry conditions.
In the indirect labelling approach, a bifunctional chelator (BFC) is attached to the biomolecule
(BM) [158, 157]. In the second step the BFC-BM conjugate is prepared and a radio isotope can
be attached by direct reduction in the presence of a sufficient amount of BFC-BM or by exchange
with an intermediates. This approach combines the advantages of direct labelling with the defined
chemistry of the pre-labelling approach. The latter approach is widely recommended in literature
for kit formulation and product development, which is aimed for in this project.
1.3 Hypothesis and project overview
Previous studies have reported significant experimental support of the anti-tumour efficacy of IgE
type antibodies. IgE may be comparable or even superior to its IgG counterpart [44, 58]. However,
the mode of action of IgE in immunotherapy is still not well understood. This thesis and the
overall project were based on the hypothesis that unique properties of IgE can trigger powerful
immune responses focused on the ability to efficiently recruit immune effector cells with its high
affinity receptor FcεRI and the low affinity receptor FcεRII. There is strong evidence that IgE class
antibodies could be employed for passive immunotherapy of solid tumours [164, 165, 13]. Different
studies form a part of a growing body of evidence suggesting that IgE antibodies may have a role
in cancer therapy [41, 58, 165, 13, 42, 166, 35, 167, 168].
The overall project that consisted of 5 specific co-ordinated PhD projects was funded with
the aim of translating IgE antibodies to a first in man (MOv18) IgE study and to develop a clinical
concept for IgE treatment in cancer. The studies involved both the anti-folate, MOv18 antibody
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and an anti-CSPG4 antibody, although only the MOv18 was initially to be taken through to clinical
trial.
The results of this PhD thesis aim to contribute to the overall project and give a better
understanding of the role of IgE and its immunological mechanism in cancer medicine.
The specific aim of this PhD thesis was to develop a method for radiolabelling IgE antibodies
and to investigate the biodistribution, targeting and clearance of these novel diagnostic and ther-
apeutic antibodies in pre-clinical imaging studies compared to their counterpart IgG antibodies.
It was important that, during the radiolabelling, full functionality of the antibodies was
maintained. It was also important that the labelling method was readily translatable to the clinic
in order to later be able to prepare labelled antibody to GMP standards for planned clinical studies
using the MOv18 IgE antibody. This is, to our knowledge, the first time the biodistribution of
a therapeutic IgE antibody was studied using preclinical imaging in a clinically relevant in vivo
model.
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radiolabelling, serum stability, antigen
binding and functional assay
2.1 Introduction
This chapter describes the development of a radiolabelling method for IgE that is straightforward,
easy to use and will therefore allow an easy translation into the clinical environment and would
enable assessment of the IgE, in comparison with IgG, without the loss of affinity or functionality.
This contributes to the overall aim for this thesis which is to compare the targeting, biodistribution
and clearance of IgE in comparison to its IgG counterpart in animal models. In addition, the aim
was to deliver important biodistribution and pharmacokinetic data to allow IgE class antibodies
to be translated into a clinical setting for applications in humans as a potential anti-cancer thera-
peutic. Six different antibodies were used and are mentioned in this chapter. To avoid confusion
and give more overview the six antibodies are summarised below together with a brief description
and are defined by using a simple numbering system (1E/G-3E/G). All antibodies are referred to
by their number throughout this chapter.
MOv18-IgG - Antibody number 1G: This antibody is a human/mouse chimeric IgG class anti-
body that targets the folate alpha receptor overexpressed on ovarian cancer cells among
others. MOv18-IgG was available at the start of the thesis in large quantities and was pri-
marily used to investigate different bifunctional chelates and other experiments where larger
quantities of antibody had to be used.
MOv18-IgE - Antibody number 1E: This antibody is the IgE counterpart to MOv18-IgG. MOv18-
IgE is also a human/mouse chimeric antibody and was engineered with the same variable
region (Fv) as the MOv18-IgG against the FRα. This antibody was available in smaller
quantities and used, for example, as an isotype control.
Rat MOv18-IgG - Antibody number 2G: This antibody was engineered as rat/mouse chimeric




Rat MOv18-IgE - Antibody number 2E: This antibody was also engineered as rat/mouse chimeric
antibody and is the IgE class counterpart to the rat MOv18-IgG. Both antibodies were only
available in very small amounts and after radiolabelling used for biodistribution experiments.
Anti-CSPG4-IgG - Antibody number 3G: A human/mouse chimeric IgG class antibody against
the chondroitin sulfate proteoglycan (encoded in humans by the CSPG4 gene).
Anti-CSPG4-IgE - Antibody number 3E: A human/mouse chimeric IgE class antibody against
the chondroitin sulfate proteoglycan overexpressed on A375 melanoma cancer cells. Both
antibodies anti-CSPG4-IgE and -IgG were engineered with only the constant (Fc) region
different as the class-determining part. Both antibodies were available and used for radiola-
belling, stability and functional tests before being used in in vivo studies.
To successfully use the radiolabelled IgG and IgE antibodies in NanoSPECT/CT and biodis-
tribution studies a suitable radiolabelling method had to be found. Antibodies, after production
and purification, can undergo degradation while stored and often lose their affinity partially or
even completely if exposed to harsh conditions of temperature or pH. The process of conjugating
a bifunctional chelator, whatever the method chosen, exposes the antibody to chemical and/or
thermal treatment of some kind. The physical handling, for example centrifugation and/or filter-
ing of protein and the storage, can also have direct or indirect negative impact on the structure
and, therefore, on the affinity and functionality of the antibody. All antibodies, IgE and IgG, were
conjugated to a bifunctional chelator and radiolabelled for later use in biodistribution and in vivo
imaging studies and therefore had to be tested for a potential loss of affinity to the target recep-
tor and contamination prior to and after conjugation with bifunctional chelators and subsequent
radiolabelling. Furthermore, in the constant region of all IgG and IgE class antibodies receptor
binding areas were located. It was important to preserve the affinity and functionality of the FcR
binding region located within the Fc-region.
In this chapter the data are presented and discussed to show that the approach taken to
conjugate and radiolabel the antibodies preserves full affinity and functional potency. Several
conditions had to be fulfilled to make a later translation process as smooth as possible.
• The imaging chemistry must not interfere with the immunological properties of the antibod-
ies.
• The antibody conjugate must be radiolabelled with high specific activity.




2.1.1 IgE and IgG antibodies
This presents the opportunity to compare IgG and IgE class of antibodies in vivo, for the first
time.
To compare antibody 3E to its IgG counterpart 3G, both antibody class types were con-
structed from the same Fv-region and therefore had the same affinity and specificity for the target
CSPG4. The existing antibody 3G targeted against the melanoma-specific antigen (the chondroitin
sulfate proteoglycan 4) was converted into IgE (antibody 3E) by cloning the existing antibody 3G
variable (Fv) region into the vector for antibody 3E. For the antibody 3E, the heavy chains, as
the antibody class-determining region, of antibody 3G was exchanged for IgE heavy chain as the
heavy chain determines the antibody class. The cDNA for the IgE (antibody 3E) was derived
from the protein sequences of the heavy and light chains variable regions from the existing V genes
from antibody 3G (CSPG4-IgG) (Vector: pSGH-CSPG4 and pSGK-CSPG4). The heavy chain
cDNA was synthesised based on the published protein sequence of antibody 1E (MOv18-IgE) in
a pVITRO1 vector, containing the epsilon heavy chain of IgE (humighae2, accession no: L00022)
and kappa light chain constant region cDNA (IGKC, accession no: BC110394). The antibody
1E (MOv18-IgE) stock used as an isotype control throughout the experiments was produced on
an older pUC8 expression vector based cloning process [41]. Vector systems were based on two
vectors, one for the mouse light chains and one for the human heavy chains. Vector, promoter
and induction options were chosen with the main aim of a high production output. Disadvantages
of these systems were higher production costs caused by two batches for each antibody and due
to the slight overproduction of the light chain potential purification issues. For this project the
genetic engineering of antibody vectors was performed by Tihomir Dodev at the laboratory and
under supervision of Dr Andrew Beavil and Prof Hannah Gould in order to produce IgG class an-
tibodies and IgE class antibodies. Antibody 3G (anti-CSPG4-IgG) was produced and purified by
Tihomir Dodev and Andrew Beavil. Antibody 3E (anti-CSPG4-IgE) productions and purification
was performed in collaboration with Tihomir Dodev and Panos Karagiannis. Antibodies 3G and
3E were produced, purified and supplied mainly by Panagiotis Karagiannis and Tihomir Dodev
and on several occasions by myself at the laboratories and under supervision of Hanna Gould,
Andrew Beavil, Frank Nestle and Sophia Karagiannis.
2.1.2 Radionuclide
To match the requirements for in vivo imaging and biodistribution of both IgG and IgE it was
important to choose a suitable radionuclide. While IgG class antibodies have been the subject
of numerous imaging and biodistribution studies in the past and suitable radionuclides are well-
established [114, 169], the requirements for these studies involving IgE class antibodies were rela-
tively unknown. It was understood that IgE has a much longer half-life in tissues than IgG, and
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a much shorter half-life in serum, but the factors influencing the biodistribution and the way IgE
would accumulate at the target site or its clearance were unknown at the outset of this project
[47, 170].
Technetium-99m (99mTc) remains the most widely used radioisotope in nuclear medicine
due to its optimal nuclear properties and easy availability at low cost. 99mTc has a half-life of 6.01
hours. The half-life gives enough time for most medical procedures while keeping the radiation
exposure low for patients. 99mTc emits gamma rays at 140 keV in a single peak energy window that
coincides with optimal imaging properties for detection in SPECT. In comparison to most other
SPECT isotopes technetium-99m based imaging will result in a high contrast and image quality.
However, for antibodies with long half-life (IgG in serum ∼20 days and IgE in tissue 14 days)
the window for imaging provided by the half-life of 99mTc was considered too short. Gallium-68
is clinically used in form of gallium-68 citrate injection and more recently has had increased use
in the somatostatin receptor imaging agent 68Ga-DOTATATE [171–174]. It is used in PET/CT
which was an imaging modality available for this project. The advantages of 68Ga over other
PET-based radionuclides are its availability from an in-house generator independent of an onsite
cyclotron. The half-life of 68Ga is 68 minutes. Eighty-nine percent of Ga-68 decays by emitting
positron of 1.92 MeV and the rest 11% by electron capture. Several suitable bifunctional chelators
have been developed, and coupled with biomolecules for gallium-68 labelling. DOTA, NODAGA
and NOTA are commonly used bifunctional chelators. Many peptides/biomolecules like receptor
peptides and antibodies have now been successfully modified by these chelating agents without
compromising their functional properties which further widened the role of gallium-68 PET/CT
imaging. These peptides/biomolecules show very fast target localisation and fast blood clearance
thus, making the short half-life ideal for smaller biomolecules in clinical studies. In the last decade
68Ga-DOTA-octreotides replaced 99mTc/111In-DTPA-octroescan used for neuroendocrine tumour
(NET) imaging [175]. However, the short half-life was seen as a disadvantage for imaging an IgE
class antibody with an expected long half-life in tissue. Other radioisotopes that were considered
because of at least partially fulfilling the requirements were, for example, zzirconium-89, copper-64
or iodine-131.
89Zr has a half-life of 78.5 h with a beta emission (897 keV, 23%) and EC (77%). Due
to its long half-life, it is an attractive isotope for radiolabelling of biomolecules over a prolonged
period of time. It was at the time of the start of the project not available and was not considered.
However, it is now available in the laboratory and would be considered because of its well-described
bifunctional chelator chemistry and the for IgE antibody imaging attractive half-life.
64Cu is another attractive isotope. The half-life (12.7 h) and decay properties (beta(+), 0.653
MeV, 17.8%; beta(-), 0.579 MeV, 38.4%; the remainder is electron capture) of 64Cu make it a good
choice as radioisotope for PET imaging and radiotherapy. The well-established coordination chem-
istry of copper allows for its reaction with a wide variety of chelator systems that can potentially
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Table 2.1: Commonly used and for this thesis considered radioisotopes.
be linked to antibodies, proteins, peptides, and other biologically relevant molecules. New chela-
tors with greater in vivo stability, such as tetraazamacrocyclic 1,4,8,11-tetraazacyclotetradecane-
1,4,8,11-tetraacetic acid (TETA), are now available and extensively covered in literature [176].
However, during the course of this project, copper-64 production was disrupted and availability
was limited and at times unpredictable in quantities. Also, it seemed very difficult to obtain very
high specific activity caused by the instability of the production process. Another reason for not
considering copper-64 was the short half-life (12.7 h) compared to other available isotopes.
Iodine-131 has a half-life of 8.02 days. The half-life would have extended the imaging
time and allowed biodistribution studies of antibodies over a much longer period than with other
radioisotopes. However, 131I emits both β and γ radiation and would have, similar to 64Cu, made
it difficult to distinguish between the potential imaging of a local therapeutic effect of IgE and
β decay. In general, direct iodination of proteins occurs on tyrosyl or to lesser extent histidyl
residues within a protein following electrophilic attack by a positive iodine species. The point of
attachment is at the most electron-dense part of the ring i.e. at the ortho position in the tyrosine
ring [177]. This method could have potentially ended in a greater loss of activity of the antibodies
and more importantly loss of radiolabel in vivo.
111In was eventually chosen as the radioisotope with the best compromise between available
labelling methods, accessible chelators, half-life and imaging quality with regards to its energy
windows and its availability. It is a cyclotron-produced isotope and has a half-life of 67.9 h (2.83
days). 111In decays by electron capture with two γ-photon emissions at 173 and 247 keV (89%
and 95% abundance, respectively), and has been widely used in gamma scintigraphy to investigate
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antibody biodistribution. The half-life resulted in an imaging time frame of at least 5 days.
indium-111 has a long history in the use of medical applications and made it reasonable choice
for the development of an imaging-guided first in man study of IgE based anti-cancer therapy.
Methods for labelling monoclonal antibodies using bifunctional chelators that can then be labelled
with indium-111 have been developed [178–180] and tested in animal models [178, 181]. The
advantages of 111In-labelled antibodies include: (a) favourable energy for imaging; (b) a 2.8 day
half-life allowing extended periods for imaging studies; (c) suitability for kit formulation; and (d)
the stability of radiolabelled antibodies [181]. Several clinical trials with 111In-labelled antibodies
have shown excellent imaging results [182, 183].
2.1.3 Bifunctional chelator
To connect the radioisotope to the antibody a bifunctional chelating agent (BFC), which consists
of a chelator to complex the radiometal and a functional group for attachment to the biomolecule,
had to be chosen. Functional groups that form amide, thiourea, urea, Schiff base, or thioether
linkages with amine or thiol groups on proteins and peptides have been described in literature
[184–186]. There were two requirements for using in In(III) complexes: indium-111 had to be
bound with high kinetic stability in biological conditions and the conjugation and radiolabelling
process had to be straightforward, reproducible, high-yielding and robust. Indium is in group
IIIB of the periodic table. Like gallium, under physiological conditions, the only stable aqueous
indium oxidation state is +3, and this is the oxidation state relevant to radiopharmaceutical chem-
istry. 111In has coordination numbers of 6, 7, and 8 depending on the ligand, and it also readily
forms 9-coordinate complexes. The tripodal NS3 chelators, EDTA, DTPA, and DOTA all complex
In(III) securely, as well as with high denticity. Differences in fundamental coordination prefer-
ences have significant consequences in their biological behaviour [187]. Popular acyclic chelators
like EDTA and DTPA form very thermodynamically stable complexes with indium. The seven-
coordinate 111In-EDTA structure features a hexadentate chelator and approximates a pentagonal
bi-pyramidal geometry with single water at an equatorial position. 111In-DTPA structures feature
both seven- and full eight-coordination by the chelator in distorted pentagonal-bi-pyramidal and
square-anti-prismatic geometries, respectively. Well known mAb agents approved for clinical use
that use DTPA to complex 111In are for example 111In-DTPA-B72.3 (OncoScint) and 111In-DTPA-
7E11.C5.3 (ProstaScint) [184–186]. A DTPA derivative with a trans-1,2-diaminocyclohexane back-
bone, p-SCN-CHX-A"-DTPA, was conjugated to a targeting peptide and antibodies, and found to
be a viable ligand for 68Ga, 86Y, and 111In radiometals for melanoma imaging (Wei et al., 2009).
The versatile octadentate macrocyclic chelator DOTA has also been shown to form a robust com-
plex with In(III) [188, 189].
The bifunctional chelator p-SCN-CHX-A"-DTPA was chosen over its non-backbone substi-
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tuted DTPA derivative for the experiments because it features a preorganised DTPA analogue,
CHX-A" (trans cyclohexyldiethylenetriaminepenta-acetic acid). Due in part to its overall acyclic
structure, CHX-A" is even more capable of achieving rapid complex formation with a variety of
radiometals at room temperature than DTPA without CHX-A" thus offering a distinct advantage
over the macrocyclic chelator, DOTA, described below. In addition, p-SCN-CHX-A"-DTPA was
developed to allow CHX-A" preorganised DTPA an optimised complexation of In(III), Lu(III),
or Y(III). At the time of the experiments other backbone substituted DTPA derivatives, like
MX-DTPA, were used in clinical setups but not commercially available. CHX-A"-DTPA was
commercially available from Macrocyclics (USA).
Initially, DOTA-NHS ester was used as BFC because of its availability in large amounts for
no cost in conjunction with other experiments in our laboratory not related to this project. The
advantage of using DOTA-NHS ester as BFCs is the kinetic inertness of its radiometal chelates.
However, the radiolabelling rate of DOTA-NHS ester is normally very slow, and more dependent on
radiolabelling conditions, including DOTA-antibody (DOTA-Ab) concentration, pH, reaction tem-
perature and heating time, buffering agent and buffer concentration, and presence of other metal
ions, such as Fe(III). At room temperature, the radiolabelling yield of the DOTA-Ab conjugate
is very low and heating at the elevated temperatures (>50°C) is needed for successful radiola-
belling. The high temperature radiolabelling often causes a significant loss of immunoreactivity of
radiolabelled antibodies.
2.1.4 Aims
The specific aim of this chapter was to produce and evaluate indium-111 radiolabelled antibodies
within a set of constraints. It was aimed to develop a robust, reproducible and straight forward
method of conjugation and radiolabelling anti-CSPG4-IgE and -IgG antibodies for the application
of in vivo imaging and biodistribution studies. Importantly, the radiolabelling method had to
be the same for anti-CSPG4-IgE and -IgG to successfully compare both antibodies in vivo. The
conjugation and radiolabelling method had to be carried out in a way to preserve full affinity of
IgE FcεR receptors and affinity of IgE and IgG to the target receptor FRα. This chapter describes
the preparation and characterisation of the labelled antibodies using indium-111 as the radiolabel
and p-SCN-CHX-A"-DTPA as the bifunctional chelator.
2.2 Materials and Methods
2.2.1 Stable expression of antibody 3G and 3E (anti-CSPG4-IgG and -IgE)
After exchange of variable- or constant-region domains within the dual antibody expression cas-
sette in pVITRO1, stable cell lines were generated to support large-scale antibody production for
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subsequent use in animal model studies. The mammalian cell line, FreeStyle™ 293-F cells (Life
Technologies), a suspension culture cell line adapted to grow in serum-free conditions, was used
for upscale antibody production. The FreeStyle™ 293-F cells were transfected and selected for 2
weeks with Hygromycin. Cells expressing anti-CSPG4 specific IgE or IgG were expanded into a
1 L shaker flask (Sigma), 1 L spinner bottle (Sigma) or 5 L WAVE bioreactor (GE Healthcare),
producing 10 mg/L, 15 mg/L and 25 mg/L of respective antibody at 30 days post-transfection.
2.2.2 Purification of antibody 3G and 3E (anti-CSPG4-IgG and -IgE)
The anti-CSPG4 specific IgE isotype was purified by affinity chromatography using IgG4-Fc-
(sFcεRIα)2 fusion protein. The anti-CSPG4-IgG isotype was purified by affinity chromatogra-
phy with a 5mLHiTrap Protein-G HP column (GE Healthcare) using an ÄKTA Prime system
(Amersham, Uppsala Sweden).
2.2.3 Expression of antibody 2G and 2E (rat MOv18-IgG and -IgE)
The rat MOv18 IgE and IgG2b were engineered as chimeric antibodies with rat constant domains
and mouse variable domains specific for the human FRα. The rat IgG2b subclass was selected
due to its reported equivalence to mouse IgG2a/b [190], which are the murine equivalent of human
IgG1 in terms of their ability to efficiently activate the complement cascade, and to mediate ADCC
[191].The antibody variable DNA sequence of MOv18 IgE specific for the epitope on the human
FRα (determined and kindly provided by Dr H. Harries, Division of Asthma, Allergy and Lung
Biology, King’s College London) was combined with the rat immunoglobulin constant (Cε, Cγ2b
and CK) DNA sequences for rat IgE and IgG2b. cDNA encoding the light and heavy chains of the
rat MOv18 IgE and IgG2b antibodies were synthesised (GeneArt®). The heavy and light chains of
each rat MOv18 antibody were then cloned into a single mammalian expression vector containing
a hygromycin resistance gene (pVITRO1) generating pVITRO-Rat MOv18 IgE and pVITRO-Rat
MOv18 IgG2b expression vectors (all cloning was performed by Mr. T Dodev, Division of Allergy,
Asthma and Lung Biology, King’s College London; all production was performed by Dr Debra
Josephs, Cutaneous Medicine and Immunotherapy Unit, St John’s Institute of Dermatology, Divi-
sion of Genetics & Molecular Medicine, King’s College London). Suspension FreeStyle™ 293-F cells
were selected for the transfection of the pVITRO-Rat MOv18 IgE and pVITRO-Rat MOv18 Ig2b
expression vectors. The cells were cultured under continuous selective pressure using hygromycin
B in FreeStyle™ 293 Expression Medium. After 7 days in culture, antibiotic selection at 50 µg/mL
hygromycin B killed the untransfected cells. To produce sufficient quantities of the surrogate rat
antibodies for the subsequent extensive in vivo studies, vectors from selected cell lines were purified
ans used to transfect new cell lines which could be frozen and stored and were stable in expression
of the antibodies 2G and 2E. Therefore, the FreeStyle™ 293-F cells transfected with the pVIT-
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RORat MOv18 IgE and IgG2b expression vectors were frozen in 10% DMSO at -80°C. After 1
month the cells were thawed, expanded under hygromycin B selection and incubated for antibody
production. ELISA analysis of harvested supernatants 5 days after transfection with pVITRO-Rat
MOv18 IgE and 5 days after thawing from frozen showed similar antibody expression levels.
2.2.4 Purification of antibody 2E (rat MOv18-IgE)
MEP HyperCel™ is a high capacity, high selectivity sorbent specifically designed for the purification
of mAbs. MEP HyperCel™ principally operates by Hydrophobic Charge Induction Chromatogra-
phy (HCIC). The functional ligand, 4-mercaptoethylpyridine (MEP) is Ig-selective and can bind
a broad range of Ig isotypes and subclasses [192]. Binding to Ig is achieved principally through
hydrophobic interactions at neutral pH, at which both the Ig and the pyridine group of the ligand
are uncharged. As the pH is lowered, both the ligand and the Ig acquire positive charges, resulting
in electrostatic repulsion and elution of the Ig [193]. The MEP HyperCel™ resin was packed into an
XK26/20 column (GE Healthcare, 56 mL packed column volume) and equilibrated at a flow rate of
5 mL/min with PBS pH 7.0. A total volume of 2 L of culture supernatant (rat IgE concentration
of approximately 10 mg/L) was loaded onto the column at a rate of 5 mL/min. After washing the
column with sufficient quantities of PBS pH 7.0 to detect only baseline levels of UV 247 absorbance,
elution of antibody with 25% isopropanol elution buffer was commenced, and a large elution peak
with an elution proportion of 1.7% was detected. Subsequent analysis of the eluted fractions on
SDS-PAGE revealed a strong band at the expected MW for rat IgE of 200 kDa. The total pro-
tein content of the eluted fractions, estimated by using a UV spectrophotometer at 280nm with
percent solution extinction coefficient (A0.1%/280nm) for IgE of 1.62 [194], was approximately 15
mg, thereby indicating an antibody yield of 75%. HPLC-SEC was subsequently used to purify
the eluting fraction using a Superdex™ 200 gel filtration column. Fractionation was performed as
a final polishing step to isolate pure monomeric antibody from remaining contaminant proteins,
antibody degradation products or aggregates according to size.
2.2.5 Purification of antibody 2G (rat MOv18-IgG)
Purification of rat MOv18 IgG2b from culture supernatants was performed using protein G affinity
chromatography as previously described, with elution using 0.2 M glycine, pH 2.3 followed by
immediate neutralisation with 1 M Tris pH 8.6 [195]. After neutralisation the antibody was dialysed
against PBS pH 7.4.
2.2.6 Tissue culture and cell lines
All cells were maintained in a 5% CO2 humidified incubator at 37°C.
HEK293E - Human Embryonic Kidney (HEK) 293, expressing the Epstein-Barr Virus nuclear
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antigen-1 (EBNA-1) [196], were cultured in Dulbecco’s Modified Eagles Media (DMEM),
10% FBS, 1% Penicillin-Streptomycin-Glutamine and 250 µg/mL G418 to maintain selec-
tion of transfected EBNA-1 plasmid, and kept between 1 - 9 x 105 cells/mL. 293-F Human
Embryonic Kidney (HEK) 293-F Suspension FreeStyle™ cells (Life Technologies) were cul-
tured in FreeStyle™ 293 Expression Medium.
U-937 - This non-adherent human monocyte-like cell line was kindly provided by Professor J.P.
Kinet (Harvard University, Boston, MA, USA). Cells were maintained in RPMI 1640 media
with standard additives at densities between 2x105 to 2x106 cells/mL. Where U937 cells were
cultured in IL-4, this involved supplementation of the standard culture media with 320 U/mL
recombinant human IL-4, four days prior to experiments. For ADCP/ADCC experiments
CD23 was upregulated with 320 U/mLrecombinant IL-4 over 2 days. This protocol was
established by Dr. Sophia Karagiannis.
A375 - Human Melanoma cell line, naturally expressing the chondroitin sulfate proteoglycan 4
(CSPG4) (CRL-1619, ATCC, Manassas, VA) was grown in DMEM supplemented with 10%
FCS, 2 mM L-glutamine, penicillin (5000 U/mL) and streptomycin (100 µg/mL).
Passaging Adherent Cells: When cells were ∼80-90% confluent, the medium was removed
from the flask and the cells washed once with 10mLPBS to remove excess medium and serum.
A minimal amount of TrypLE™ Trypsin (Invitrogen) was used to coat the flask surface and
incubated for 5 minutes at 37°C. The cells were observed under a microscope to confirm cell
detachment. 10mLof fresh medium was added to stop trypsinisation. The solution was pipet-
ted up and down to break up clumps of cells and 1mL(to split them at 1/10) was transferred to
a new 75 cm3 flask and 14mLfresh medium was added (with selection agent where required).
Cells were incubated in a humidified, 37°C, 5% CO2 incubator until 80-90% confluent and
then passaged again. All tissue culture was performed under sterile conditions in a laminar
flow hood. Cells were grown in a humidified atmosphere at 37°C in 5% CO2. Culture media
was specifically supplemented with FCS and 1% Penicillin/Streptomycin/Glutamin for every
cell line. For storage aliquots of 7x106 cells in 1mL freezing medium (90% FCS, 10%DMSO)
were prepared and kept in liquid nitrogen.
2.2.7 SDS-PAGE analysis of antibodies 1G and 1E (MOv18 IgG and IgE)
Antibodies were provided in PBS and the same buffer was used for further dilutions to a stock
antibody solution of 1 mg/mL. 1 µL of stock solution was mixed with the NuPAGE lithium
dodecyl sulfate (LDS) sample buffer (Invitrogen, Carlsbad, CA). It was then heated to 70°C for
10 min to denature the protein. For sample reduction, 3 µL of the NuPAGE reducing agent (0.5
M DTT in stabilised liquid form) was added prior to heating for 10 min at 37°C and loading
the sample. For non-reducing conditions, the NuPAGE reducing agent was not included. The
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acrylamide/bis-acrylamide 4-12% Bis-Tris gels (1.0 mm thickness) were purchased from Invitrogen
and were pre-casted in 8x8 cm format. The NuPAGE MES SDS running buffer (Invitrogen) was
used, which contains 2-(N-morpholino) ethane sulfonic acid. The voltage was 200 V (constant) and
120 A, with a total run time of approximately 35-45 min. Gels were then stained with SimplyBlue
Safe Stain (Invitrogen, Paisley, UK) for 45 minutes followed by 3 washes with deionised water.
2.2.8 Conjugation and radiolabelling
Conjugation of antibody 1G (MOv18-IgG) with Bi-functional chelator DOTA-NHS
ester
Metal ion free conditions were used to protect the bifunctional chelator (DOTA-NHS) from
binding free metal ions. To achieve this, buffers were prepared using TraceSELECT® chemicals
(Sigma Aldrich) and water for irrigation (Baxter). All buffers were pH adjusted using 2 M NaOH
solution or 1 M HCl solution. The usual amount of antibody 1G used for conjugation with DOTA-
NHS ester was 2 mg in 1mL(2 mg/mLstock solution). The antibody was supplied in PBS, pH 7.4.
For the conjugation the calculated amount for a 1:20 antibody to chelate ratio of DOTA-NHS ester
was mixed with DMSO at RT. The DOTA-NHS ester in DMSO was added instantly to the anti-
body 1G in PBS buffer. The conjugation reaction was transferred to a dialysis cassette (Thermo
Scientific™ Slide-A-Lyzer™ Dialysis Cassettes, 20K MWCO) and dialysed over night at 4°C against
phosphate buffer Na2HPO4 0.05M, pH 6.8. The next day the conjugation reaction mixture was
transferred into a glass vial for radiolabelling.
Radiolabelling of DOTA conjugated antibody 1G with indium-111
A glass vial containing the DOTA-NHS conjugated MOv18-IgG (2mg/mL) was transferred
into a heating block and set to a temperature of 40°C. 50 µL (3-8 MBq) of 111In chloride solution
(Covidien, UK) added to the radiolabelling reaction (the activity being higher or lower dependent
on the reference date of the 111In chloride solution). The reaction mixture was incubated for 1
hour at 40°C. After incubation, the reaction mixture was transferred into a Vivaspin™ ultracen-
trifugation tube and 1 mLof Na2HPO4 0.05M, pH 6.8 was added and centrifuged at 1,000-1,700g
for 10-15 min so that the protein solution volume was reduced by a factor of 2-3. This step was
repeated 2-3 times to wash excess indium-111 off. The radiolabelled antibody was transferred into
a vial and samples were analysed by TLC and SEC HPLC for radiolabelling efficiency (TLC and
HPLC methods described below).
Conjugation with Bi-functional chelator p-SCN-CHX-A"-DTPA
In general, free metal ions and especially free iron ions have always been a major source
of contamination in conjugation and radiolabelling methods. Free iron ions can bind to freshly
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conjugated chelators and block them during later radiolabelling with metal radionuclides. The
conjugation method was based on the method described by Maggie S Cooper et al. in the Nature
protocol publication 2006 [197].
For HEPES, the pH was adjusted with 1M NaOH and for ammonium acetate buffers, the
pH was adjusted with acetic acid. All other buffers were pH adjusted using 2 M NaOH solution
or 1 M HCl solution.
The minimum amount of protein used for conjugation with a bifunctional chelator was 2.5
mg (and up to 12 mg) in 1 to 6 mL. The solution was pipetted into the a Vivaspin™ centrifugal
concentrator (Hydrosart membrane, 30,000 MWCO) and 50 µL of 50 mM EDTA in 0.1 M ammo-
nium acetate was added for every 10 mg of protein to chelate free metal ions. The solution was
left at room temperature for 30 min and then diluted 15 mLwith 0.1 M HEPES buffer, pH 8.5.
The tube was subsequently centrifuged at 1,000-1,700g for 30-40 min so that the protein solution
volume was reduced by a factor of 2-3. In the next step the ultrafiltrate (flow through <50kDa
passing the membrane) was discarded and the above described steps were repeated for two or three
times. Finally, the tube was spun until the volume fell to a level that corresponded to a protein
concentration of about 10 mg/mLand pH was checked to be pH 8.5. The contents of the ultrafiltra-
tion tube were transferred to a metal-free plastic test tube (Nalgene, USA). Protein concentration
was measured on a Nanodrop 2000c UV-spectrometer (Thermo Scientific, USA). The total mo-
lar amount of protein was calculated and the amount of p-SCN-CHX-A"-DTPA (Macrocyclics,
USA) calculated to give a 20-fold molar excess over the protein. Initially, molar ratios added were
between 5- and 40-fold excess of the antibody and it was found, in a series of experiments that
quantified the chelator-to-antibody ratio and compared different chelate-to-antibody ratios in func-
tional and FACS binding experiments, that a 20-fold excess gave optimal conjugation. A sufficient
quantity of the chelator was dissolved in 100% dimethyl sulfoxide (DMSO) at a concentration of
50 mg/mL, such that the volume of DMSO was not more than 10% of the total protein solution
volume, and added to the antibody solution. The solution was mixed immediately and incubated
at 4°C overnight. The next day the reaction mixture was pipetted into a Vivaspin™ centrifugal
concentrator and diluted to 15 mL with 0.1 M sodium phosphate buffer, pH 7.4. The tube was
then spun in the centrifuge at 1,000-1,700g for 30-40 min. The centrifugation was repeated and
after every centrifugation the absorbance in the ultrafiltrate was measured with the Nanodrop
until measurement at 280 nm was zero (meaning that no more free chelating agent was being elim-
inated from the solution). After free chelating agent was cleared the ultrafiltrate was concentrated
to a protein concentration of ∼2-5 mg/mL. The antibody conjugate was test labelled with 111In
chloride to ensure that all the excess ligand had been removed and that the radiolabelling was
satisfactory. This is described below. If the radiolabelling efficiency was below 95% (as assessed
by thin layer chromatography) then further wash steps, as outlined above, were carried out and
the test radiolabelling repeated. If the labelling efficiency was satisfactory (>95%), the reaction
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mixture was filtered with a 0.22 µm spin filter (Fisher Scientific).
Radiolabelling with indium-111
Typically, to 20 µL of CHX-A"-DTPA-mAb (2-5 mg/mL) was added 10 µL (3.7-7.4 MBq) of
111In chloride solution (Covidien, UK). The reaction mixture was incubated at room temperature
(RT) for at least 30 min and then labelling efficiency was assessed by thin layer chromatography
(TLC) and high-performance liquid chromatography (HPLC). Adjustment of pH was not necessary
for further analyses or in vivo/in vitro experiments. In preparation for in vivo injection, the
radiolabelled antibody was diluted with 0.1 M sodium phosphate buffer, pH 7.4 to 150 µL total
volume (total volume of injection per animal).
ITLC-SA: To determine the efficiency at which indium-111 associated with the protein in sample,
1 µL of radiolabelled sample was spotted at 10mm on a thin layer chromatography (ITLC)
(10mm x 90 mm, ITLC-SA, Varian, UK). The mobile phase comprised of 0.1 M sodium
citrate, pH 5 with 5 mM ethylenediaminetetraacetic acid (EDTA). The solvent front was
allowed to run to 80 mm, and plates were analysed with a gamma-ray TLC scanner (Lablogic
and Laura software). Radiolabelling efficiency was expressed as the radioactivity associated
with radiolabelled protein peak integral (Rf=0) as a percentage of the total radioactivity on
the strip. In this system, unincorporated indium-111 runs to the solvent front (Rf=1.0).
TLC on Silica 60F with aluminium back: At a time during the experiments the supply of Varian
iTLC-SA paper ran out because of production stop. During this time iTLC-SA was replaced
by a TLC utilising Silica 60F coated aluminium with a mobile phase of 0.2 M citric acid,
pH 2. The labelling efficiency can be calculated in the same way as outlined above and is
expressed as the radioactivity at the origin as a percentage of the total radioactivity on the
strip.
High-performance liquid chromatography (HPLC): Binding of radioactivity to protein was also
confirmed with analysis using an analytical size exclusion chromatography column on HPLC
(Series 1200, Agilent, UK) equipped with an in-line gamma detector (Lablogic, UK) and
according to manufacturer’s instructions. For SEC-HPLC a 20 µL sample of the radiola-
belling reaction mix was loaded onto a BioSep s3000 gel filtration column (BioSep 5 µm
SEC-S 3000 LC Column 300 x 7.8 mm, Phenomenex, UK), which had been equilibrated with
size exclusion buffer (PBS pH 7.4 and 2 mM EDTA). Size exclusion buffer was then passed
at 1 mL/min and signals were detected in-line by a variable wavelength detector (Variable
Wavelength Detector G1314B, Agilent Series 1200, Agilent, UK) and gamma detector. For
reverse-phase HPLC a 5 µL sample of the radiolabelled conjugate was loaded onto a C18
column (Extend-C18 5um, 4.6 x 250mm, Agilent, UK) which had been equilibrated with
reverse-phase buffer (5% methanol and 0.1% formic acid). Reverse-phase buffer was then
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passed gradually at 0.5 mL/min with 5% methanol in water as the initial solvent, and 100%
methanol as the final solvent. To both buffer ingredients, water and methanol, 0.1% formic
acid was added. Signals were detected in-line by a variable wavelength detector (Variable
Wavelength Detector G1314B, Agilent Series 1200, Agilent, UK) and gamma detector. Data
were analysed using the software Laura (Laura, version 4.0.2.75, Lablogic, UK).
Phosphorimaging: Radiolabelled antibodies were analysed by reduced and non-reduced SDS PAGE
(200 V, 120 A, 50 min). Gels were then stained with SimplyBlue Safe Stain (Invitrogen, Pais-
ley, UK) for 45 minutes followed by 3 washes with deionised water. SDS PAGE gel samples
were laid in contact with the phosphor screen in the exposure cassette for a predetermined
period of 10-15 min. The exposed phosphor screen was of medium size and scanned with the
Cyclone Plus phosphorimager (PerkinElmer, MA, USA). The image obtained was stored as
a digital file with 300 DPI and analysed by the Optiquant software (PerkinElmer).
Competitive assay to determine the quantity of chelators per antibody
For this experiment 100 µg of the antibody were taken from a 4 mg/mLantibody solution
(4 mg/mL = 25µL required). A 0.25 mM stock solution of carrier added 111In was made up
from no carrier added 111In and indium (III) acetate standard solution (Sigma Aldrich, indium
(III) acetate 10,000µg/mL solution). The 25 mM trace-labelled solution was made with 1 mL
indium(III) standard solution combined with 5.787 g of water for irrigation in a metal free vial.
1.7 mL of the resulting indium solution was added to the entire contents of the 111In vial. A 1:100
dilution was made of this 25mM stock solution using metal free buffer solution 0.1M ammonium
acetate, pH5.9 to give a 0.25mM solution.
Vials were prepared with 10:1 indium(III) to antibody ratio. Into the vials 100 µg (25
µL) of antibody solution was added and combined with 26.7 µL of indium(III) (25µL, 6.7 x 10-10
moles). The vials were then made up to the volume of 100 µL using 0.1M ammonium acetate,
pH 5.9 buffer. The indium/antibody mixture was then gently mixed and centrifuged. The vial
was then left for 1 h incubation at RT. After incubation 10 µL of 50 mM EDTA solution was
added and incubated for another 5 min at RT to chelate any unbound or non-specifically bound
111In. Thin layer chromatography was carried out in triplicate for each vial using iTLC-SA. Strips
(10 mm x 90 mm) were cut in half and radioactivity measured in each half of the strip in the
gamma counter (Wallac, 1282 Compugamma). The percentage of radioactivity in each bottom
half strip was calculated as this represents the activity bound to the antibody. Since a 10 molar
excess of indium was added to each antibody dilution the number of chelators was calculated as
% bound antibody. This experiment was repeated for antibody conjugates, which were previously
conjugated with CHX-A"-DTPA in 5, 10, 20 and 40 times molar excess of chelator to antibody,
to assess the number of chelates per antibody under these different conditions in order to optimise
the conjugation methodology.
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Stability of 111In-Antibody conjugates in serum and phosphate buffered saline
10 µL of CHX-A"-DTPA conjugated and 111In labelled antibody 3G, 3E or isotype control
antibody 1E (2-5 mg/mL antibody radiolabelled with 10 µL (3.7-7.4 MBq of 111In) were added to
5 mL AB type human serum (Sigma) or 5 mL 0.1 M PBS (Gibco) at 1:4 v/v and incubated at
37°C for 72 h. Samples were analysed at 0, 24, 36 and 72 h by HPLC-SEC using a BioSep SEC-300
column (Phenomenex, Macclesfield, UK) with an isocratic mobile phase of 100 mM phosphate
buffer, 5 mM EDTA, pH 7.0, at a flow rate of 1 mL/min. Stability was calculated as the area
under the antibody peak as a percentage of the total activity.
Antigen binding assays
To assess the antibody binding to the tumour-associated antigens FRα (MOv18) and CSPG4
and to FcεR (IgE) and FcγR (IgG) receptors on receptor-expressing cells, flow cytometric assays
were used. For CSPG4 experiments, 2 x 105 U937 cells were used and for MOv18 experiments,
2 x 105 IGROV1 cells were used. Cells were incubated in triplicate in 12 x 75 mm FACS tubes
(Falcon, Becton Dickinson) with 0.5 µg/mL of either the non-radiolabelled antibody conjugates
(10 µg/mL IgE and IgG) or the unconjugated (native) antibody version of both (IgE and IgG)
for 30 min at 4°C, followed by two washes in FACS buffer (PBS, 5% normal goat serum). Cells
were then incubated with anti-human IgE-FITC or antihuman IgG-FITC (10 µg/mL) for 30 min
at 4°C, washed in FACS buffer and fixed in 1% paraformaldehyde-FACS buffer prior to acquisition
and analysis on a dual laser FACSCalibur™ (BD Biosciences). For quantitative assessments of Fcε
and Fcγ cell surface receptors, cells were stained with mouse mAbs by indirect immunofluores-
cence using the QIFIKIT® (Dako). For analysis, a threshold was set on forward and side scatter
plot to exclude cell debris. Fluorophores bound to cells were excited at 488 nm generated by an
Argon laser. CFSE+ labelled cells were detected in the FL1 channel (530/30 nm band pass filter).
PE-labelled (Phycoerythrin) effector cells were detected in the FL2 channel (585/42 nm band pass
filter). PI (propidium iodide) was used to identify dead cells and was detected in FL3 channel
(670 nm LP band pass filter). Photomultiplier voltages were set to place the CFSE-labelled cells
within the third log decade of the FL1 channel and the first log decade of the FL2 channel. Based
on this setting, a series of voltage and compensation adjustments were made using control tubes.
Control tubes included live unstained cells, live PE+ effectors and live unstained cells with added
secondary antibody against tumour cell line (488Alexa Fluor).
Functional assay (cytotoxicity/phagocytosis assay)
A flow cytometric assay was adopted previously by Bracher et al. to quantify killing induced
by antibodies against tumour cells by monocytic effector cells [198]. The assay makes it possible to
detect the proportion of cells which have been phagocytosed by effector cells and the ones which
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have been killed by cell-mediated cytotoxicity. To distinguish between tumour cells and effector
cells they are differently labelled: tumour cells were labelled with CFSE, effector cells were labelled
with PE and dead cells were labelled with propidium iodide (PI). Tumour cells (U937 for CSPG4
and IGROV1 for MOv18) were incubated with CHX-A"-DTPA-antibody conjugates against the
FRα on IGROV1 (antibodies 1G and 1E) and CSPG4 (antibodies 3G and 3E) receptor. Effector
cells that had phagocytosed tumour cells showed a CFSE/PE double positive staining. Tumour
cells were stained with CFSE one day prior to performing the assay. Cells were trypsinised and
resuspended in serum-free medium, following another wash in RPMI 1640 medium free of phenol
red and FCS. Cells were then counted with trypan blue to check cell viability and warmed at
37°C. After cell counting, 0.75 µL CFSE per 1x106 cells were added to the tumour cells. Cells
were gently mixed and incubated at 37°C for ten minutes. Staining was stopped by washing with
serum-enriched medium and cells were stored overnight in cell culture flask until used in the as-
say. For the assay, tumour cells were trypsinised, washed in culture media and re-suspended to a
number of 100,000 cells/100 µL media. Effector cells were washed and re-suspended in different
concentrations according to the effector cell: target cell ratio of 3:1 in aliquots of 100 µL media.
Aliquots (100 µL) of each effector and target cell suspension were added and mixed in FACS tubes.
Antibodies or PBS (control), were added at a defined concentration or volume and incubated at
37°C (5% CO2) for 2.5 hours. After incubation, cells were washed once with 2 mL of ice cold FACS
buffer. After washing, 4.5 µL of anti-CD89 PE per tube was added to stain effector cells for 30
minutes at 4°C. Staining was followed by one wash in 2 mL of FACS buffer and staining with 7.5
µL of PI at 10 µg/mL for 15 minutes, 4°C. Cells were than washed in ice-cold FACS buffer and
re-suspended to 350 µL in FACS buffer for acquisition analysis on a FACSCalibur®. The analysis
was set up as described by Bracher et al. using CellQuest® software on a FACSCalibur® flow
cytometer [198]. Two dot plots were created to follow the acquisition of the events of each tube.
The different conditions were performed in triplicate. The average number of events in the region
R1 of the dot plot from the control tubes containing effector and target cells but no antibodies
was evaluated and was used as ‘R1 total events’. From this number the number of events in R1 of
the test tubes was subtracted. If the value was positive it was added to the number of events in
R3, divided into the ‘R1 total events’ and multiplied by 100. This value represents the percentage
of target cell killed by cytotoxicity. The number of target cells killed by phagocytosis is calculated
as follows: number of events in R2 divided into ‘R1 total events’ and multiplied by 100. R1 =
number of CFSE+ tumour cells; control R1 = mean number of CFSE+ tumour cells from control
tubes (n=3) given no antibody; X = (control R1 ï¿½ R1); R2 = number of PE+ tumour cells; R3
= number of CFSE/PE stained tumour cells.
3-colour functional flow cytometry assay
CFSE-labelled tumour cells were detected in FL1 (530/30 nm band pass filter), PE-labelled
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monocytic effector cells in FL2 (582/42 nm band pass filter) and PI+ dead cells in FL3 (670 nm LP
band pass filter) channels, whilst control samples were set for compensation adjustments between
fluorochromes. Two dual colour flow cytometric dot plots were generated to calculate ADCC and
ADCP as previously described [198, 13, 170]. Briefly, one dot plot depicted CFSE + tumour cells
and PI + cells, allowing quantitation of tumour targets killed externally by effector cells (ADCC,
cytotoxicity) (CFSE +/PI + cells). The second dot plot depicted CFSE + tumour cells and CD89-
PE + effector cells in order to quantitate total CFSE + tumour cells and the number of tumour
cells present within PE + effector cells, depicting phagocytosis (ADCP) by effector cells (CFSE
+/PE + cells). This dot plot would also indicate any non-specific uptake of CFSE fluorescence by
PE + U937 effector cells.
Confocal imaging of cell contact and antibody-mediated ADCC/ADCP
U937 monocytes, which served as effector cells, were incubated on Lab-Tec II glass chamber
slides (SLS Ltd, Manchester, UK) with CFSE-labelled A375 tumour cells at an original effector
cells:tumour cells ratio of 2:1. Mixed cell cultures were incubated for 3 h with antibody 3E. At the
end of the incubations, cells were then given anti-CD33-APC for 40 min at 4°C, to label monocytic
cells (U937). Cells were then washed, fixed in 4% paraformaldehyde-FACS buffer and mounted
with fluorescence preserver (Dako). Fluorescence microscopy was performed on a Zeiss Axiovert
200 confocal microscope (63x oil immersion objective). Acquisition and analysis was performed




2.3.1 SDS-PAGE prior to radiolabelling
SDS-Page was used to assess the quality of the samples of antibody 1G and 1E. Denatured and
native folded proteins were differentiated by size using electrophoresis. Degradation products
or contamination with foreign proteins of different size were made visible by protein staining of
the SDS-Gel. IgE and IgG antibodies were loaded onto a pre-cast gel (Invitrogen) reduced and
unreduced and in two different amounts. Dominant bands were expected and observed for the
reduced IgE at 80 kDa and slightly lower than 30 kDa and a lighter band is present with the
higher protein amount loaded at around 60 kDa. This result (Figure 2.1) is in accordance with the
expected full size of the MOv18-IgE of 215 kDa. Bands are present at 50 kDa and 25 kDa for the
reduced antibody 1G according to the full size of antibody 1G of 150 kDa. Unreduced antibody
1E loaded onto the gel appears in a prominent band between 160 and 260 kDa (approx. 215 kDa)
with fainter bands observed at 160 kDa and 110 kDa. Unreduced antibody 1G shows a narrow
double band at 150 kDa with faint bands at 80, 50, 25 kDa.
Figure 2.1: SDS-Page of antibody 1G and 1E (MOv18-IgG and -IgE) reduced (RED antibody
volume per lane 3 µL and 3 µL concentration 1mg/mL) and unreduced (IgE and IgG).
PM= protein marker (kDa ).
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2.3.2 Conjugation and radiolabelling analysis of antibody 1G with
DOTA-NHS-ester
At the initial stage of the project different bifunctional chelators (BFC) were considered. First
experiments were carried out with DOTA-NHS-ester chelates to assess feasibility in regards to
stability and labelling efficiency. Conjugation of antibody 1G with DOTA-NHS-ester was carried
out according to the methods described earlier. DOTA-NHS-ester is known to hydrolyse in aqueous
solutions and hydrolysis of DOTA-NHS-ester was observed on quality control assays, ITLC and
C18 column with HPLC. The results showed a high level of hydrolysis of DOTA-NHS-ester and a
low labelling efficiency. DOTA-NHS-ester was assessed and final evaluation resulted in the rejection
of DOTA-NHS-ester in favour of p-SCN-CHX-A"-DTPA.
Thin layer chromatography showed >96% labelling efficiency (Figure 2.2) with <4% detected
DOTA:indium-111 complex. The iTLC was carried out after the BFC was mixed with the antibody
at 40°C for at least 40 min.
Figure 2.2: Thin layer chromatography of indium-111 labelled DOTA-antibody 1G. Red peak shows
radiolabelled protein, green peak shows free indium-111:DOTA complex. Area under
the peaks shows a labelling efficiency of >96%.
Reverse-phase HPLC of DOTA-NHS-ester
Further evaluation of DOTA-NHS-ester BFC in buffer was performed using a reverse-phase
C18-HPLC. Products observed were DOTA (red peak, Figure 2.3) and DOTA-NHS-ester (green
peak, Figure 2.3). Both products showed a distinct retention time 1:50 min and 2:20 min, re-
spectively, on the reverse phase column on the HPLC. Figure 2.3 A and B show the degree of
hydrolysis of DOTA-NHS-ester after contact with aqueous buffer solutions (UV detection). HPLC
reverse phase analyses started 5 min after DOTA-NHS-ester was dissolved in DMSO and mixed
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with H2O. Measurements were carried out repeatedly throughout the 120 min. Figure 2.3 A and
B show changes in hydrolysis after 120 min.
A 
B 
Figure 2.3: A. HPLC C18 column UV-detection profile of DOTA-NHS-ester after solution in water.
DOTA-NHS-ester 5 min after solution in water. B. The second figure shows the hy-
drolysis process 120 min after solution in water. Retention time (RT) for DOTA=1:50
min and for DOTA-Nhs-ester=2:20 min. The region 2 (green) shows DOTA-NHS-ester
region 1 (red) shows hydrolised DOTA.
The hydrolysis process progresses at a linear rate within 105 min after dissolving in aqueous
solution (Figure 2.4). One example is the hydrolysis of DOTA-NHS-esters. For radiolabelling
antibody 1G with 111In DOTA-NHS-ester was used with a ratio of 1:20 of antibody to chelate. To
analyse the conjugation of antibody 1G with DOTA-NHS ester the antibody was radiolabelled with































Figure 2.4: Hydrolysis of DOTA-NHS-ester in % over the time course of 105 min. After 15 min
60% of the DOTA derivatives were hydrolised, after 105 min 90% of DOTA-NHS-ester
was hydrolised. HPLC measurement by γ detection of indium-111
HPLC. To remove hydrolised DOTA chelate and excess DOTA-NHS-ester, antibody 1G conjugated
with DOTA-NHS-ester was purified by PD-10 desalting columns before it was radiolabelled with
111In. It was then analysed with HPLC using a size exclusion column appropriate for the size of
the molecule (Figure 2.5).
EDTA was added to the HPLC mobile phase to prevent potentially free 111In binding to
the column. The results of the HPLC show a labelling efficiency of >76% and an EDTA: indium-
111 complex of <6%. In addition a peak of a small molecule, indicating a small protein fraction
with high UV absorption, showed a radiolabelling of <20% (Figure 2.5). The labelling efficiency
could have been improved by a purification step after the radiolabelling incubation to remove free
indium-111. But it was not possible to reach a high specific activity after repeated conjugation





Figure 2.5: Top figure shows UV-detection of the 111In labelled antibody 1G conjugated with
DOTA-NHS ester in a HPLC using a BioSep 3000 size exclusion column (Phenomenex)
and 0.1 M sodium phosphate buffer, pH 7.4 with 10 mM EDTA added. Antibody
1G=red peak (region 1), RT=8:15 min. Violet peak (region 2) at RT=10:50 eluted
as EDTA: indium-111 complex. The pink peak (region 3) is indicating a radiolabelled
protein, possibly a degradation product of antibody 1G. Bottom figure shows the par-
allel monitored gamma detection. Red peak (region 1) shows the detection of the
radiolabelled antibody at RT= 9 min, green peak shows the detection of free EDTA:
indium-111 complex at RT=10:30 min and pink peak shows a small protein fragment.
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FACS of DOTA-NHS ester conjugated antibody 1G
The flow cytometric assay compares the binding to the antigen receptor FRα on IGROV1
cells of conjugated and unconjugated antibody 1G. It was done to confirm that the conjugated
antibody’s ability to bind to the target receptor (FRα) was not affected by the conjugation. The
FACS binding assay was performed on folate receptor alpha (FRα) overexpressing IGROV-1 tu-
mour cells. IGROV-1 cells are known to down-regulate expression levels of FRα after several cell
passages. At the time IGROV-1 cells available were not selected and sorted for high expression of
FRα. The heterogenic FRα expression levels resulted in broader peaks (Figure 2.6). Binding of
DOTA conjugated antibody 1G and binding of unconjugated (native) antibody 1G was therefore
detected only partially (Figure 2.6), blue= DOTA-NHS-ester conjugated MOv18-IgG and green
line unconjugated MOv18-IgG). The fluorescent signal excited by the FACS laser and picked up
by the detector originates from a secondary antibody which has a fluorophore of a specific wave
length attached. Secondary antibodies were used to bind the human heavy chain of the chimeric
antibody 1G.
Figure 2.6: FACS binding assay on folate receptor alpha overexpressing IGROV-1 cell line. Red=
IGROV1 cells; brown=control IGROV1+ secondary AB with fluorescence marker




2.3.3 Radiolabelling of antibodies 1G and 1E conjugated to
p-SCN-CHX-A"-DTPA
SEC radioHPLC was used for quality control throughout the experiments to make sure radiola-
belling efficiency was at an optimum and ensure that a purification step could be avoided. SEC
radioHPLC showed three peaks with > 95% of activity eluted at 8.4 min for IgG (Figure 2.9) and
8.3 min for IgE (Figure 2.7), corresponding to antibody fraction, and a proportion (< 3%) eluted
at 12 min of a complex of free 111In with EDTA. In most analyses a small peak of up to 2% activity
eluted at 7.6 min for IgG and 7.4 min for IgE corresponding to aggregated antibody (see Figure
2.3 and 2.5). In figure 2.7 free indium-111 eluted at 12 min compared to figure 2.9 with 10.5 min.
The reason was that for cMOv18-IgE a guard column was used to protect the HPLC column and
this changed the elution time for 111In-EDTA. Figures 2.8 and 2.10 show the corresponding TLCs
for antibodies 1E and 1G. The TLC control with free indium can be found in figure 2.11.
Figure 2.7: Size exclusion HPLC of radiolabelled antibody 1E following conjugation with p-SCN-
CHX-A"-DTPA. Antibody 1E was radiolabelled with indium-111. Figure shows UV-
detection at 280nm (blue) and gamma ray detection (red) over time course of 16 min-
utes. Activity is mainly eluted with the antibody (t= 8.3 min, >96%) with a small
peak showing aggregated antibody at 7.4 min (<2%). Free indium-111 complex with
EDTA is eluted in a small peak (<2%) at 12 min.
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Figure 2.8: 111In-CHX-A"-DTPA- MOv18-IgE; TLC on Silica 60F with aluminium back; mobile
phase: 0.2 M citric acid, pH 2.
Figure 2.9: Size exclusion HPLC of radiolabelled antibody 1G. Following conjugation with p-SCN-
CHX-A"-DTPA antibody 1G was radiolabelled with indium-111. Figure shows UV-
detection at 280nm (blue) and gamma ray detection (red) over time course of 16 min-
utes. Activity is mainly eluted with the antibody (t= 8.3 min, >95%). Aggregation is
below 1% (t=7.6 min) and free indium-111 is below 4% (t=10.5 min).
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Figure 2.10: TLC of conjugated and radiolabelled antibody 1G. TLC on Silica 60F with aluminium
back; mobile phase: 0.2 M citric acid, pH 2. Region 1 shows radioactivity associated
with the protein. Region 2 shows free radioactivity in complex with EDTA.
Figure 2.11: TLC control with free indium-111. Region 1(red): 111In: EDTA complex, y-axis:
gamma counts; x-axis distance (mm) moved with the mobile phase on TLC strip
(10mmx 90mm).TLC on Silica 60F aluminium back; mobile phase: 0.2 M citric acid,
pH 2 with 10mM EDTA.
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2.3.4 Radiolabelling of antibodies 2G and 2E conjugated to
p-SCN-CHX-A"-DTPA
Radiochemical purity and yield were assessed by SEC radioHPLC. SEC radioHPLC of antibody 2E
showed two peaks at > 96% of activity eluted at 8.3 min, corresponding to antibody fraction, and
a proportion (< 4%) eluted at 12 min of free indium-111 (Figure 2.12). Antibody 2G (Figure 2.13)
showed a labelling efficiency of 84% with some degradation products. Radiolabelling efficiency it-
self was excellent with only 2% free indium-111. It was identified that a significant fraction (>9%)
of antibody showed accelerated degradation in storage specific to rat antibodies and resolved with
an added purification step prior to the conjugation and radiolabelling. The purification step was
added for antibody 2G and 2E.
Figure 2.12: Size exclusion HPLC of radiolabelled rMOv18-IgE, mobile phase 0.2M sodium citrate,
pH 7.4 with 10mM EDTA added. Following conjugation with p-SCN-CHX-A"-DTPA
rMOv18-IgE was radiolabelled with indium-111. Figure shows UV-detection at 280nm
(blue) and gamma ray detection (red) over time course of 16 minutes. Activity is
mainly eluted with the antibody (t= 8.3 min, >96%). 2nd peak (t=12 min) is free
indium-111 complexed with EDTA, <4% radioactivity.
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Figure 2.13: Size exclusion HPLC (mobile phase: 0.2M sodium citrate, pH 7.4 + 10mM EDTA)
of radiolabelled rMOv18-IgG. Following conjugation with p-SCN-CHX-A"-DTPA
rMOv18-IgG was radiolabelled with indium-111. Figure shows UV-detection at 280nm
(blue) and gamma ray detection (red) over time course of 16 minutes. Activity is
mainly eluted with the antibody (t= 9 min, >84%). Aggregated antibody (t=7.1
min) was observed with <9%. 3rd peak (t=12 min) was free indium-111 in complex
with EDTA at <2%. Along with the free indium-111 peak a 4th peak of degraded
antibody material elutes at 13 min (<5%).
Phosphor imaging on SDS-PAGE of 111In labelled antibody 1E
The phosphor imaging technique was used for evaluation of the radiolabelling because of
its sensitivity by relying on high energy particle decay. Phosphor imaging was able to detect
radioactivity in case it was bound to contaminating products not seen on SDS-Gel-PAGE when
dyed with a visual marker. For further validation of radiolabelling with indium-111, a Western blot
was performed and from this blot a phosphor imager was used to show co-localisation of antibodies
and 111In. Thus, not only showing the association of the radionuclide to the antibody but also
showing if any radioactivity was bound to a contaminant. Furthermore, in a reduced state of the
antibody it was possible to determine that most of the radioactivity is associated with the heavy
chain or the light chain of the antibody. IgE was loaded onto the gels in a reduced (Figure 2.14),
right line reduced and left line non-reduced) and unreduced state. It shows that 111In is completely
associated with the antibody. The reduced antibody gel shows that most radioactivity was bound
to the Fc-part of the antibody.
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Figure 2.14: Autoradiography of gel electrophoresis of indium-111 radiolabelled MOv18-IgE. Left:
Autoradiography of reduced (left lane) and non-reduced (right lane) MOv18-IgE.
Right: Picture of the SDS-PAGE Gel (Precision Gel, Thermo Fisher).
2.3.5 Study to assess the best chelate-to-antibody ratio on antibody 1G
To investigate the ideal amount of chelator to use for the conjugation reaction to give a conjugate
that could be labelled with high specific activity while not affecting its functionality, an experiment
was performed. An increasing ratio of bifunctional chelator to antibody was added in conjugation
reactions and then the ratio of chelator to antibody in the antibody conjugate was determined [199].
A further study was conducted to assess functionality using FACS. Conjugates were prepared using
5:1, 10:1, 20:1 and 40:1 ratios of chelator (p-SCN-CHX-A"-DTPA) over antibody. Each conjugate
was then radiolabelled with 111In-chloride to determine radiolabelling efficiency (Figure 2.15).
The chelator to antibody ratio was then determined by radiolabelling with a trace amount of
111In-chloride in the presence of a 10 times molar excess of ‘cold’ indium(III) chloride compared
with antibody conjugate. All antibody conjugates showed a high labelling efficiency of >95% on
average, with exception of the 1:40 ratio, with a drop down to an efficiency of >84%, showing
<16% of unconjugated indium-111 impurities, most likely excess 111In bound to chelator that was
not removed during the purification steps in the conjugation process. The average number of
chelators bound per antibody when increasing amounts of bifunctional chelator were added to the
conjugation reaction are shown in table 2.2. The fall in the number of chelators per antibody
when a 40 times molar excess of CHX-A"-DTPA was used probably reflects the fact that there is
still chelator present in the antibody conjugate solution rather than a real drop in the number of
ligands per antibody. However, this indicates that at high molar ratios of bifunctional chelator,
purification becomes increasingly difficult and hence, to optimise the reaction a slightly lower molar
ratio (e.g. 1:20) of chelator to antibody should be used.
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Figure 2.15: iTLC-SA of MOv18-IgG conjugated with 1:5, 1:10, 1:20 and 1:40 excess of p-SCN-
CHX-A"-DTPA over antibody and radiolabelled with 111In. Chromatogram shows a
labelling efficiency of >97% for 1:5 excess of chelate, >99% for 1:10, >96% for 1:20
and >84% for 1:40 ratio of mAb to chelate. Red = radiolabelled antibody; green =




Table 2.2: Different ratios investigated for optimal ratio of antibodies to chelators (1:5, 1:10, 1:20,
1:40). The specifically bound 111In added with 10 fold excess of indium(III) in percent
of labelling efficiency. Chelates (p-SCN-CHX-A"-DTPA) attached to the antibody on
average.
2.3.6 Stability of conjugated Antibodies in human serum
To test the stability of the antibody in similar environment as in vivo experiments, the antibodies
were incubated with human serum and analysed by size exclusion HPLC. At certain time points
a sample was taken to look for radioactivity associated with the antibody or other serum proteins
and if any radioactivity has become dissociated from the antibody conjugate. This assay is one
indicator of likely stability in vivo. Over the 120 h time course of the stability assay (Figure 2.16),
there was no evidence of instability of the radiolabelled antibody conjugates. For 111In-labelled
antibody 3G there was a slight decrease in the amount of activity associated with the antibody
conjugate after 120 h, (89% of radioactivity being associated with antibody at this time point)
with the remaining activity being associated with a shoulder on the main elution peak of antibody
3G which is possibly related to indium-111 binding to serum proteins but could be an artefact of
the HPLC since the levels of radioactivity were quite low for detection. The activity associated
with antibody 3E (anti-CSPG4-IgE) and antibody 1E (MOv18-IgE) remained unchanged at 100%
during all measurements although slight shoulders appeared to be present on the main antibody
peaks possibly an artifact of the HPLC analysis since the levels of radioactivity are quite low. The
amount of activity associated with the shoulder was difficult to quantify but was <10% of the total
activity in all cases.
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Figure 2.16: Serum stability SEC radioHPLC of 111In labelled anti-CSPG4-IgE, -IgE and MOv18-
IgE after 120 hours after incubation with human serum at 37C.
60
2.3 Results
2.3.7 FACS of CHX-A"-DTPA conjugated antibody 1G
To investigate the ideal amount of chelator to use for the conjugation reaction the above described
experiments were conducted. To further investigate interference of the conjugation reaction with
antibody functionality and binding to the target receptor FACS analysis were performed. To detect
possible changes in the affinity, conjugated antibody 1G was compared to its unmodified equivalent,
using FACS binding assays to the target receptor (FRα) overexpressing cell line IGROV1. To assess
possible effects of the conjugation reaction on the functionality and FcγRI receptor binding, FACS
binding studies with a monocyte cell line U937 were performed. This study was conducted to assess
the optimal chelate to antibody ratio. Antibodies which were conjugated with 1:5, 1:10, 1:20 and
1:40 fold excess of chelate in the conjugation reaction and which resulted in 1.2, 2.07, 3.22 and 2.63
chelates per antibody on average (Table 2.2), respectively, were compared to unconjugated native
antibody. All conjugated antibodies were used without any radiolabelling.
Figure 2.17: Graph shows the binding of antibody 1G to the folate binding receptor (FRα) on
the surface of IGROV1 cells in different chelator-to-antibody ratios. Unconjugated
and conjugated antibodies did not show any difference in the binding of the FRα.
Black= IGROV1 native antibody (cell line without antibody 1G or secondary anti-
body added); blue= control IGROV1+Secondary antibody with attached fluorescence
marker; orange= 5:1 ratio chelator-to-antibody ratio; green= 10:1; dark green= 20:1;
violet= 40:1 and red= unconjugated native antibody 1G
Figure 2.17 compares the binding to the target FRα receptor, expressed on the surface of
IGROV1 cells, of CHX-A"-DTPA conjugated antibody 1G to its native unconjugated antibody
1G. The antibodies were conjugated with different molar ratios of chelator in excess as shown in
table 2.2. The different conjugates of antibody 1G were compared to unconjugated antibody 1G
and are represented in the different coloured lines with chelate-to-antibody ratio of 5:1 (orange),
10:1(green), 20:1(dark green) and 40:1 (violet). The conjugated antibody 1G shows the same shifts
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Figure 2.18: Graph shows the binding of CHX-A"-DTPA conjugated antibody 1G to the FcγRs
of U937 cells (monocytes cell line) in different chelator-to-antibody ratios (molar ex-
cess of chelate used in conjugation reaction). Black= U937 (base line of U937 cells);
blue= U937+Secondary Antibody with fluorescence marker; pink= 5:1 ratio chelate-
to-antibody 1G; orange= 10:1; dark green= 20:1; violet= 40:1 and green= unconju-
gated antibody 1G.
at all ratios as the native version of antibody 1G. The shift is a result of positive excitation of the
bound fluorophores when positive binding to the cell is detected. Similar shifts of unconjugated
and conjugated antibody 1G derivatives show, therefore, positive and comparable binding.
In figure 2.18 the binding of the FcγRI of conjugated antibody 1G to the FcγRI-receptor on
the surface of U937 cells was shown positive when compared to the control (black) and the cell line
+ the secondary antibody with fluorescence marker (light blue). Unconjugated and conjugated
antibody 1G showed the same shift in this FACS assay. However, a slight downshift in binding
for the antibody 1G with a chelate-to-antibody ratio of 40:1 was detected when compared to the
unconjugated antibody 1G could be interpret that the number of chelators present is beginning to
affect binding to target cells at this chelator-to-antibody ratio.
2.3.8 FACS of CHX-A"-DTPA conjugated antibody 3G and 3E
Here, the same process of binding assessment described above was followed with the antibody 3G
and 3E. To detect changes in affinity and binding of the antibodies 3G and 3E after the conjugation
with 20-fold molar excess of chelator used in the conjugation and which resulted in ∼3.22 chelates
per antibody on average (Table 2.2), a flow cytometric binding assay was carried out. The FcγRI
expressing cell line U937 was used to show binding of antibody 3G, conjugated with CHX-A"-
DTPA, via the Fc-receptor (Figure 2.19). Furthermore, a FACS binding study was performed
with both CHX-A"-DTPA conjugated versions of the antibodies 3G and 3E on an A375 cell line
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which overexpresses the chondroitin sulfate proteoglycan 4 antigen (CSPG4). Positive binding on
the A375 cell line and comparison to FACS data on native unconjugated antibody 3G and 3E
versions (unconjugated antibody control not shown, data from Panos Karagiannis) showed that
the binding was unaffected by the conjugation reaction for both conjugated antibodies 3G and 3E
(anti-CSPG4-IgG and -IgE), respectively (Figure 2.20). Conjugated antibody 3E was analysed by
two different flow binding assays to show unaffected binding to the high affinity FcεRI-receptor and
the low affinity FcεRII receptor on primary monocytes (Figure 2.21). CHX-A"-DTPA conjugated
antibody 3G and 3E showed a clear positive binding to their specific receptors, both, via the FcR
and the target receptor FRα. The conjugation of both antibodies with the bfc p-SCN-CHX-A"-
DTPA using a 20 fold molar excess of chelator resulted in ∼3.22 chelates per antibody on average.
It was successfully shown that the binding capacities via FcR and to the antigen receptor were
fully functional.
Figure 2.19: Graph shows the binding of p-SCN-CHX-A"-DTPA conjugated anti-CSPG4-IgG anti-
body to the FcγRI-receptor of U937 cells. Blue= CHX-A"-DTPA conjugated antibody
3G (anti-CSPG4-IgG) on U937 cells; red= U937 cells + Secondary Ab with attached
fluorescence marker as control.
63
2.3 Results
Figure 2.20: Graph shows the binding of CHX-A"-DTPA conjugated antibody 3E (anti-CSPG4-
IgE) (left) and antibody 3G (right) on A375 cells overexpressing the target antigen
receptor chondroitin sulfate proteoglycan 4. Red= control secondary antibody with
attached fluorescence marker + A375 cells; blue= Antibody 3G or 3E conjugated with
CHX-A"-DTPA.
Figure 2.21: Graph shows the binding of conjugated antibody 3E to the high affinity FcεRI (left)
and the low affinity FcεRII (right) on primary monocytes expressing FcεR recep-
tors (monocytes were recovered from an anonymised patient melanoma skin sample).
Red= control shows secondary antibody with fluorescence marker attached + A375
cells; blue= antibody 3E conjugated with CHX-A"-DTPA.
2.3.9 ADCP/ADCC assay
The tumour cell killing properties of the CHX-A"-DTPA conjugated antibody 3E were evaluated
using the three colour flow cytometric functional assays. The assay assessed the ability to mediate
tumour cell killing by human effector cells and is able to distinguish tumour cell killing by ADCC
and ADCP (Figure 2.22). Antibody 3E directed monocytic cells to kill tumour cells expressing
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the CSPG4 antigen by ADCC, a mechanism clearly different from ADCP typically employed by
antibody 3G and monocytic cells. The antibody concentrations (0.5 µg/mL) required to achieve



























Figure 2.22: Evaluation of antibody 3E (anti-CSPG4-IgE) targeted against CSPG4 overexpress-
ing A375 cancer cells in presence of monocytes (U937). Quantification of ADCC
and ADCP using CHX-A"-DTPA conjugated versions of antibody 3G (anti-CSPG4-
IgG) and antibody 3E (anti-CSPG4-IgE). Both antibodies mediated killing of CSPG4
expressing target cells by U937 monocytes after 2.5 h in the ADCC/ ADCP assay.
Cytotoxicity: black bars; phagocytosis: grey bars. Results are means ± SD. Results
compared to isotype control IgG and IgE antibody or no antibody control samples.
2.3.10 Confocal imaging of CHX-A"-DTPA conjugated antibody 2E
The tumour-targeting activities of CHX-A"-DTPA conjugated antibody 2E were studied by confo-
cal microscopical imaging (Figure 2.23 B). IGROV1 cells (FRα expression) were pre-labelled with
CFSE (green), incubated with U937 cells which were labelled with anti-CD33-APC (blue). Next,
both cell lines were combined with either the FRα antigen specific and CHX-A"-DTPA conjugated
antibody 2E or an unspecific IgE control antibodies for 3 h on glass chamber slides. In samples
incubated with antibody 2E, contact between IGROV1 tumour cells and U937 monocytic cells,
was clearly evident, and two or more monocytic cells were frequently observed in contact with or
in close proximity to a single tumour cell. Tumour cell killing was observed and visualised by the
appearance of red stained dead cells and the reduction of IGROV1 tumour cell appearance (green).
In contrast to the observations with conjugated antibody 2E the unspecific control IgE did not
mediate or enhance any tumour cell killing (Figure 2.23 A).
65
2.3 Results
Figure 2.23: Representative confocal fluorescence images of tumour-effector cell interactions me-
diated by antibody 2E. CFSE-stained IGROV1 FRα expressing tumour cells (green)
and CD33-APC labelled U937 cells (blue) combined at 2:1 E:T ratio after 3 h in
culture. U937 cells (blue) given antibody 2E (B) showed enhanced contact with tu-
mour cells (green) and killing of tumour cells (dead cell population in red). Neither
effector-target cell contact nor phagocytosis was observed when cells were incubated
with isotype controls (A). Original magnification x63 (Scale bar 15 µm).




Both IgG and IgE classes of antibodies were conjugated to the bifunctional chelator, p-SCN-CHX-
A"-DTPA, and radiolabelled with indium-111. The impact of the conjugation on antibody function
and integrity was investigated. As part of this process, the method for conjugation was optimised
to achieve a high enough chelator to antibody ratio in the antibody conjugates to afford high
radiolabelling efficiency whilst retaining biological activity. The conjugation and radiolabelling of
the IgE class of antibodies has not previously been described in the literature so it was essential
to ensure that binding and functionality were retained by comparing these antibody conjugates to
their unconjugated native and IgG counterparts.
Prior to conjugation, antibodies were assessed by SDS-PAGE for contamination and degra-
dation. All antibodies used within the project corresponded to the expected size of an intact
monoclonal IgG antibody (approx. 150 kDa) or IgE antibody (190 kDa). In addition, all antibod-
ies were also loaded on the SDS-PAGE in a reduced form and results showed the characteristic
bands at 25 kDa and 50 kDa corresponding to the light and heavy chain of IgG, respectively.
Intact IgE showed intact bands at 190 kDa due to alternative glycosylation [200] and light contam-
ination around 25 kDa. Alternative glycosylation in IgE is thought to play a role for the correct
three-dimensional folding of the protein [201].
The reduced antibody 3E (anti CSPG4-IgE) resulted in corresponding bands at 25 kDa
and 70 kDa, respectively with light contaminations around the 50-60 kDa mark. Light chain
contamination was expected by the antibody supplying team and seen before in experiments and
described in literature [202, 203]. The IgG and IgE antibody production for anti-CSPG4 (antibody
3G and 3E) and MOv18 (antibodies 1G/E and 2G/E) antibodies used in this project was based on
a two vectors system. Vectors, one for heavy chains and one for the light chains, were introduced
to a HEK293 eukaryotic cell production system. The heavy chain is synthesised more slowly
than for the light chain because the light chain plays a crucial role in the intracellular folding
of the heavy chain. The light chains possesses five cysteine residues, four of them are involved
in two disulfide bonds that stabilise the variable (V) and constant (C) domains respectively, and
a carboxyl terminal cysteine that is responsible for the intermolecular disulfide bond to the Ig
heavy chain. It is, therefore, desirable to offer light chain polypeptides in a higher quantity that
ensure the maximum of correctly folded antibodies can be yielded in production [203]. Since the
contamination with light chain fragments was very low a re-purification was disregarded because of
first the resulting additional loss of protein for each additional purification step. All radiolabelled
antibodies used in later experiments were evaluated in the same way and proved to be intact, at
the right size and pure.
Initial conjugations were carried out using DOTA-NHS ester. However, it was found that
extensive hydrolysis of the ester during the conjugation reaction led to poor conjugation and low
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radiolabelling efficiency. The pure solid form of DOTA-NHS contains a few water molecules in the
crystal lattice and undergoes significant autohydrolysis at a rate depending on the storage temper-
ature. To obtain a consistent conjugation ratio between DOTA and the antibody, the percentage of
intact DOTA-NHS, which varies with batches as well as with time, must be accurately determined
prior to the well-controlled conjugation. The unactivated free DOTA does not contribute to the
conjugation, and has to be discounted in calculating the molar input of DOTA-NHS for the reac-
tion. Due to DOTA-NHS’s ease of hydrolysis back to DOTA, the comparison of different batches
of DOTA-NHS is difficult; a straight forward and not too time consuming quality control scheme
could not be used in this analysis [204]. Furthermore, once mixed with aqueous buffer solutions,
DOTA-NHS hydrolysis reaction is a first-order reaction because H2O is in large excess.
Another reason for discarding the DOTA-NHS in favour of p-SCN-CHX-A"-DTPA was that
HPLC data of the DOTA-NHS conjugated antibody 1G showed another small radiolabelled protein.
This indicated antibody degradation, most likely triggered by the extended incubation period at
40°C of the DOTA conjugated antibody with indium-111 chloride. Therefore, it was decided instead
to adopt the conjugation protocol of Cooper et al. [197] using the isothiocyanobenzyl derivative
of DTPA, p-SCN-CHX-A"-DTPA. It was important to try to achieve high radiolabelling efficiency
such that the antibody could be labelled to high specific activity for in vivo imaging. Therefore,
the conjugation method was optimised by adjusting the molar ratio of chelator to antibody added
during the conjugation reaction. It was found that a 20 times molar excess of chelator over antibody
gave optimum results in terms of final chelator to antibody ratio in the antibody conjugate (2.6:1)
whilst retaining biological activity, as assessed in binding studies compared to the native antibody.
Higher molar ratios of chelator in the conjugation reaction led to two main problems. Firstly,
it was difficult to remove the excess chelator from the antibody conjugate at the end of the conju-
gation reaction. Purification was carried out by using ultracentrifugation in Vivaspin centrifugal
concentrator tubes. However, the excess chelator had a tendency to stick to and block the ul-
tracentrifugation tube membrane and would leach back into the solution containing the antibody
conjugate, therefore making it difficult to remove, and more extensive washing was required. Since
the method would need to be translated to clinical scale production later for clinical trials, the
method needed to be as straightforward as possible so extra purification steps were unwanted and
would have been detrimental to translation to clinical production. The second problem was that
at higher chelator to antibody ratios, it was noted that there was a decrease in the binding of the
antibody with the conjugation ratio of 1:40. Conjugation is via the lysine residues in the antibody.
Initially the most accessible lysine residues are used for the conjugation and, as the chelator excess
is increased, the less accessible lysine residues begin to get conjugated. If these less accessible
lysine residues are in the binding region of the antibody then increasing the chelator to antibody
ratio can lead to a decrease in binding to the target receptors. Additionally, steric hindrance due
to bulky chelator groups close to the binding region of the antibody will have a similar effect.
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The average number of chelators attached to each antibody was calculated for the dif-
ferent conjugates prepared (where different ratios of chelator to antibody had been used in the
conjugation reaction). Several methods for determining the ligand-to-antibody ratio for chelates
that bind radiometals have been described in the literature including tests utilising radionuclides,
matrix-assisted laser desorption/ionisation time of flight (MALDI TOF) mass spectrometry (MS),
ultraviolet/visible light (UV/VIS) spectrometry, electrophoresis and terbium fluorescence (TF)
[205–209]. The method used in this project was based on the published method of Langford et
al. [199] which uses a 57Co assay. This was adapted to use trace amounts of 111In with a known
excess of indium(III) over antibody rather than using cobalt.
A main limitation of the analysed chelate to antibody ratio is that the average of chelators
per antibody is measured. This describes a heterogenenous population of chelators per antibody.
Antibodies with more chelators attached are more likely to show loss of binding or affinity and
functionality but will account for a larger amount of radioactivity. Therefore, the results can lead
to a under estimation of the damage to function when function is measured using the antibody
conjugate rather than the radiolabelled antibody. The here shown assays were not able to detect
this ‘average’ effect and the consequences may be under-estimation of this effect on the functionality
and binding of the antibodies.
To investigate the binding ability and antibody functions translated by the FcR binding
region of anti-CSPG4-IgG and -IgE (antibody 3G and 3E) and MOv18-IgE (antibody 1E) in
regards to the optimal antibody to chelate ratios, FACS binding studies and a 3-colour FACS
functional assay were performed. Since the bifunctional chelator p-SCN-CHX-A"-DTPA was at-
tached non-specically to any lysine and terminal amine within the amino sequence of the antibody,
it was possible that the chelator would attach to lysine or terminal amine within the antibody’s
complementarity determining regions (CDRs) or FcR binding regions. This would influence the
antibody’s ability to bind to the antigen with the same affinity as the unconjugated FcR binding
region. Therefore, binding studies and functional studies of the radiolabelled antibodies (antibod-
ies 1G, 1E, 3G and 3E) were performed to show full binding and functionality of all employed
antibodies. All binding and functional FACS studies showed positive results for conjugated anti-
CSPG4-IgE and -IgG and MOv18-IgE antibodies. Only the 40 fold molar excess of chelate used in
the conjugation showed slight interference with slightly off-peak results compared to unconjugated
antibody counterparts.
All antibody conjugates were labelled with high efficiency as assessed by both instant thin
layer chromatography (ITLC/TLC) and size exclusion high performance liquid chromatography
(SEC HPLC). Results showed a minimum of 95% of the radioactivity associated with the antibody
for all antibody conjugates. A 95% yield was considered as a successful radiolabelling antibody
batch - suitable for clinical use. Antibody aggregation if seen at all was always less than 1% of
the overall batch in terms of radioactivity, which is excellent since antibody aggregates can lead to
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higher liver or kidney accumulation of the antibody compromising diagnosis and giving unnecessary
radiation dose to the liver or kidney. In the SEC HPLC system, unchelated indium-111 complexes
with EDTA, which was added to the mobile phase. The 111In-EDTA complex is well resolved
from the antibody peak and elutes somewhat later. The unchelated indium-111 never exceeded
4% of the overall radiolabelling. This excellent radiolabelling yield meant that the conjugation and
radiolabelling methods employed were suitable both for in vivo imaging and for later translation
into the clinic.
The overlaying signal from the gamma detector and UV detector showed, as expected,
an association of radioactivity with the protein. The delay in signal between the two detectors
(maximum of 30 seconds) results from the fact that the detectors are in-line with the UV detector
before the radionuclide detector.
Throughout this project, radiolabelled antibody was not used for further experiments unless
radiolabelling efficiency was above 95%. Radiolabelling efficiency below this would have required
an additional purification step which was undesired. The streamlined conjugation and labelling
process was one of the main aims. It was important for a future clinical translation that the
production steps were kept to a minimum to enable a straight-forward production at the clinical
site. It was necessary to develop a method that would allow the labelling without the use of
specialised equipment and training rather than production off site associated with higher costs,
time and transport limitations. For laboratory research it was important to keep antibody loss to a
minimum. The antibody 3E (anti-CSPG4-IgE) and even more the antibody 1E & 2E (MOv18-IgE
human/mouse and rat mouse chimeric) were only available at limited quantity due to more difficult
production. Purification or wash steps were associated with a loss of about 0.5 to 1 mg of antibody
unrelated to the original stock amount to begin with. The high loss of protein was mainly caused
by the protein sticking to the Vivaspin 2 centrifugal concentrator membrane. Later, Hydrosart
membrane by Vivaspin 2 centrifugal concentrator replaced the polyethersulfone membrane and
reduced initial loss of up to 1mg per wash step to about 0.5 mg or less.
The radiolabelled antibody (anti-CSPG4 and MOv18) reaction mixture was intended for
use directly for i.v. injection into the in vivo models (see chapter 3 and 4). The final pH of
the radiolabelled antibody solutions was approximately pH 6, which was not expected to affect
the in vivo models negatively in any way. The radiolabelled antibody formulations (buffers and
radionuclide) used have previously been used for injection into patients in clinical trials and are
pharmaceutically acceptable [210].
Stability in human serum of 111In-anti-CSPG4-IgE and -IgG and -MOv18-IgE (antibodies
1G, 1E, 3G and 3E) was analysed using SEC HPLC. HPLC showed that labelled IgE and IgG
antibodies were fully intact and radiolabel remained with the antibody throughout the 120 h time
course; however after 72 h all peaks identified as antibodies developed a small shoulder. This
shoulder seemed to show a slow and only partial degree of degradation described in literature by
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Jones et al. and Rogers et al. [211, 212]. They concluded that about 35% of the radioactivity
found in the liver originated from antibody labelled 111In-DTPA in the form of the degradation
product 111In-DTPA-ε-lysine. In the study by Jones et al.[211] looking at metabolites of an IgG
antibody conjugated with DTPA and labelled with 111In, four distinct degradation products were
identified:(i) greater than 400,000 Da; (ii) 150,000 Da; (iii) 15,000-50,000 Da; (iv) and less than
10,000 Da. Overall degradation seen with human serum was between 0% and ∼10% for all anti-
bodies IgG and IgE. Degradation was difficult to quantify because elution peaks became broader
or showed a small shoulder not easily defined for quantification. The size exclusion column used for
HPLC does not have the ability to clearly resolve the full antibody from the degradation products.
The shoulder observed associated with the main antibody peak on the HPLC traces may have been
as a result of degradation products described by Rogers et al.[212], but without further analysis it
would be difficult to determine if this was the case. However, it is clear that the labelled antibodies
are very stable in serum for a prolonged length of time and therefore it was deemed appropriate
to move forward to in vivo studies based on these results.
At the early stage of the project, radiolabelled samples of MOv18-IgE were run on a SDS-gel
followed by autoradiography using a phosphor imager. Data showed an association of 111In with
the antibody. Standard SDS-PAGE with radiolabelled MOv18-IgE was followed by an autoradio-
graphy. A marker spotted with radioactivity at 190 kDa, 25 kDa, and 90 kDa was than aligned to
the results and compared to the SDS-gel. This showed that nearly all radioactivity was bound to
the MOv18-IgE antibody and especially within the Fc-region of the IgE where most lysine amino
groups were located as described in literature [34, 213]. Lysine and terminal amines are the re-
active groups for the attachment of the p-SCN-CHX-A"-DTPA bifunctional chelator. Sayers et
al.[213] described not only high lysine content in the low affinity receptor area (CD23-receptor) but
a complete loss of function depending on the lysine Lys-352 [213]. However, the constant domain
in IgE antibodies replacing the hinge region known from IgG is folded back onto the remaining
constant domains of IgE and undergoes a conformational change only when bound to a FcR. This
might protect the FcεRI and FcεRII and the lysine within the receptor region so they are not
accessible to reactive groups of the BFC [49, 213, 55].
2.5 Conclusion
Overall, the main aims for this part of the project were met. All antibodies were successfully
conjugated, the conjugation was optimised and is robust and straightforward enough for later
translation into the clinic. Radiolabelling efficiency was excellent (>95%) for all antibodies, the
radiolabelled antibodies were stable in serum and all antibodies retained functionality of binding
the target receptor to FcεRI and FcεRII. Therefore, it was possible to move onto the next stage of
the project, in vivo imaging.
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3.1 Introduction
IgE is a class of antibodies with prolonged tissue half-life and commonly associated with allergies.
IgE has a very strong affinity to particular FcR receptors on effector cells, like FcεRI and FcεRII,
which potentially make IgE class antibodies attractive as a cancer therapeutic. In this chapter in
vivo imaging and biodistribution studies were used to research IgE class antibodies and to compare
them to their IgG counterpart, investigating the biodistribution and in vivo trafficking of cancer
targeted IgE.
IgE is known for its powerful immune responses from allergic reactions, which differs from
IgG class antibodies used as the main antibody class in cancer therapy today. IgE and IgG are
also known to have oppositional half-lives, with IgG having a long half-life in serum and IgE a long
half-life in tissues. Different modes of action are based on the different Fc-receptors of IgE and
IgG and the subsequent difference in recruiting an immune response.
The induction of the immune response follows an allergic-like reaction mediated through
the interaction of IgE with FcεRI on the surface of effector cells. The affinity of IgE for its high
affinity receptor, FcεRI (Ka =1011 M-1), is two to five orders of magnitude higher than that of IgG
for the FcγRs (FcγRI-III) [34, 214, 45]. Its affinity for the low affinity receptor, CD23 (Ka=108
M-1), is as high as that of IgG for FcγRI [45]. The binding of IgE with its Fc receptors has been
shown to efficiently recruit mast cells and basophils and other effector cells compared to IgG class
antibodies [44, 170]. As described for allergens [44], tumour cells are thought to bind IgE and
crosslink the receptors leading to rapid degranulation of these effector cells, resulting in the release
of multiple factors, including histamine, enzymes, and lipid mediators as seen in IgE mediated
(allergic) inflammatory responses [45, 44, 170, 215, 216].
More precisely, IgE antibodies used for this project that target the chondroitin sulphate
proteoglycan 4 (CSPG4) overexpressed on A375 tumour cells showed in vitro and ex vivo superior
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anti-tumour efficacy compared to the IgG version in an in vivomouse xenograft model (efficacy data
provided by P. Karagiannis, Cutaneous Medicine and Immunotherapy Unit, St. John’s Institute
of Dermatology, Division of Genetics and Molecular Medicine, KCL).
The anti-CSPG4-IgE antibody and mouse tumour model used for the efficacy studies (Figure
1) was here used in NanoSPECT/CT imaging and biodistribution studies to show organ distribu-
tion, targeting and clearance and to compare them to those of its IgG counterpart.
Figure 3.1: Efficacy study of CSPG4-IgE, CSPG4-IgG, unspecific chimeric IgG and IgE and PBS
control in a NOD/SCID mouse model with engrafted human peripheral blood lympho-
cytes (hPBMCs) over time (days) comparing tumour growth inhibition. CSPG4 IgE
restricts growth of an A375 human melanoma xenograft grown subcutaneously com-
pared to CSPG4 IgG1 (***p<0.001) and non-specific antibody isotype controls when
administered intravenously in a humanised mouse model with splenic engraftment of
human immune effector cells.
3.1.1 The chondroitin sulphate proteoglycan 4 (CSPG4) target receptor
Human chondroitin sulfate proteoglycan 4 (CSPG4), originally named high molecular weight-
melanoma-associated antigen (HMW-MAA) or melanoma chondroitin sulfate proteoglycan (MCSP),
was first identified 30 years ago on human melanoma cells [75]. CSPG4 is a cell surface proteoglycan
that consists of an N-linked 280 kDa glycoprotein and a 450 kDa chondroitin sulfate proteogly-
can [81, 217, 218]. Stallcup and colleagues identified in the rat an ortholog of CSPG4 termed
nerve/glial antigen 2 (NG2) (Stallcup, n.d.). CSPG4 and NG2 are highly conserved, and concepts
regarding the significance and functions of CSPG4 are based on studies from both orthologs. It is
73
3.1 Introduction
important to mention that complete structural/functional comparisons between each ortholog are
still in process.
CSPG4 and NG2 are expressed in a number of normal tissues throughout development,
suggesting an important role in the development and homeostasis of adult tissues [81, 219]. NG2
has also been found to play an important role in the development of vascular tissue, as it is
expressed by angiogenesis-associated pericytes (both normal and pathologic) and mice lacking
NG2 have defective vasculature [220, 221]. Expression of CSPG4 and Ng2 in several pluripotent
progenitor cell populations also indicates a role for CSPG4 in tissue development and stem cell niche
maintenance. CSPG4 is detected in stem-like cells associated with the interfollicular epidermis,
where it regulates the position and motility of these progenitor cells [222, 223]. CSPG4 has a
high expression in >80% of primary and metastatic melanoma lesions and limited interlesional
and intralesional heterogeneity. Because of this and its restricted distribution in normal tissues, it
has been successfully used as a marker to locate melanoma lesions with radiolabelled monoclonal
antibodies (mAb) and as a target of immunotherapy [73, 224].
CSPG4-positive stem cells in the epidermis are important for the renewal of epithelial ker-
atinocytes. CSPG4/NG2 is also expressed in both fetal and adult articular chondrocytes [225, 74],
bone marrow mesenchymal cells [226], and smooth muscle cells [227, 228]. CSPG4 is expressed on
melanocytes, although at levels lower than what is seen on most melanomas [229, 230, 81, 231].
CSPG4 is associated with the progression of various cancers other than melanoma including
oligodendrocytomas, gliomas, triple-negative breast carcinomas, and squamous cell carcinoma
[74, 232].CSPG4 seems essential to the growth of melanoma tumours aiding it in form of modula-
tion of integrin function and enhanced growth factor receptor regulated pathways like activation
of ERK 1,2. This activation of integrin, RTK, and ERK1,2 function by CSPG4 modulates numer-
ous aspects of tumor progression. CSPG4 expression has further been correlated to resistance of
melanoma to conventional chemotherapy [74].
3.1.2 Tumour models
There are significant limitations in the use of animal models. The most important reason is the
fact that human IgE does not interact with rodent FcεRs and there is a distinct difference in
cellular distribution of FcεRs in humans and rodents [164, 44]. The expression of murine FcεRI
is restricted to mast cells and basophils while human FcεRI is expressed on mast cells, basophils,
eosinophils, monocytes, Langerhans cells, and DC [6]. Compared with murine expression levels of
FcεRI on mast cells and basophils the human cell types show higher expression levels of FcεRI [6].
Despite the limitations different rodent models have been used with success to evaluate the in vivo
anti-cancer activity of several IgE antibodies. These models include wild-type immunocompetent
animals bearing syngeneic tumours, xenograft models using immunocompromised mice bearing
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human tumours and reconstituted with human effector cells, and human FcεRIα transgenic mice
bearing syngeneic tumours [164, 41, 42, 13, 233, 58]. Immunocompetent syngeneic in vivo rodent
models using tumour cells from the same genetic background are commonly found in literature to
evaluate antibody-targeted therapy.
Xenograft models are an alternative approach to the described syngeneic studies in in vivo
models. This type of model is based on the use of human cancer cells in order to assess the
anti-cancer efficacy. These types of models are the preferred option when studying the efficacy
of species specific monoclonal antibodies. Animals used in these xenograft studies are commonly
immunocompromised. Severe combined immunodeficiency (SCID) in nude mice that have impaired
cellular and humoral immune responses is one of the best known and most commonly used in vivo
models with immunosupressive gene defect. Although xenograft models allow the transfer of human
tumour grafts to an animal model, these models cannot be used to evaluate the adaptive immune
response elicited by immunotherapies, including therapeutic antibodies. Moreover, these models
cannot be used to examine the anti-cancer activity triggered by human IgE effector functions
because of their lack of interaction with murine FcεRs [164].
Despite the limitations, previously published results have highlighted the applicability of
this type of animal model in some respects, showing at the same time anti-cancer effects of a
tumour-specific IgE [234].
3.1.3 NOD/SCID/Il2rg-/- mouse model employed for the experiments in
this study
To investigate and compare the anti-tumour efficacy of anti-CSPG4-IgE and -IgG and to overcome
some of the limitation of commonly used in vivo model described earlier an immunocompromised
(NOD/SCID) mouse model with genetic deficiency of regulatory T cells (NOD/SCID/Il2rg-/-) was
used. Commonly referred to as NSG mice, they lack mature T cells, B cells, and natural killer
(NK) cells. NSG mice are also deficient in multiple cytokine signalling pathways, and they have
many defects in innate immunity [235–237]. NSG mice were injected with human peripheral blood
mononuclear cells (PBMC) to provide the mice with a human immune effector cell function that
was known to show splenic engraftment [238]. This NOD/SCID mouse model was used for all
in vivo experiments in this chapter, including the efficacy study (Figure 3.1), biodistribution and
imaging studies. The animals were tested for splenic engraftment to make sure only animals with
successful engraftment of PBMC and steady proliferation and supply of human immune effector
cells were used in the experiments.
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3.1.4 Biodistribution & Imaging
To help to identify the role of IgE in a tumour disease process that showed antibody efficacy in
vivo and to understand more of the IgE interactions or modes of actions in vivo, imaging and
biodistribution studies were performed. The mechanisms that lead to IgE mediated anti-tumour
activity in vivo are not well understood. Biodistribution of IgE used as an immunotherapeutic
agent has not been investigated. Careful assessment of IgE biodistribution in a relevant (therapeu-
tic) tumour model and direct comparison to the corresponding IgG are likely to provide further
insight into the mode of action. Radionuclide imaging and ex vivo biodistribution studies with
radiolabelled antibodies might represent a critical bridge between discoveries at the molecular level
and implementation of clinically relevant diagnostics or therapeutics [26]. Based on differences on
the FcRs, size and metabolism of IgE and IgG, the kinetics of biodistribution and clearance for
IgG and IgE were expected to show different biodistribution [239–242].
The main aim of the overall project was to develop and translate IgE based therapeutics
into a clinical application. In vivo imaging and biodistribution tests are a critical part of this
preclinical development as they offer important insight on how IgE provides anti-tumour effects
in vivo. Additionally, they can provide valuable animal pharmacokinetic and pharmacodynamic
information that can be used to plan the starting dose and schedule of subsequent first-in-man
studies. Animal pharmacokinetic data including absorption, distribution, metabolism and organ
distribution were thought to help to predict and avoid adverse drug interactions [147, 169].
3.1.5 Factors governing the biodistribution of IgE antibodies
While very few data are available on the elimination pathways of therapeutic IgG and IgE type
monoclonal antibodies, there can be some data found on IgE serum and tissue half-life in general.
The half-life of IgE in human serum is found in literature with variations ranging from 1.5 to 3
days and everything in between. Most publications seem to suggest a compromise of 2 or 2.5 days
as IgE serum half-life for humans [45–47, 42, 48, 49]. The half-life of IgE in tissue or cell-bound
was found in literature to be 14 days based on measurement of IgE in skin of rats [48] and based on
the affinity calculations for the interactions of the FcεRI with its corresponding receptors [45, 49].
For rodents, however, less data are available on the serum half-life of IgE antibodies. IgE half-life
in rodents is reported as 5-12 hours. Haba et al. into the clearance of IgE in mice [46] found a
half-life of 1-2 hours initially after injection. A longer half-life of 5-8 hours and a slower clearance
were later (5 hours post injection) measured. In agreement with its function in humoral immunity
IgG has a long serum half-life of ∼20 days and ∼2-3 days in tissues. This is to a large extent
mediated by interaction with the neonatal Fc receptor. The receptor is expressed on endothelial
cells where bound IgG gets internalised, is released in the acidic environment of the endosomes
and is then recycled back to the cell surface. In a similar way, FcRn is also responsible for the
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transfer of IgG through the placenta and into the foetus. [50]. The significance of this mechanism
with regard to IgG serum half-life has been shown in FcRn-knock out studies were the the plasma
half-life of IgG in mice was reduced from 9 days to 1.4 days [47]. Thus, indicating that the main
reason for the difference in half-life between IgG and IgE is this stabilising interaction between
IgG and FcRn. The FcRn receptor possesses two main functions: the transport of IgG known
as transcytosis and the control of IgG catabolism [51, 50]. The IgG in excess (not bound to the
saturable FcRn) undergoes degradation in lysosomes [52, 50]. Antibodies of the IgE isotype do not
bind to FcRn. But the factors influencing the half-life of IgG can give further evidence to support
the conclusion that the turnover of IgE may be much faster than that of IgG and a substantially
higher amount of IgE may be produced than what is reflected in its plasma levels. As a result of
the high affinity interaction of IgE with the FcεRI, the vast majority of IgE molecules at any time
are bound to basophils and mast cells or the low affinity receptor FcεRII on B-cells [44, 55, 35].
This is in marked contrast to IgG that instead is primarily found in free circulating form.
The IgE-FcεRI interaction has a potentially stabilising effect on IgE half-life [47]. The half-life
of receptor bound IgE has been estimated to be approximately 14 days, which indicates that IgE
may have a half-life similar to IgG, despite its much lower plasma half-life, once bound to FcεRI
immune effector cells [47, 56].
3.1.6 Free indium-111
Free indium-111 and 111In-DTPA are known to accumulate in the liver. Degraded 111In-DTPA or
transferrin bound radionuclide could account for in vivo liver binding and excretion of radioactive
signal. Several studies performed with 111In-labelled IgG type antibodies showed accumulation of
significant signal in the liver. In all cases it appeared that the DTPA-amino acid linkage remained
intact even after degradation. The main radiolabelled excretion product recovered was a low
molecular weight metabolite of 111In-DTPA-ε-lysine. Free 111In-DTPA was trapped and remained
in the liver when injected in vivo but was not found as a metabolic product in liver of 111In-
DTPA labelled in vivo models. The studies suggested that the sequestration of 111In after the
injection of 111In-DTPA-labelled antibody was the result of a normal hepatic cellular mechanism
which was largely dependent on the presence of the Fc portion of the molecule and not affected
by radiolabelling [211, 212]. In addition, Jones et al., [211] showed that when 111In-DTPA was
injected into rats, 111In was not transferred to ferritin in liver but remained as 111In -DTPA.
3.1.7 Hypothesis and chapter outline
This project was based on the hypothesis that the high affinity (FcεRI) and low affinity (FcεRII)
receptor of IgE can trigger powerful immune responses via recruitment of immune effector cells
and therefore IgE could be employed for passive immunotherapy of solid tumours such as ovarian
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and breast carcinomas [35]. IgE properties may translate to longer retention of the administered
antibodies in tissues and longer anti-tumour immune surveillance [35]. The purpose of the work
described in this Chapter was to analyse IgE tissue biodistribution, targeting properties and sys-
temic clearance using an indium-111 labelled CSPG4 specific chimeric (mouse/human) IgE in the
human PBMC engrafted mouse tumour model described above. A preliminary therapeutic study
with the same in vivo model by Panagiotis Karagiannis to evaluate and compare efficacy and effi-
ciency of anti-CSPG4-IgE compared to its counterpart anti-CSPG4-IgG showed superior tumour
growth inhibition with anti-CSPG4-IgE. The CSPG4 specific IgE, injected into this ‘humanised’
mouse model resulted in a significantly higher anti-tumour activity compared to CSPG4-IgG, a
PBS control or unspecific antibody treatment (Figure 3.1). In this chapter NanoSPECT/CT and
biodistribution studies were used to analyse targeting, distribution, clearance and common phar-
macological markers like tumour-to-blood ratio. Results were compared to its IgG counterpart and
an unspecific IgE isotype control.
3.2 Materials and Methods
3.2.1 Human cell isolation and ex vivo stimulation assays
Peripheral blood B cells from patients with melanoma and healthy volunteers were isolated using
the B cell enrichment cocktail (Stemcell Technologies) and cultured at a density of 500 cells per well
(in 96-well plates). PBMC were activated and cultured in combination with (3,010 cGy) irradiated
autologous PBMCs, Epstein-Barr virus, and the TLR9 agonist CpG 2006, as previously described
[243]. Single cell suspensions were derived from patient tissues (lymph nodes or melanoma skin
lesions) using a Gentle MACs Tissue Dissociator (Miltenyi) and filtered through a 100 µm strainer.
In ex vivo stimulation experiments, human peripheral blood B cells were co-cultured for 5 days
together with irradiated PBMCs and tumour cells at 1:5:10 ratios in RPMI 1640 medium, 10% FCS,
2 mM l-glutamine, penicillin (5,000 U/mL), and streptomycin (100 µg/mL) (all Life Technologies)
[244]. Primary human monocytes from patients with melanoma were obtained using the monocyte
enrichment cocktail (Stemcell Technologies) according to the manufacturer’s instructions [13].
3.2.2 Subcutaneous human melanoma xenograft model
Male and female NOD/SCID/Il2rg-/- mice (NOD.cg-Prkdc SCID Il2rg tm1Wjl/SzJ [NSG]; The
Jackson Laboratory) were used at between 6 and 10 weeks of age. Mice were maintained under
specific pathogen-free conditions and handled in accordance with the Institutional Committees on
Animal Welfare of the UK Home Office (The Home Office Animals Scientific Procedures Act, 1986).
NSG mice were injected on day 0 subcutaneously with 5 x105 A375 melanoma cells in 150 µL PBS
into the lower left side above the leg. On day 5, mice received an intravenous injections of 10 x106
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human PBLs (derived from whole human blood by lysis of red blood cells). Tumour growth was
monitored and measured using callipers. Tumour size (mm3) was calculated using the following
formula: mm3 = d2 x (D/2), where d stands for the small diameter of tumour and D stands for
the large diameter of the tumour. Animals were used for imaging and biodistribution studies once
the first animal was measured with a subcutaneous tumour size no greater than 750 mm3. Spleen
engraftment of 40%-70% human CD45+ cells (against mouse cells, human CD45-) was confirmed
by flow cytometry for all experiments. In case of the assessment of tumour inhibitory effects of IgE
compared to IgG a dose of 10 mg/kg of antibody was injected on day 12. Subsequent injections of
antibody treatments were given 2 times on days 18 and 25 at doses of 10 mg/kg each in 150 µL
PBS. A control group was treated with 10 x 106 human PBLs on day 12 and injected with 150 µL
of PBS on days 18 and 25.
3.2.3 NanoSPECT/CT imaging of anti-CSPG4 antibody in vivo.
Anti-CSPG4 IgE or IgG (5-7 mg) were conjugated with the bifunctional chelator CHX-A"-DTPA
prior to experiments (chapter 2), and on the day of imaging (∼25-28 days after tumour injection),
the antibodies were radiolabelled with 20 MBq of indium-111 (St. Thomas’ and Guy’s Trust, KCL,
London, Radiopharmacy) (described in chapter 2) and administered intravenously at ∼10 mg/kg.
Images were captured under isoflurane anaesthesia after 4 h, 12 h, 24 h, 48 h, 72 h and 120 h
using a NanoSPECT/CT preclinical imager (Bioscan) equipped with a multipinhole (9 pinholes;
aperture 1.0 mm) collimator. After an initial low resolution CT image for spatial orientation the
scanning parameters were set (general parameters: tube voltage - 45 kVp, exposure Time - 500ms,
topogram direction - side view, mouse position - prone and feet-first). Subsequently, a CT of the
chosen range was acquired (parameters: acquisition field; number of projections - 180, pitch - 1,
number of scans - 1, frames field; frame resolution - standard, tube voltage - 45kVp, exposure
time - 500ms). Finally, SPECT imaging was carried out using 1mm multi (9) pinhole mouse
apertures and pyramid collimators in helical scanning mode (parameters: detected energy range
- 126-143 keV, number of projections - variable, time per projection - ∼60 seconds). Scan times
were approximately 5 min for topogram, 6 min for CT, and variable from a minimum of 25 min to
up to 60 min for SPECT acquisition. The scan time was adjusted depending on injected dose and
calculation of decay of indium-111. Images were reconstructed using InVivoScope (IVS) software
(Bioscan).
3.2.4 Biodistribution Studies
Mice for biodistribution studies were prepared in the way described in the methods earlier. NSG
mice showed splenic PBMC engraftment and were confirmed of bearing a A375 tumour xenografts.
Tumour-bearing mice were injected through the tail vein with 111In labelled anti-CSPG4-IgE or
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-IgG antibodies conjugated with CHX-A"-DTPA that had been prepared using the methods out-
lined in chapter 2. A group of male and female NOD/ SCID/Il2rg-/- mice bearing A375 tumours
were injected with either anti-CSPG4-IgE or anti-CSPG4-IgG (70 µg, ∼5 MBq). If a group were
of mixed gender mice, mice were held in different cages with only male or female mice. Mice (three
per group) were culled at 4 h, 12 h, 24 h, 48 h, 72 h or 120 h post injection of the radiolabelled
antibody. Blood, tumour, and various organs were collected immediately, weighed and the radioac-
tivity was measured by gamma counting after the last collection at 120 h together with standards
prepared from the injected material. The percentage of the injected dose/g (% ID/g) for each
organ was determined, and tumour-to-tissue ratios were calculated.
3.2.5 Excretion of indium-111
To gain the data necessary to calculate the excretion of indium-111, all radioactive signals measured
for each specific time point and found in organs, tissues and carcass were added and then deducted
from the overall injected radioactive dose. This was done for each time point of biodistribution
and all values were decay corrected. All radioactivity measured was assumed to be attached to a
fully functional anti-CSPG4-IgE or a degradation product of this antibody. Excretion was defined
here as radioactivity outside of the body of the NSG mouse. To calculate the excretion rates a
single 3-parameter exponential equation was applied. The calculations are shown below where f is
in the percent of indium-111, x is time in hours, a is an amplitude change (i.e., the change in value
of the data on the y-axis) b is the first-order rate constant and y0 is an end-point value for y-axis
data.
Exponential Decay, Single, 3 Parameter:
f = y0 + a ∗ exp(−b ∗ x) (3.1)
Using the loss of IgE from the mouse it was defined as analogous to an irreversible first order
reaction like radioactive decay or excretion (i.e. once indium-111 comes out of the animal it can’t
go back in) to simplify the mathematics. The means of the construct of the equation as below
where d[IgE]/dt is the rate of change of IgE at a particular time, k is fundamental underlying rate
constant for the process (i.e. the RATE changes with time as the absolute amount of IgE lost per a
fixed unit of time changes but the RATE CONSTANT for the physical process that is rate-limiting
for loss of IgE does not change). So the relevant numbers quoted are the rate constants for the
process NOT the rates.
d[IgE]
dt
= k[IgE at start] (3.2)
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3.2.6 N-Deglycosylation of anti-CSPG4-IgE
To remove the high mannose sugar residues from the anti-CSPG4-IgE the enzyme peptide-N-
glycosidase F (PNGase F) was used. PNGase F is a widely used enzyme for the deglycosylation
of glycoproteins. The enzyme releases asparagine-linked (N-linked) oligosaccharides from glyco-
proteins and glycopeptides. A tripeptide with the glycan-linked asparagine as the central residue
is the minimum substrate for PNGase F. PNGase F is commonly used for deglycosylation of gly-
coproteins with high-mannose residues, hybrid or complex type. Deglycosylation was performed
under native conditions without the addition of detergents. PNGase F works at a pH range of
6-8 and is used under native conditions with PBS buffer. Prior to the deglycosylation the anti-
CSPG4-IgE antibody was conjugated with p-SCN-CHX-A"-DTPA and subsequently radiolabelled
with 4 MBq of indium-111 as described in chapter 2, sections ‘conjugation’ and ‘radiolabelling’.
PNGase F (8 µL) was added to indium-111 labelled anti-CSPG4-IgE (70 µg) in a volume of 0.5
mL of PBS buffer, pH 7. The reaction mixture was incubated over 24 h at 37°C. The mixture of
PNGase F, deglycosylation products and radiolabelled anti-CSPG4-IgE was then injected into one
NSG mouse as described here in chapter 4 under biodistribution studies. The mouse was culled
for ex vivo biodistribution after 48 h.
3.3 Results
3.3.1 NanoSPECT/CT and biodistribution of anti-CSPG4-IgE and-IgG
NanoSPECT/CT was used to determine the biodistribution and tumour accumulation of the
indium-111 labelled anti-CSPG4-IgE and -IgG antibodies over time (120h). A non-specific IgE
isotype control (human/mouse chimeric MOv18-IgE) was used to assess the contribution of Fc-
receptor interaction on biodistribution. The isotype control was used in the imaging study as
well as in the ex vivo biodistribution studies. In all of the NanoSPECT/CT studies, one mouse
was injected with ∼70µg (∼20MBq) of 111In labelled anti-CSPG4-antibody or 111In labelled iso-
type control and imaged. The mouse was culled and dissected for biodistribution studies. For
biodistribution studies, each time point three mice were injected with ∼70µg of 111In labelled anti-




NanoSPECT/CT images of anti-CSPG4-IgE
Whole body imaging (Figure 3.2) showed rapid and strong accumulation of 111In-anti-
CSPG4-IgE in the liver and spleen, with a rapid drop in blood pool activity. Imaging also revealed
111In signal in the gastrointestinal tract. Visible accumulation of radiolabelled antibody in the
tumour was not observed. This was also true when overlaying stronger signal of liver, spleen and
intestines were removed by software processing post imaging and underlying weaker signal was
boosted to better visualise weaker signals. Residual activity from the i.v. injection in the tail was
detected.
Blood clearance appeared to be fast and no signal was found in organs with high blood
perfusion like the heart or lungs even in the first images acquired at 4h p.i.
Figure 3.2: NanoSPECT/CT images of a NSG mouse with subcutaneous tumour located in the
lower left side and engrafted human PBLCs after injection of In-111 labelled CSPG4-
IgE. Mouse injected i.v. with 20 MBq of 111In-anti-CSPG4-IgE (70µg). A-E: SPECT
acquisitions at 4 h, 12 h, 24 h, 72 h and 120 h post-injection, overlaid with CT image
acquired following the SPECT scan. Images normalised by image software processing
to the same arbitrary threshold limits.
Ex vivo biodistribution of anti-CSPG4-IgE
For each time point 3 mice were injected with anti-CSPG4-IgE (70µg, 3-5 MBq). As observed
in the NanoSPECT/CT images, high uptake in the liver and intestines was confirmed in the
dissections and determined via gamma counting. Additionally, moderate uptake in the spleen was
evident (Figure 3.2 and Table 3.1). In line with SPECT/CT imaging, there was no significant
uptake in the tumour. As seen in the NanoSPECT/CT images radioactivity remained mainly in























































Figure 3.3: Biodistribution of 111In labelled anti-CSPG4-IgE in an s.c. tumour xenograft
NSG mouse model with splenic engrafted human PBMC’s. Values in graph
on linear y-axes in % injected dose per gram in relevant tissue (x-axis) at
measured time points. 4h time point (olive); 12h (green); 24h (blue); 48h
(orange); 72h (red); 120h (grey). Data plotted in Mean with SEM bars.
Accumulation of 111In-anti-CSPG4-IgE was seen at 4 h post injection in the liver and spleen
with 37 % ID/g and 6.2 % ID/g, respectively. The signal in the liver gradually decreased over
the 120 h period from 37% ID/g at 4h to 18% ID/g at 24h and to 14% ID/g at 48h. After 120h
radioactivity measured in the liver was at 9% ID/g. Signal in spleen increased from ∼6% at 4h and
12h to ∼9% ID/g at the 24 h time point before gradually decreasing to 4.2% ID/g over time. Blood
levels dropped rapidly and were measured at 4h post injection with only 2% ID/g with further
decline in blood levels of ∼1% ID/g at 12h and 0.36% at 24h. Blood levels measured between 48h
and 120h post injections were <0.1% ID/g.
High accumulation of radioactive signal from 111In-anti-CSPG4-IgE or its degraded radioac-
tive products were observed in the intestines with values of 14% ID/g at the 4 h time point.
Accumulation at the tumour site was initially at 0.8% ID/g increasing to 1.44% ID/g at 12
h and 1.2% ID/g at 24 h. Values observed at 48 h show a decline to 0.85% ID/g, and at 72 h and
120 h to a level of 0.7% ID/g and 0.35% ID/g, respectively. Muscle tissue values measured around
∼0.1 %ID/g gradually declining to values of < 0.05% ID/g.
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Table 3.1: Biodistribution over the time course of 120h of indium-111 labelled Anti-CSPG4-IgE
injected NSG mice. Data of relevant tissue in %ID/g (n=3).
3.3.2 NanoSPECT/CT and biodistribution study of anti-CSPG4-IgG
NanoSPECT/CT imaging anti-CSPG4-IgG
The IgG study was carried out analogously to the IgE study with 70 µg of antibody (20
MBq indium-111) Figure 3.4 illustrates 111In-anti-CSPG4-IgG tissue biodistribution and tumour
accumulation 4, 12, 24, 72 and 120 hours after administration. Significant accumulation of the
radiolabelled antibody in tumours was seen from 4 hours p.i. with degrease of background radioac-
tivity by antibody clearance from blood over time. Antibody not yet cleared from circulation is
particularly apparent in the heart. In addition accumulation was detected in the spleen. Circu-
lating antibody signal was visualised in the blood over the whole imaging time of 120 hours. The
imaging time course showed the tumour was clearly visible from the earliest imaged time point
and throughout the imaging study (Figure 4).
The SPECT/CT imaging data of 111In-anti-CSPG4-IgG was in line with other published
biodistributions of IgG type antibodies. A prolonged half-life in the blood pool and a strong
accumulation in the subcutaneous tumour over time were observed.
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Figure 3.4: NanoSPECT/CT images of mice with subcutaneous tumour injected with In-111 la-
belled anti-CSPG4-IgG. Sequence of images of the same mouse over time of 120 h
(from left to right: 4h, 12h, 24h, 72h and 120h after injection). 70µg of anti-CSPG4-
IgG labelled with 20 MBq 111In and injected i.v.. Arrows indicate the position of the
tumour.
Ex vivo biodistribution of anti-CSPG4-IgG
Following the protocol described in section (Methods, Subcutaneous human melanoma
xenograft model), three mice per time point were injected with 3-5 MBq of 111In labelled anti-
CSPG4-IgG and organs were dissected at planned time points. Observations were in line with
the imaging data acquired and high uptake was found at the tumour site and in the spleen. A
moderate to high uptake in the spleen was apparent (Figure 3.4). Activity seen in circulation was
gradually decreasing over 120 hours resulting in an increased signal-to-background ratio in tumour
and spleen. Blood levels were observed at 25% ID/mL at 4 h time point and around 13% ID/mL
at 12 h post injection. Radioactivity measured in blood then slowly declined over time from 13%
ID/mL at 12 h and 24 h, respectively, to 5.8% ID/mL at 48 h and ∼4% ID/mL at 72 h and 120
h post injection. High levels of 111In-anti-CSPG4-IgG accumulated in the spleen over the time
course of 120 h. High levels of radioactivity were measured with initially 24% ID/g at 4 h p.i. and
20% ID/g at 12 h p.i.. Further increases in values were observed at 24 h and 48 h with 25% ID/g
and 46% ID/g, respectively. Activity observed in spleen reached a high at 72 h p.i. and 120 h
p.i. with about 69% ID/g. Activity levels in the liver were above 10% ID/g throughout the time
course of 120 h. Intestine levels of 111In-signal were ∼5% ID/g at 48 h p.i. and increased to >8%
ID/g at 72 h and 120 h, respectively. Accumulation levels at the tumour site were 13% ID/g at
4h, 18% ID/g at 12 h, 26% ID/g at 24 h and highest at 48 h with 27% ID/g. At 72 h and 120 h





















































Figure 3.5: Biodistribution of of 111In labelled anti-CSPG4-IgG. Biodistribution in an s.c.
tumour xenograft NSG mouse model with splenic engrafted human PBMCs.
Values on y-axis in % injected dose per gram in relevant tissue (x-axis) at
measured time points. 4h time point (olive); 12h (green); 24h (blue); 48h
(orange); 72h (red); 120h (grey). Data plotted are mean with SEM bars.
Table 3.2: Biodistribution over the time course of 120 h of indium-111 labelled anti-CSPG4-IgG
injected NSG mice. Data of relevant tissue in %ID/g (n=3).
86
3.3 Results
3.3.3 Imaging and biodistribution of an IgE class isotype control antibody
(MOv18-IgE)
Unspecific IgE isotype control for the CSPG tumour model (MOv18-IgE)
A NanoSPECT/CT imaging study was performed in the same in vivo model using a non-
specific IgE as isotype control in order to assess the influence of the targeting on the biodistribution
of IgE. A similar biodistribution of the IgE isotype control antibody was observed compared to the
specific anti-CSPG4-IgE. Results showed a very high accumulation of signal in the liver and spleen
accompanied by a rapid drop in blood pool activity (Figure 3.6+3.7). Like for anti-CSPG4-IgE
images, the IgE isotype control showed strong radioactive signal in the intestinal lumen concordant
with excretion of antibody degradation products via liver and bile. At no time point a visual signal
could be confirmed at the tumour site.
No underlying weaker signal in other organs could be detected when overlaying stronger
signal of liver, spleen and intestines were removed by software post imaging processing.
Due to a technical defect in the software the image at 120 h was not saved in the usual data
format. The picture was in a low quality format which did not allow the enlargement to a size
appropriate for work and publication. The imaging at the 12 h time point was cancelled due to
stress related ethical reasons for the animal.
Figure 3.6: NanoSPECT/CT images of mice with subcutaneous tumour in-
jected with indium-111 labelled IgE isotype control (MOv18-IgE).
Sequence of images of the same mouse over time of 120 hours (from
left to right: 4 h, 24 h and 72 h after injection). 70µg of IgE iso-
type control labelled with 20 MBq 111In and injected i.v.. Arrows
indicate the position of the tumour.
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Biodistribution of unspecific IgE isotype control (MOv18-IgE )
The biodistribution measurements confirmed the high liver and spleen uptake seen in the
SPECT/CT scans (Figure 3.6). Liver showed uptake values of more than 25% ID/g at 4 h. Further
measurements showed a progressive decline in radioactivity with 20% ID/g at 12 h p.i. and 14%
ID/g 24 h p.i.. Between 24 and 48 h values decreased further to 7% ID/g and ∼5% ID/g at 72
and 120 h. Spleen showed an uptake from 3.8% ID/g at 4 h and highest accumulation of activity
was measured at 12 h with 6% ID/g. Signal decreased to 4.3% ID/g at 24 h and at 48, 72 and
120 hours p.i. consistent signal of around 3-4% ID/g was observed. The intestines showed high
signal, as expected from the NanoSPECT/CT, from the first time point at 4 h post injection with
an uptake value of more than 36% ID/g. The signal showed a strong decline and after the 24 h
time point about 11% ID/g was observed before further decline to <3% ID/g at 48 h and below




















































Figure 3.7: Biodistribution of 111In labelled unspecific isotype control IgE in an s.c. tu-
mour xenograft (CSPG) NOD/SCID mouse model with splenic engrafted
humann PBMCs. Values are on linear y-axes in % injected dose per gram
in relevant tissue (x-axis) at measured time points. 4h time point (red); 12h
(blue); 24h (pink); 48h (green); 72h (yellow); 120h (orange). Data plotted
are mean with SEM bars.
Blood levels observed initially were very low at 0.5% ID/g at 4 h with further decrease to
<0.2% ID/g at 12 h post injection, and then progressively further decline to 0.03% ID/g at 120 h
post injection.
Accumulation on the tumour site remained low during all time points but significantly higher
than blood. Values observed were between 0.5% ID/g and 0.2% ID/g.
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Table 3.3: Biodistribution over the time course of 120h of indium-111 labelled non-specific IgE
isotype control injected in tumour bearing NSG mice. Data of relevant tissue in %ID/g
(n=3).
3.3.4 Comparison of anti-CSPG4-IgE and -IgG
Figure 3.8 shows a comparison of the % ID/g observed for indium-111 labelled anti-CSPG4-IgE
and -IgG and the unspecific IgE isotype control at 4 h, 48 h and 72 h post injection. Antibody
data compared here originates from the biodistribution studies. The acquired data showed that
most of the IgE was taken up by liver, intestines and spleen. Anti-CSPG4-IgG showed also a very
high spleen uptake but did not show a high liver uptake. In contrast to anti-CSPG4-IgE the IgG
variant showed a clear tumour targeting with elevated uptake. This was not seen with its specific
IgE counterpart or the isotype control, although, the tbr of anti-CSPG4-IgE was still high. In
addition, IgE antibodies showed a very strong and exclusive excretion via liver. Anti-CSPG4-IgG




Figure 3.8: Comparison of the biodistribution of 111In labelled anti-CSPG4-
IgE and -IgG and an unspecific isotype control in an s.c. tu-
mour xenograft NOD/SCID mouse models with splenic engrafted
of hPBMC’s at 48h post i.v. injection in % injected dose per gram
of dissected tissue (lungs, liver, spleen, intestines, kidneys, muscle,




3.3.5 Biodistribution of a deglycosylated anti-CSPG4-IgE after 48 hours
The results of the deglycosylated anti-CSPG4-IgE show distinct differences to the anti-CSPG4-
IgE with native glycosylation (Figure 3.9, Table 3.4). The measured values of deglycosylated
IgE originate from only one s.c. tumour bearing NSG mouse, which was engrafted with human
PBMC’s as described for all studies in this chapter. Biodistribution was performed after 48 h.
Activity observed in liver showed a markedly lower uptake of 5.7% ID/g compared to the normal





















































































Figure 3.9: (A) shows a comparison of deglycosylated (violet) and native glycosylated anti-CSPG4-
IgE 48 h post injection in %ID/g. (B) shows a comparison of the % ID of the same
anti-CSPG4-IgE (deglycosylated and native) 48 h post injection. Anti-CSPG4-IgE was
deglycosylated after labelling using PNGase F enzyme. Deglycosylated anti-CSPG4-
IgE was injected in 1 mouse and ex vivo biodistribution was performed after 48 h. For
native anti-CPSG4-IgE n = 3 and data plotted in mean including SEM error bars.
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Table 3.4: Biodistribution of deglycosylated anti-CSPG4-IgE in %ID/g and %ID 48 h post injection
(n = 1).
3.3.6 Tumour-to-Blood-Ratios
Tumour-to-Blood ratio (TBR) is commonly used to correct for the contribution of blood pool
activity to the uptake observed in tumour tissue and shows how much more signal is in the tumour
tissue than in blood. The TBR of 111In-anti-CSPG4-IgE (Figure 3.10, red) was calculated at 4 h
time point to be 0.4. Ratios increased further over 12 h and 24 h to 1.3 and 4.5 before reaching
the highest ratio at 48 h of 11.4. While TBR usually accounts for the background of blood pool
signal, in case of IgE the progression of increased TBR might originate at least in part from the
strong decline of blood pool signal. 111In-anti-CSPG4-IgG showed a similar starting point at the 4
h time point compared to IgE with a ratio of 0.5. 111In-labelled IgE isotype control (Figure 3.10,
, green and Table 3.5) showed a higer TBR starting point compared to anti-CSPG4-IgE and -IgG
with 1.7 at 4h post injection.
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Table 3.5: Tumour-to-Blood ratios of anti-CSPG4-IgE and -IgG and IgE isotype control over the
time course of 120 h.










Figure 3.10: Tumour-to-Blood ratio. Data shown in this figure compares the tumour-to-blood
ratios of the dissected tumour tissue and blood from the tumour bearing NSG mice
injected with 111In labelled anti-CSPG4-IgE (red) and 111In labelled anti-CSPG4-IgG
(violet) and IgE isotype control (green) Time points at 4, 12, 24, 48, 72 and 120 hours
post injection. Data plotted ratio (y-axis) over time (h) (x-axis).
3.3.7 Tumour-to-Muscle-Ratio
Anti-CSPG4-IgE and -IgG antibody tumour-to-muscle (TMR) ratio compares the accumulation
of antibody in the tumour tissue and unaffected tissue (here muscle). This ratio was compared
between the antibodies. Together the tumour-to-blood ratio the tumour-to-muscle ratio can be an
important marker to evaluate specific accumulation and help interpret the biodistribution data.
TMR showed a manifold higher accumulation of antibody in tumour tissue against non-
tumour tissue for all antibodies. Here antibody accumulation and biodistribution patterns are
shown both comparing anti-CSPG4-IgE and -IgG or anti-CSPG4-IgE against its isotype control
(Figure 3.11).
111In-anti-CSPG4-IgG TMR increased from 11.0 at the 4 h time point to 27.8 at 48 h and
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Table 3.6: Tumour-to-Muscle ratios of Anti-CSPG4-IgE and -IgG and IgE isotype control over the
time course of 120 h.
remained at >25 till 120 h post injection. The TMR of In-111 labelled anti-CPSG4-IgE increases
from 9.1 at 4 h p.i. to 21.1 TMR during the first 72 h. From 72 h post injection a decrease to 14.2
in TMR was observed at 120 h post injection.
TMR of the IgE isotype control antibody 111In-MOv18-IgE showed a lower TMR compared
to anti-CSPG4-IgE and -IgG (see Figure 3.11 and Table 3.6). Anti-CSPG4-IgE showed a progres-
sive increase in ratio over time as described above.










Figure 3.11: Comparison of the tumour-to-muscle ratio of s.c. tumour bearing NSG mice (n=3)
injected with 111In labelled anti-CSPG4-IgE and -IgG or IgE isotype control. Samples
were dissected at 4, 12, 24, 48, 72 and 120 h post injection.
3.3.8 Blood clearance and excretion of anti-CSPG4-IgE
Blood clearance (Table 3.7, Figure 3.12) of anti-CSPG4-IgG at the first time point 4 hours post
injection was 25% ID/mL. Activity levels remained at 12 h and 24 h around 13% before declining
to 5% at 48 h. Anti-CSPG4-IgE at the 4 hour time point was 2.2% ID/mL with further strong
decline in to 1% at 12 h p.i. and to <0.1% ID/mL after 48 h post injection. The IgE isotype
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Table 3.7: Blood clearance of Anti-CSPG4-IgE and -IgG and IgE isotype control over 120 hours.
Values are %ID/mL (n=3).
control showed even lower values, at 0.5% ID/mL at 4 h p.i.. Measurements taken at the 24 h time
point and later remained at or below 0.1% ID/mL.
Biodistribution data collected in the in vivo experiments were used to research the elimina-
tion and metabolism of IgE (Figure 3.13; Table 3.8). The main way of elimination of anti-CSPG4-
IgE was via liver and excretion via the intestinal way. At the 4 h time point almost 21% of the
overall injected dose was already excreted. Levels of activity inside the mouse dropped to about
55% of the injected dose at 24 h. 120 hours post injection more than 80% of the injected dose were
excreted.
99% of the injected dose of the unspecific isotype control was measured at 4hours p.i. drop-
ping within 12 hours to 50% ID. Compared to anti-CSPG4-IgE elimination was very similar. Be-
tween the time points of 48 h and 120 h p.i. the values observed for the isotype control remained
∼10% ID below the values measured for anti-CSPG4-IgE.
Blood clearance











Figure 3.12: Blood clearance of Anti-CSPG4-IgE (red) and -IgG (violet) and IgE isotype control
(green) over 120 hours.
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Figure 3.13: % 111In-anti-CSPG4-IgE (red) and IgE isotype control (green) retained inside the
mouse over the time of 120 h. Half-life of indium-111 inside the mouse was calculated
t1/2 = 24 hours for anti-CSPG4-IgE and t1/2 = 17 hours for the IgE isotype control.




The imaging and biodistribution studies were conducted to complement the positive results of a
treatment study comparing anti-CSPG4-IgE with its IgG counterpart (PhD thesis of P. Karagian-
nis, Cutaneous Medicine and Immunotherapy Unit, St. John’s Institute of Dermatology, Division
of Genetics and Molecular Medicine, KCL). The results were of the treatment study (Figure 3.1,
Introduction) compared anti-CSPG4-IgE to PBS, unspecific isotype controls for IgG and IgE and
anti-CSPG4-IgG. Anti-CSPG4-IgE showed significantly better tumour growth inhibition at the
same administered dose.
The anti-CSPG4-IgE antibody used in these studies and the presented imaging studies was
a human/mouse chimeric IgE with a fully human Fc-region. Since human IgE does not bind to
rodent FcεR [4], the results of the treatment study suggest that the observed anti-tumour activity
of anti-CSPG4-IgE is mediated by the co-administered human PBMC. The treatment study was in
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line with previous studies in other in vivo models looking into general IgE anti-tumour efficacy and
reviewed in chapter 1 (Introduction) and chapter 3 (Introduction, in vivo models) [42, 35, 245].
3.4.2 The NSG mouse model with splenic engraftment of human PBMCs
In earlier studies, described in literature, various rodent models have been used with success to
evaluate the in vivo therapeutic activity of several IgE antibodies. Here, a similar immunocom-
promised mouse model (NOD/SCID/Il2rg-/-) bearing a human tumour (CSPG overexpression)
was used. NSG mice were injected with PBMC prior to the injection of antibodies and splenic
engraftment was validated by an ELISA assay (Data from PhD thesis of P. Karagiannis).
Disadvantages of the here used in vivo model were that cytokines secreted by human effector
cells presumably did not interact with the murine system [246]. Furthermore, PBMC present only
a partial cell population that express FcεRs and, in addition, based on the preparation method
were restricted to certain cell types such as monocytes but excluding basophils and mast cells
[247]. Therefore, biodistribution and targeting of antibodies tested in this model, such as the
human/ mouse chimeric anti-CSPG4-IgE, could show differences in biodistribution and targeting
when injected into humans and the anti-tumour effects could be even greater in humans without
the drawbacks noted above and the source of FcεR-expressing effector cells is natural and constant.
With the human tumour xenograft in conjunction with human lymphocytes carrying FcR’s
for both IgE and IgG an environment was engineered that allowed a meaningful analysis of thera-
peutic IgE biodistribution and targeting and comparison to its IgG counterpart. In preparation for
the in vivo experiments a tumour xenograft of A375 melanoma cells was subcutaneously injected
into the lower left flank of each mouse.
3.4.3 Imaging and biodistribution of anti-CSPG4-IgE
The imaging data and biodistribution patterns were expected to be different from the biodistribu-
tion seen in general IgG biodistribution. Based on the knowledge of many other radiolabelled IgG
antibodies anti-CSPG4-IgG was expected to circulate for a long time in blood and show targeting
and accumulation rather quickly [248, 249]. For IgE, it was hypothesised by us, it would bind
via its high affinity receptor FcεRI on the surface of human immune effector cells and ‘patrol’
pre-armed on the surface of these effector cells through tissues, slowly accumulating at the target
side [41, 165].
Images were acquired from a mouse systemically injected with indium-111 labelled anti-
CSPG4-IgE, anti-CSPG4-IgG or IgE isotype control antibody. Biodistribution data were obtained
from dissected organs of mice injected with radiolabelled IgE, IgG or isotype IgE antibody from
the same indium-111 labelled antibody stock prepared for imaging but with lower specific activity.
Anti-CSPG4-IgE results showed a distribution with a very rapid blood clearance and accumulation
97
3.4 Discussion
of radioactivity in the liver. Nearly all signal seemed trapped in the liver, with some signal in the
spleen. Signals from the intestines indicated a fast excretion from the liver.
Biodistribution data confirmed the short serum half-life of IgE seen in the imaging study.
The calculated biological half-life was 17 hours for IgE isotype control and 25 hours for anti-CSPG4-
IgE. This half-life was calculated from excretion data of indium-111 and shows the half-life based
on all tissues combined and is not to be confused with half-life calculated from blood clearance.
From early IgE turnover studies by Waldmann et al., it is known that IgE has the lowest serum
concentration compared to all other immunoglobulin classes and subclasses [250]. Intact IgE has a
half-life in serum in healthy human adults of ∼2 days measured in blood samples [251]. Half-life of
IgE in rodents is considerably shorter than in humans (5-12 h). For the half-life it has to be taken
into account that anti-CSPG4-IgE is a chimeric mAb in a humanised mouse model and IgE half-life
in rodents were measured by different serological quantification assays in different non-disease or
tumour bearing mouse models.
In line with the publications by Haba et al. [46] of IgE half-life in rodents, an initial clearance
phase of IgE could be seen in the biodistribution data presented in this chapter during the first
hours. Haba et al. [46] determined the half-life of IgE in rodents at initially 1-2 hours with a
progression of a relatively constant half-life of 5 to 8 hours after the first rapid blood clearance.
Here, similar to observations by Haba et al,. after the first fast blood clearance phase a very
small amount in the ng/mLregion seemed to remain in circulation with a longer half-life. This was
calculated using the %ID in blood against the overall injected dose. Waldmann and colleagues [250]
described a high catabolic rate for IgE and postulated two clearance mechanisms responsible, the
intravascular and extravascular catabolic pathway. The intravascular pathway is the same to all
immunoglobulins but later studies confirmed an extravascular pathway that is specific to IgE only
[252]. Iio and colleagues [251] proposed the cellular catabolism of IgE may be related to the binding
of IgE to basophils and mast cells through FcεRI. However, in those experiments, a rapid catabolic
rate of 125I- and 131I-labelled IgE was demonstrated by their finding that a high proportion of free
radiolabel was recovered from urine. This observation suggested that IgE antibody available to
FcεRI-bearing cells were constantly being turned over rather than sequestered on FcεRI-bearing
cells, where they would be unavailable for degradation. No further literature with strong evidence
could be found and the full catabolic pathway of IgE remains not clearly identified today. The
results in this chapter show that the extravascular pathway dominates and is based on liver uptake.
The blood clearance was in direct relation to the liver accumulation of anti-CSPG4-IgE.
Several factors may be responsible for this accumulation in liver. The high mannose glycosylation
of IgE and B cells residing in the liver that can bind IgE via the CD23 receptor.
In vivo data observed here suggests that IgE circulating free in serum could be cleared by
several mechanisms. In earlier studies by Baenziger, Fridriksson and Arnold [201, 253, 200] IgE
was identified to have high-mannose structures present, which included several terminal mannose
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structures on its glycosylation sites located within the heavy chains [200]. It is known that terminal
mannose or galactose groups, presented after antigen-antibody binding, lead to a rapid clearance of
IgG and IgD immunoglobulins through the liver by lysosomal degradation [254]. These mannose
sugar residues are otherwise not exposed on antibodies other than IgE. The terminal mannose
sites, thus, might account for the IgE accumulation in the liver. Free IgE could also be bound in
serum by mannose binding lectin (MBL) which is part of the innate immune system complement
cascade. However, the complement system was not fully developed in the in vivo model used
(NOD/ SCID/Il2rg-/- mice) and, therefore, the mechanism remains questionable as a reason for
mediating the extensive liver binding of IgE.
An interesting experiment which points clearly at mannose glycosylation as main factor of
the extensive liver binding was the injection of deglycosylated anti-CSPG4-IgE into one mouse and
the biodistribution study at 48 h post injection. Although, the data is statistically not significant
because only one animal was used and the experiment was crude, it showed clearly a reduction
of liver uptake by two thirds and a higher 14% ID/g tumour uptake. By removing the mannose
glycosylation of IgE the biodistribution characteristics resemble more the ones of IgG. However,
this experiment has to be repeated for obvious reasons and more data is needed.
The comparison of imaging and ex vivo distribution data of IgE and IgG revealed a very
different picture of the two mAbs. Anti-CSPG4-IgG share the same variable region (Fv) with anti-
CSPG4-IgE, with the same affinity and epitope recognition [41, 4]. However, the Fc-region is isotype
dependent. Anti-CSPG4-IgG followed in the NanoSPECT/CT scan and in the biodistribution a
familiar distribution pattern seen in other publications looking into targeted full size IgG antibodies
[255, 98, 248, 256, 242].
Accumulation in the spleen based on FcR interaction with lymphocytes residing in large
numbers in the spleen is known from previous studies on IgG. Here, anti-CSPG4-IgG showed a
very high signal uptake in spleen. This was based on the very small developed spleen in NSG
mice and the engraftment of PBMCs in the spleen. The high spleen uptake was also observed
for anti-CSPG4-IgE but less high than IgG. This may indicate FcR interaction of IgE and IgG
antibodies to human PBMCs since the spleen was the main site of PBMC engraftment.
3.4.4 Tumour-to-blood ratio and tumour accumulation
Processing biodistribution data as tumour-to-blood ratios (tbr) for IgG is used to unmask contam-
inating blood signal effects. The perfusion effects of IgG circulation in blood can distort results
to some extent. Thus, higher blood activity represented in target organs can account for signal
originating from blood perfusion and an increased non-specific organ uptake. Significantly higher
uptake of tumour specific IgE compared to unspecific IgE were observed. Uptake in tumour com-
pared to blood levels of 111In-anti-CSPG4-IgE was comparable to its IgG counterpart. This cannot
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be explained by a contaminating effect of IgE circulation and tumour blood perfusion. In general,
IgE did not show the extended half-life in serum and blood circulation like IgG [46, 257, 241].
However, IgE did show some specific targeting despite its fast clearance because the tbr was simi-
lar.
3.4.5 Tumour-to-muscle ratio
A different measurement of IgE activity is the tumour-to-muscle ratio (TMR). TMR is mostly used
as an important marker for [18F]FDG to confirm standard uptake values (SUV) and establish the
anti-tumour activity of inhibitors [258]. IgE half-life in serum is very short (2-4 hours) but the
half-life of IgE in tissues, presumably bound to FcεR receptors on the surface of immune effector
cells, is estimated at approximately 2 weeks [44, 47]. To compare IgE in the tumour tissue to
non-tumour tissue was of major interest as both tissues were expected to show signal originating
from IgE bound to FcR receptors on the surface of immune effector cells located in tissues. It is
not clear from the data, tbr or tmr on anti-CSPG4-IgE if the accumulation at the tumour site was
from circulating IgE (even if it was only a very small amount) or an accumulation of IgE actively
trafficked into the tumour site bound on the surface of immune effector cells. The hypothesis of
IgE bound to the surface of FcεR expressing effector cells actively infiltrating the tumour cannot
be answered with the imaging and biodistribution data gathered in this thesis.
3.4.6 Comparison with IgE isotype control (MOv18-IgE)
Chimeric MOv18-IgE was used as an unspecific IgE isotype control. The target of MOv18-IgE
is the folate receptor alpha (FRα) which is expressed in normal tissues at the luminal surface of
epithelial cells and inaccessible to the circulation [91, 259]. FRalpha was not overexpressed on A375
tumour cells. Comparison of the NanoSPECT/CT scans and biodistribution data showed overall
a similar distribution pattern of the IgE antibodies, anti-CSPG4-IgE and MOv18-IgE. However,
IgE isotype control signal accumulation in liver was ∼40% lower than anti-CSPG4-IgE at 48 hours,
signal in spleen was 53% lower while signals from the intestines were 40% higher indicating a faster
catabolic rate of unspecific IgE. Tumour uptake of anti-CSPG4-IgE was ∼80% higher compared to
its isotype control. Therefore, a significant influence of the specificity of anti-CSPG4-IgE against
the tumour receptor in biodistribution over time and treatment were observed. This was seen in
the tmr as well.
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4 In vivo comparison of an engineered rat MOv-18-IgE and -IgG in a immunocompetent
disseminated tumour rat model
4 In vivo comparison of an engineered rat




4.1.1 Aim of the work on rat MOv18 IgE
The aim of the work presented in chapter 4 is the comparison of the in vivo fate and biodistribution
of therapeutic antibodies rMOv18-IgE and rMOv18-IgG targeted against the human folate alpha
receptor (FRα). Both antibodies were engineered to allow a comparison of IgG and IgE with
identical variable domains (Fv) but different antibody class determining region (Fc). In a series of
experiments rMOv18-IgE and -IgG antibodies were radiolabelled and biodistribution studies and
NanoSPECT/CT scanning were employed to visualise and compare targeting, organ and tissue
distribution and clearance of both antibodies. For the in vivo studies a new fully immunocompetent
surrogate rat model system was introduced. Rat MOv18-IgE (rMOv18-IgE) and rat MOv18-IgG
(rMOv18-IgG) antibodies were engineered as chimeric (rat/mouse) antibodies with rat constant
domains and mouse variable domains specific to the human FRα. The antibodies were targeted
against a human ovarian carcinoma antigen, the human folate receptor alpha (FRα), which is
overexpressed and upregulated on a number of human tumours, including over 90% of ovarian
carcinomas. For these studies an engineered rat cell line expressing FRα was used. Both antibodies
were conjugated to CHX-A"-DTPA and radiolabelled with indium-111 using the method described
in chapter 2.
To identify the potential role of therapeutic MOv18-IgE and effect in the tumour therapy,
biodistribution studies and NanoSPECT/CT imaging of indium-111 labelled MOv18-IgE were
performed. The methods of the imaging and biodistribution studies followed the description of
imaging and biodistribution in chapter 3. The focus of the experiments in this chapter was on
the deployed immunocompetent surrogate rat model described below and the comparison of rat
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MOv18-IgE and -IgG in a native environment.
4.1.2 In vivo Model
The model used in chapter 3 whilst providing a comparison of IgE and IgG antibodies in vivo, does
not provide a full picture of the biological behaviour of these two antibody classes in their normal
biological setting because the antibody Fc-domains (human) and the host organism (mouse) are
from different species. This is not fully resolved by grafting of human immune cells into the mouse.
This leads to the following specific limitations:
• In contrast to human IgG which binds to murine Fc receptors, human IgE does not interact
with rodent FcεRs. There is also a different cellular distribution of FcεRs in humans and
rodents [260, 6]. Rodent models can, therefore, not readily be used to assess antibody efficacy
that depends on FcεR mediated recruitment of effector cells. As described in more detail in
chapter 3, this was one disadvantage of the NSG mouse model used for anti-CSPG4-IgG and
-IgE.
• FcεRI receptor distribution and structure in mice and humans show significant differences.
Murine FcεRI is expressed solely on mast cells and basophils but human FcεRI is expressed
on mast cells, basophils, eosinophils, monocytes, Langerhans cells, and DC [6].
• human and rat FcεRI but not the murine FcεRI show structural similarities. While murine
FcεRI is always found in a tetrameric configuration, functional human and rat FcεRI can
exist either as an αβγ2 tetramer or as an αγ2 trimer [64, 6]. Importantly, the α chain of the
human receptor is sufficient to bind human IgE [261].
• In addition, the expression level of human FcεRI is much higher on mast cells and basophils
compared to the other human cell types [6]. These expression levels and the above described
effector cell distribution are similar between human and rat but not mouse, with the exception
of FcεRI expression on human Langerhans cells and DC cells which is not found in rats or
mice.
• The low affinity receptor FcεRII shows differences in expression pattern in mouse and hu-
mans. In humans, CD23 is expressed on eosinophils, monocytes, lymphocytes, follicular DC,
Langerhans cells, and platelets. In the mouse, CD23 is expressed mostly on B cells and a
subset of T cells [260, 262].
• Another limitation referring to the NSG mouse model employed in chapter 3 is that the self-
replenishing supply of human effector cells was only partly overcome by the injection and
engraftment of PBMC in xenograft models of immunocompromised mice. Limitations re-
maining were that human cytokines secreted by human effector cells may have not interacted
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with the murine immune system [246]. In addition, the type of effector cells that express
FcεRs in the PBMC preparations is restricted [247]. Thus, the full spectrum of human ef-
fector cells (including basophils and mast cells) were not active in the model used in chapter
3.
Therefore, in this chapter we compare the behaviour of the two classes of antibody in which
the constant domains and the host animal are the same species - i.e. the rat. This serves two
purposes: it enables the study of the effect of the interactions of the constant domains of the
antibodies with their host immune system; and it provides a model for the use in the clinical
setting of IgE as a therapeutic antibody, in which biodistribution, tumour targeting and potential
toxicities can be evaluated.
The immunocompetent rat lung metastases model was developed and validated in coopera-
tion and under the lead of Debra Josephs (D.H. Josephs, Cutaneous Medicine and Immunotherapy
Unit, St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine & NIHR
Biomedical Research Centre at Guy’s and St. Thomas’s Hospitals and King’s College London,
London, UK). Further investigations of efficacy, toxicology and pharmacodynamics of rMOv18-
IgE were performed by Debra Josephs.
4.1.3 MOv18-IgG
The murine monoclonal antibody MOv18 IgG1, binding the FRα, originated from an immunisation
experiment in mice using a surgical specimen of ovarian carcinoma [263]. Later, Buist et al.
demonstrated localisation of chimeric MOv18-IgG antibody [264] in ovarian carcinoma tissue and
was able to show a prolonged accumulation in the tumour relative to normal tissues. Several
clinical studies presented the targeting of FRα with a chimeric MOv18-IgG as a safe and promising
potential therapeutic for the treatment of ovarian carcinoma [109, 265].
For the work with the rat surrogate in vivomodel the variable region was re-engineered based
on the original chimeric MOv18-IgG. The rat MOv18-IgE and -IgG antibodies were designed as
chimeric antibodies with rat constant domains and mouse variable domains specific for the human
FRα. The heavy and light chains of each rat MOv18 antibody were cloned into a single mammalian
expression vector containing a hygromycin resistance gene (pVITRO1) allowing the transfection,
selection and antibody expression by HEK293-F cells (cloning performed by T. Dodev, Randall
Division, King’s College London). Rat IgG2b class corresponds to the human IgG1 class antibody
in terms of effector function [266].
MOv18-IgE efficacy studies
Earlier studies showed a significant therapeutic efficacy advantage of MOv18-IgE over MOv18-
IgG across different xenograft tumour models and different routes of injection, [41, 165, 13, 170, 35].
To further investigate the hypothesis that IgE antibodies may offer some advantages over IgG
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in passive immunotherapy of cancer and to translate MOv18-IgE into clinical first-in-man stud-
ies, a rat MOv18-IgE, targeting the ovarian tumour associated antigen FRα was engineered and
compared to MOv18-IgG. MOv18-IgE was evaluated in an immunocompromised mouse xenograft
model of ovarian carcinoma. Results showed inhibition of tumour growth in treatment with MOv18-
IgE and -IgG when co-injected with PBMCs. After 19 days no longer-lasting effect of IgG could be
seen while MOv18-IgE continued to show significant growth inhibition to the end of the experiment
at day 35 and 48 [41]. Karagiannis and colleagues confirmed anti-tumour efficacy of MOv18-IgE
in a different nude mouse model using patient-derived human ovarian carcinoma xenografts. Re-
sults seen were similar to earlier experiments and in addition to the tumour growth inhibition the
tumour infiltration of human monocytes could be shown. MOv18-IgE was again co-injected with
human PBMC [165]. A later study published by Karagiannis et al. analysed the mechanisms of
MOv18-IgE anti-tumour activities. The study highlighted that within the heterogeneous cell group
of peripheral blood lymphocytes, monocytes were essential to mediate the enhanced anti-tumour
capabilities of IgE [13].
4.2 Materials and Methods
4.2.1 Rat MOv18-IgE and -IgG Antibody Production and Purification
Transfected cells were grown in AppliFlex Single Use Bioreactors (Applikon Biotechnology) and
antibody production was monitored in culture supernatants by ELISA. Pilot experiments deter-
mined that the optimum timeframe for supernatant harvest, at which point the maximum level of
antibody was detected in the cultures, was between 7 - 10 days following transfection. Following
rat IgE and IgG detection by ELISA, culture supernatants were collected. Volumes of less than
5 L were filtered using Vacuum Stericup® filter units (0.22 µm pore size; Millipore). Larger vol-
umes were filtered using a pump-driven Sartoclean® MidiCap pre-filter unit (3 + 0.8 µm pore
size; Sartorius Stedim Biotech) followed by a pump-driven Sartpore® 300 filter unit (0.45 + 0.2
µm pore size; Sartorius Stedim Biotech). After addition of sodium azide (0.1% final concentra-
tion) the supernatants were directly applied to the appropriate purification medium. Purification
of rat MOv18-IgE and -IgG was investigated using different methods. FPLC-SEC was used for
analysis and fractionation of the purified antibodies. Fractionation was performed to isolate pure
monomeric antibodies from oligomers and aggregated materials according to size.
4.2.2 CC531tFR Cell Line
The adherent CC531 cell line is derived from a chemically-induced colon adenocarcinoma of a
WAG rat model for hepatic colon cancer [267] and transfected with to express human FRα (Dr.
S. Canevari, Prof M. Colnaghi, Instituto Nazionale Tumori, Milan, Italy) and provided as a gift.
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Cells were maintained in RPMI 1640 with standard additives, additionally supplemented with 0.4
mg/mL G418 to maintain selection of the transfected human FRα plasmid. Cells were passaged
at a ratio of 1:6.
4.2.3 WAG rats
As part of this work, an immunocompetent rat model bearing a syngeneic rat tumour expressing
human FRα antigen was established in collaboration with Debra Josephs. This model was used
to further evaluate the biodistribution and for NanoSPECT/CT imaging of rMOv18-IgE. The rat
colon carcinoma cell line CC531tFR (where tFR stands for transfected with human FRα) was trans-
fected to express the human FRα and was syngeneic with the WAG rat strain. CC531tFR grows as
lung metastases when injected intravenously. To evaluate the optimal dose of i.v. CC531tFR tu-
mour cell inoculation in the development of the lung metastasis model in WAG rats, rats were given
CC531tFR tumour cells i.v. in 250 µL PBS at increasing concentrations. Lung tumour burden
was determined by two different methods; the first calculated the mean number of surface-visible
metastases counted in 3 separate demarcated 1 cm2 areas (reported as number of metastases/cm2)
[268, 269]. For the second method, each lung was dissected into 3 sections and each section imaged
using a Nikon SMZ1500 Stereo Microscope (Nikon UK Ltd.). Analysis was performed using NIS
Elements Basic Research software (Nikon) in order to determine the total surface area (mm2) oc-
cupied by the entire lung section and by the white tumours. After 20 days the rats were sacrificed
and the lungs infused with 15 % Indian ink solution followed by destaining in Fekete solution for
24 hours. The number of lung metastases per cm2 surface lung area was determined for each rat.
Representative image of a rat lung 26 days after i.v. injection of syngeneic CC531tFR tumour cells
is presented in figure 4.1. At a dose of 4x106 CC531tFR injected cells an average of 8.5 ± 2.9 lung
metastases/cm2 was observed (n = 5 rats) and this dose was chosen as optimal for all following
experiments (PhD thesis of Debra Josephs, ‘Antibodies of the IgE Class: Preclinical Evaluations
for Therapeutic Use in the Treatment of Solid Tumours’). WAG rat in vivo work was in line with
approved guidelines for the humane treatment of animals (Home Office, 1995). Animal studies were
carried out in accordance with UK Research Councils’ and Medical Research Charities’ guidelines
on Responsibility in the Use of Animals in Bioscience Research, under UK Home Office Project
and Personal licences.
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Figure 4.1: Rat lung 26 days after i.v. injection
of syngeneic CC531tFR tumour cells.
The lung was infused with 15 % In-
dian ink solution followed by destain-
ing in Fekete solution for 24 hours. A.
Overview of the whole lung, B. Close
up
4.2.4 Conjugation and radiolabelling of rat MOv18-IgE and -IgG antibodies
with Bi-functional chelator p-SCN-Bn-CHX-A"-DTPA
Methods describing the conjugation and radiolabelling of MOv18-IgE and -IgG are described in
detail in chapter 2.
4.2.5 NanoSPECT/CT imaging of rat MOv18-IgE and -IgG in the lung
metastasis tumour model
Imaging experiments were performed using a NanoSPECT/CT instrument/scanner (Bioscan, US).
Generally, an intravenous tail vein injection was performed on WAG rats with ∼100-150µL of ∼10-
20 MBq of 0.07 mg protein under anaesthesia (Isoflurane, VetOne, UK). WAG rats were injected
intravenously on day 0 with tumour cells (CC531) and on day 28 a dose of 111In-rMOv18-IgE or
111In-rMOv18-IgG was injected via a tail vein. Following the injection, rats were scanned at 20 min,
24 h, 48 h, 72 h and 144 h using NanoSPECT/CT. Rats were transferred onto the NanoSPECT/CT
heated (37°C) rat bed which supplied anaesthesia throughout the imaging experiment. A low
resolution CT (topogram) of the whole animal was first acquired so that a scanning range could
be set (parameters: tube voltage - 45 kVp, exposure time - 500ms, topogram direction - side view,
rat position - prone and feet-first). Next a CT of the chosen range was performed (parameters:
acquisition field; number of projections - 180, pitch - 1, number of scans - 1, frames field; frame
resolution - standard, tube voltage -45kVp, exposure time - 500ms). Finally SPECT imaging was
carried out using 1mm 9-pinhole Rat apertures and Pyramid collimators in helical scanning mode
(parameters: detected energy range - 126-143 keV, number of projections - variable, time per
projection ∼60 seconds). Scan times were approximately 5 min for topogram, 6 min for CT, and
variable from minimum of 25 min to up to 60 min for SPECT acquisition. The scan time was
variable, adjusted depending on injected dose and time lapsed after protein injection. Images were
reconstructed using InVivoScope software (Bioscan).
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4.2.6 Ex vivo Biodistribution Studies
Tumour-bearing rats were injected through the tail vein with 111In labelled rMOv18-IgE or -IgG
antibodies conjugated p-SCN-Bn-CHX-A"-DTPA chelator using the methods outlined in chapter
2. A group of male and female WAG rats bearing CC531tFR metastatic lung tumours were
injected with one of the radiolabelled antibodies. Rats (three per group) were killed at 8 h, 24 h,
48 h and 144 h post injection of the radiolabelled antibody. Blood, tumour, and various organs
were immediately collected and weighed on an analytical balance. Radioactivity in all organs was
measured by gamma counting after the last biodistribution time point at 144 h together with
standards prepared from the injected material. Percent injected dose (% ID) was calculated. The
blood volume was estimated in mL based on 6% of the total body weight of the rat. Percent of
injected dose/g (% ID/g) was calculated for each organ, as well as tumour-to-blood and tumour-
to-muscle ratios.
4.3 Results
4.3.1 NanoSPECT/CT and biodistribution study
The aim of this study was to compare the rat MOv18-IgE and rat MOv18-IgG antibody in an
immunocompetent syngeneic tumour model. This was performed using NanoSPECT/CT to vi-
sualise antibody targeting, clearance and organ and tissue distribution continuously over specific
time points up to 144 hours post injection. The imaging study served as a ">rangefinder"< study
to find the best time points for biodistribution and identify organs that needed sampling. For each
indium-111 labelled rMOv18-IgE and -IgG antibody, a rat was injected with ∼100 µg of the radio-
labelled (5 MBq) rMOv18-IgE antibody or with ∼100 µg the radiolabelled (5 MBq) rMOv18-IgG
antibody. This was for the imaging study only. Imaging was performed at 20 min, 24 h, 48 h and
144 h post injection via NanoSPECT/CT.
In addition, ex vivo biodistribution studies were performed in order to quantify biodistri-
bution. At each time point (8h, 24h, 48h, 144h post injection of radiolabelled rMOv18-IgE or
-IgG) 3 rats were were culled for biodistribution, tumour targeting and clearance studies. For
biodistribution studies, for each time point a number of rats (n=3) were systemically injected with
∼100 µg of 111In labelled rMOv18-IgE antibody or rMOv18-IgG antibody, respectively, with ∼5
MBq at the beginning of the study. The biodistribution study included culling time points at 20
min, 24 h, 48 h, and 144 h post injection. Antibody radiolabelling results are discussed in chapter
2. Also, antibody production and purification results are described in the PhD thesis of Debra
Josephs (PhD thesis of Debra Josephs, ‘Antibodies of the IgE Class: Preclinical Evaluations for





One WAG rat was injected intravenously on day 0 with tumour cells (CC531) expressing
the human FRα and on day 28 a single dose of 111In-rMOv18-IgE was injected via tail vein. The
individual rat was scanned at 20 min, 24 h, 48 h, and 144 h using NanoSPECT/CT (Figure 4.2).
Figure 4.2: NanoSPECT-CT images of tumour bearing rat injected with In-111 labelled rMOv18-
IgE. Sequence of images of an individual rat over the time course of 144 hours (from
left to right: 20min, 24h, 48h and 144h after injection).
Whole body imaging showed rapid (20min p.i.) accumulation of 111In-rMOv18-IgE in the
liver (signal in spleen can be observed in 3D rotating images). Additional signal can be seen in
the intestines at 20 min post injection. No signal was detected from the lungs were the tumour
metastases were located. No signal was observed in blood or heart.
At 24 h post injection signal from the liver was decreased compared to 20 min post injection.
Stronger signal from the intestines was visible. 48 h post injection of indium-111 labelled rMOv18-
IgE the strongest signal was still visible in liver. Signal from the intestines was still apparent.
At the last scan at 144 h post injection signal has decreased overall. Low but distinct signal
was observed from the liver. At no time point could a visual signal be confirmed at the tumour
site (lung tissue with tumour metastases).
Biodistribution
For organ and tissue distribution studies (Figure 4.3, Table 4.1) of rat MOv18-IgE WAG
rats were injected intravenously with human FRα expressing CC531tFR tumour cells. About 28
days post tumour cell injection 111In-MOv18-IgE was injected i.v. via tail vein. 3 Rats were culled
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per time point, at 8 h, 24 h, 48 h, and 144 h post injection and organs were collected to assess
antibody biodistribution. Biodistribution of 111In-MOv18-IgE showed high accumulation in the
liver (13.7% ID/g) at the first time point, 8 h post injection). The second time point at 24 h
showed a significant drop to 8% ID/g. Radioactivity in the liver declined further to 6% ID/g at







































Figure 4.3: Biodistribution in a disseminated tumour bearing rat injected with radiolabelled
rMOv18-IgE in % injected dose per gram of tissue at different time points. 8h time
point (red); 24 h (blue); 48h (pink); 144 h (green). Data plotted including SEM error
bars.
Activity measured in the blood pool was 0.25% ID/mL after 8 h post injection, progressively
dropping to below 0.01% ID/mL at 144 h. In the spleen a moderate accumulation of radioactivity
was measured over the first 48 h post injection. At 8 h 2.5% ID/g, at 24 h 2.7% ID/g and 2.6%
ID/g at 48 h were observed. Signal from the spleen then decreased over the next time point at
144 h but remained at a higher level compared to other organs (other than liver) at 1.4% ID/g.
Intestines showed a high signal at 8 h (3.1% ID/g) and the signal decreased steadily and fast to
1.9% ID/g at 24 h and 0.8% ID/g at 48 h to 0.17% ID/g over the next 144 h. An injected dose per
gram of around 2.0% was observed in the kidneys over the first 48 hours before dropping to 1.5%
ID/g. Lung tissue (including the tumour) showed only minimal uptake with 0.17% ID/g of 111In-
rMOv18-IgE measured at 8 h, 0.1% ID/g at 24 h and 0.05% ID/g and 0.02% ID/g, respectively,
for 48 h and 144 h.
The biodistribution is shown as injected dose per organ for each time point in Figure 4.4.
Data values are shown as mean with SEM (n = 3 rats) and showed distribution of gamma signal
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Table 4.1: Biodistribution of rat Mov18-IgE in WAG rats over the time course of 144 hours. Data







































Figure 4.4: Biodistribution of rat Mov18-IgE in selected organs and tissue showing the calculated
percentage of the injected dose. Values are mean with SEM (n=3 rats). 4 time points of
biodistribution colour coded for time post injection in olive=8h, green=24h, blue=48h
and orange=144h.
without the normalisation for weight. At 8 hours post injection about 75% of the injected dose
was measured in the liver. Radioactivity in the liver then dropped to 50% ID at 24 hours and 37%
ID at 48 hours, respectively. The last value observed in the liver at 144 h p.i. was 16% of the
injected dose.
Signal in the spleen, although relatively high when normalised against its weight, was low
when seen in % injected dose. 8 h post injection it was observed at 0.6% ID with an increase at
24h and 48 h to about 0.7% ID. The last value showed a declined to about 0.4% ID. The intestines
showed the highest accumulation of radioactivity after liver with 27% of the injected dose at 8
hours post injection. Values decreased steadily to 16% ID and 7.7% ID at 24 h and 48 h post
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injection, respectively. At 144 h the %ID was at 1.6.
Both kidneys were collected together and therefore account for a relatively high organ weight.
The % of injected dose was very stable throughout the first 48 hours post injection. Values were
at 2.9% at 8 h, 2.4% at 24 h and 2.2% at 48 h post injection. The value at 144 hours was at 1.6%
of the injected dose.
At 8 hours post injection overall 1.8% of the injected dose were measured in the blood pool.
Values declined to 0.6% at 24 h, 0.5% at 48 h and 0.05% after 144 hours. Blood pool was generally
estimated with 6% of the rat’s body weight.
Lung which included the metastatic tumour tissue accounted for about 0.18% of the injected
dose at 8 hours post injection. The signal in lung declined to 0.08% at 24 h. At 48 h an increase




Analogous to the rMOv18-IgE NanoSPECT/CT imaging described above rMOv18-IgG was
radiolabelled with indium-111 under the same conditions and used for in vivo imaging studies.
One WAG rat was injected intravenously on day 0 with tumour cells expressing the human FRα
(CC531tFR). About 28 days after the initial tumour cell xenograft injection a single dose of 111In-
rMOv18-IgG was injected via tail vein. Following the injection, the individual rat was scanned at
20 min, 24 h, 48 h and 144 h using NanoSPECT/CT (Figure 4.5). NanoSPECT/CT showed the
characteristic distribution in the blood pool known from IgG antibodies in general. Strong signal
was originating from the heart 20 minutes post injection. This was in line with the signal from blood
pool showing in the major arteries and veins. Whole body imaging showed a clear accumulation
of 111In-rMOv18-IgG within the lung tissue. The lung was also the metastatic tumour area.
The overexposed, bright signal of activity accumulation in the abdominal area of the rat
at the 20 min scan was identified as an artefact. The signal did not show up at the 12 h and 48
h scans. It was not possible to locate the activity to the outside or to a subcutaneous location.
Therefore, the area was dissect after the 144 h time point but did not show any activity or visual
signs of unexpected tissue (e.g. tumour). This suggests that during the transfer of the rat to the
scanning table or at the beginning of the scan a small amount of urine contaminated the abdominal
area or the scanner bed.
At 24 h post injection with indium-111 labelled rMOv18-IgG signal was decreased overall.
Signal was observed in the blood pool and subsequently in the heart. Significant signal was
observed in the lung tissue which contained the metastasis of CC531tFR expressing human FRα.
In addition, strong signal from the kidneys was determined.
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Figure 4.5: NanoSPECT-CT images of tumour bearing rat injected with In-
111 labelled rMOv18-IgG. Sequence of images of an individual rat
over time of 144 h (from left to right: 20 min, 24 h and 48 h after
injection).
48 hours post injection of 111In-rMOv18-IgG a similar NanoSPECT/CT image was taken
compared to 24 h post injection. Signal and shapes from heart, lungs and kidneys were visible.
General background signal originating from blood pool was seen.
Biodistribution
WAG rats were injected with indium-111 labelled rat MOv18-IgG. Rats for biodistribution
were injected intravenously with CC531tFR tumour cells expressing the human FRα receptor. On
day 28 111In-rMOv18-IgG was injected i.v. via tail vein and rats were culled for dissection at
specific time points (8 h, 24 h, 48 h and 144 h) post injection. Tissues (intestines, stomach, spleen,
kidney, blood, liver, thymus, heart, lung including tumour metastases, salivary glands, trachea,
thyroid, muscle, femur and bladder) were collected and analysed (n=3/time point, full data set in
the appendix).
Biodistribution (Figure 4.6, Table 4.2) of 111In-labelled rat MOv18-IgG showed accordance
with the NanoSPECT/CT images including high retention of activity in the blood pool at the first
time point. 8 h post injection signals observed in blood were at 13% ID/mL. Signal from the blood
pool dropped down to 5% ID/mL at 24 h post injection and remained at 5% ID/mL at 48 hours
post injection. At 144 hours post injection activity from the blood pool showed 2% ID/mL. Signal
from the spleen was measured initially at 8.4% ID/g at 8 h post injection and remained at roughly
the same level between 48 h and 144 h post injection at 4.7% ID/g and 5.1% ID/g at 24 and 48









































Figure 4.6: Biodistribution of tumour bearing rats (n=3) injected with radiolabelled rMOv18-IgG
in % injected does per gram of tissue at different time points. 8h time point (olive); 24
h (green); 48 h (blue); 144 h (orange). Data plotted are mean with SEM error bars.
values measured at 9.4% at 8 h 5.6% ID/g at 24 h. At 48 h and 144 h post injection 5.8% ID/g
and 5.4% ID/g were observed. Accumulation of 111In-MOv18-IgG in liver was observed at the 8 h
time point with 11.4% ID/g declining to 4.1% and 3.9% ID/g at 24 h and 48 h, respectively, before
a further decline to 2.5% ID/g at 144 h. Metastatic tumour bearing lung tissue showed activity
accumulation of 10.3% ID/g at the 8 h time point. Measurements showed progressive decline to
4.3% ID/g at 24 h and 4.1% ID/g at 48 h before dropping to 3.5% ID/g at 144 h. Muscle uptake
of 111In-rMOv18-IgG was at negligible levels of below 0.5% to 0.25% ID/g over the time course of
144 hours. Figure 4.7 shows the distribution of the injected dose in organs and tissues over a time
course of 144 hours post injection of rat MOv18-IgG as % injected dose. Values were not corrected
against the weight of the organ or tissue collected. Most activity was observed in blood circulation
with about 95% of the injected dose. Activity levels in blood pool declined to about 40% at 24
h and 37% of the injected dose at 48 h, respectively. After 144 hours post injection 16% of the
initially injected dose was still found in the blood pool in circulation. Liver showed the second
highest accumulation of % injected dose after blood pool. 59% of the injected dose was found in
liver at 8 h post injection. A substantial amount of the signal measured in the liver originated from
blood perfusion. Metastatic tumour tissue was located within the lung tissue. Lung accounted
for about 10% of the injected dose at 8 hours post injection. Signal values were observed at little
under 5% ID at 24 and 48 hours before declining to about 3.5% of the injected dose at 144 hours
post injection of indium-111 labelled rMOv18-IgG.
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Figure 4.7: Biodistribution of lung tumour bearing immunocompetent rat injected with radiola-
belled rat MOv18-IgG in % injected dose in selected organs and tissues at different
time points. 8 h time point (olive); 24 h (green); 48 h (blue); 144 h (orange). Data
plotted in mean (n=3) with SEM error bars.
4.3.4 Blood clearance of rat MOv18-IgE and rat MOv18-IgG
Blood clearance of MOv18-IgE and -IgG antibody was plotted as % injected dose found in blood
over time in hours. Biodistribution data shows blood clearance at time points 8, 24, 48 and144 h
post injection (Figure 4.8). At time point 0 h it was assumed that 100% of the dose was injected
into the blood via tail vein (the time point 0 h was not measured in the biodistribution study).
Figure 4.8 shows blood clearance of MOv18-IgE at 0.25% ID 8 h post injection with further decline
to 0.08 and 0.05% ID at 24 and 48 hours, respectively. Signal observed at 144 h post injection was
0.008% ID.
In comparison, MOv18-IgG showed much slower clearance and higher signal in blood at all
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time points. Starting at about 94% ID signal from blood pool showed almost no or very slow
clearance over the first 8 hours post injection. Signal measurements subsequently declined to 40%
ID at 24 h post injection and 37% ID at 48 h. Blood pool observed at 144 hours showed still
16% ID. Analysis of the blood clearance with a one phase exponential decay equation resulted in
a half-life of 18.25 hours for MOv18-IgG and 0.9 h for MOv18-IgE in blood.





















Figure 4.8: Blood clearance plotted in %ID over time in hours. Comparison of blood clearance of
rat MOv18-IgE versus rat MOv18-IgG in a disseminated tumour rat model (n=3).
4.3.5 Excretion rate of rat MOv18-IgE
The excretion rate of rMOv18-IgE (Figure 4.9, Table 4.3) shows the total signal originating from
indium-111 inside the whole rat plotted against time. The signal from inside the rat body was
calculated for each time point by the addition of the activity measured in all dissected organs and
tissues (excluding tail) against the injected dose.
The values were fitted into a single exponential equation to calculate the excretion of rat
MOv18-IgE. The excretion rate constant of MOv18-IgE was 0.025 h-1. The rate constant was
then used to calculate the half-life of MOv18-IgE in an immunocompetent metastatic lung tumour
bearing rat. Half-life using the single exponential equation was 27.7 hours. This half-life was
measured summarising all radioactivity inside the rat and includes not only full functional free or
bound MOv18-IgE but also degraded and metabolised IgE products. The calculation of excretion
was only performed for MOv18-IgE but not possible for IgG. The excretion could only be calculated
for IgE because of the blood clearance which avoids a ‘double’ measurement of blood and blood in
organs in regards to the % ID.
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Figure 4.9: Graph plotting the % ID of signal from inside the rat injected with indium-111 labelled
MOv18-IgE against time in hours. Single exponential equation fitted resulting in a
constant rate of excretion of 0.025 h-1 (n=3).
Table 4.3: Excretion table showing 111In-MOv18-IgE excretion rate over the time course of 144h
post injection.
4.3.6 Comparison of IgE excretion data between the mouse model and the
rat model
The excretion rate constant of IgE was expected to be similar for the IgE antibodies compared
over the two different animal models used (NSG mouse model-Anti-CSPG4-IgE and Rat-MOv18-
IgE; Figure 4.10, Table 4.4). % ID from indium-111 measured inside the animal was added and
subtracted from the initial % injected dose. Results were plotted against time in hours for each time
point and a single exponential equation was used to calculate the rate constant of the excretion.
Excretion rate constant for anti-CSPG4-IgE in NOD/SCID mice was 0.032 h-1. The result was a
half-life of 21.2 hours.
116
4.3 Results
Table 4.4: Comparison of excretion rate constants from indium-111 labelled mice injected with
anti-CSPG4-IgE and WAG rats injected with rat MOv18-IgE. Rate constant and half-
life expressed with exponential decay equation.


























Figure 4.10: Excretion rate. Percentage of injected dose inside the NOD/SCID CSPG4 overex-
pressing s.c. tumour bearing mice with splenic engraftment of human PBLC (green)
and the WAG rat human FRα overexpressing disseminated tumour model (violet)
plotted against time in hours. Excretion rate constant and half-life were calculated
with single exponential decay.
4.3.7 Comparison of rat MOv18-IgE and rat MOv18-IgG
Comparison of %-injected dose per gram at 48h of rat MOv18-IgE and -IgG
To better compare the differences in biodistribution between 111In-MOv18-IgG and 111In-
MOv18-IgE the data of the two antibodies were compared at one specific time point in each graph
(Figure 4.11). The biodistribution data showed that relative to IgG uptake IgE showed high

























































































































Figure 4.11: Biodistribution of disseminated lung tumour bearing rats at 8 h(A), 24 h (B) and 48 h
(C) post injection of radiolabelled rat MOv18-IgE (violet) and rat MOv18-IgG (green),
respectively, in % injected dose per gram of dissected tissue (Intestines, Spleen, Kidney,
Blood, Liver, Lung, Muscle, Femur). Data plotted including SEM error bars (n=3).
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Table 4.5: Tumour-to-blood ratio of MOv18-IgE and -IgG over the time course of 144 h.
Tumour-to-Blood ratio comparison for 111In-rMOv18-IgE and -IgG
Tumour-to-Blood ratios (tbr) were calculated (the lung tissue is holding the metastatic
tumour tissue and was therefore accounted as tumour tissue). Tbr was used to correct for the
influence of blood pool signal and show specific uptake of indium-111 signal in tumour tissue (Ta-
ble 4.5, Figure 4.12). 8 h post injection of rat 111In-MOv18-IgE the tbr ratio was at 0.7 times in
tumour/lung tissue than in the blood pool. Data showed an increase of IgE in tumour/lung tissue
over 24 h and 48 h post injection of IgE to 1.47 and 1.64, respectively, times higher accumulation
compared to the activity measured in blood pool. Tumour-to-blood ratios progressively increased
to 3.4 at 144 h post injection. 111In-MOv18-IgG showed a similar picture at the 8 h time point
compared to its IgE counterpart with a ratio of 0.77 before an increase was observed that progres-
sively over 144 h increased to a tbr of 1.7 of higher accumulation of IgG in tumour tissue compared
to blood. This is a 48% lower rise in tumour-to-blood ratio compared to 111In-MOv18-IgE (ratio
at 24 h: 0.8 ; 48 h: 0.86).
























Figure 4.12: Comparison of the ratio between the tumour bearing tissue (lung) and blood in rats
injected with rMOv18-IgE and -IgG over time (h) (n=3).
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Table 4.6: Tumour-to-muscle ratio of MOv18-IgE and -IgG over the time course of 144 h.
T/M	  ra'o	   8	  h	   24	  h	   48	  h	   144	  h	  
Mov-­‐18-­‐IgE	   11.02	   8.53	   6.56	   3.08	  
Mov-­‐18-­‐IgG	   19.49	   11.88	   9.11	   13.14	  
Rat antibody tumour- to-muscle ratio comparison between rat MOv18-IgG and -IgE
Tumour (lung)-to-Muscle ratios showed accumulation in tumour tissue against internal non-
tumour muscle tissue (Figure 4.13, Table 4.6). Comparing the tmr of 111In-MOv18-IgE to 111In-
MOv18-IgG over time shows significant differences. At 8 h the tmr was 11 for IgE but nearly 20
for IgG. Both ratios progressively decrease to a tumour-to-muscle ratio of 3 for IgE and 13 for IgG
at 144 h.

























Figure 4.13: Comparison of the ratio between the tumour bearing tissue (lung) and muscle tissue




The antibodies in this chapter were investigated in regards to their biodistribution, targeting and
clearance. MOv18-IgG showed a familiar pattern in distribution characterised by the long serum
half-life. MOv18-IgE, like IgE observed in the previous chapter 3, showed a very strong clearance
from serum and liver uptake. Although, efficacy results showed better outcome for IgE, no direct
or indirect tumour targeting of IgE was measured.
4.4.1 In vivo model
On the basis of a immune effector cell reservoir and the FcR distribution comparable to the human
reservoir and distribution, it was proposed that the use of a fully immunocompetent rat model with
a syngeneic metastatic lung tumour would overcome limitations seen in in vivo models described
in chapter 3 (NOD/SCID mouse model with splenic engraftment of human PBMC) and earlier
studies looking into the anti-cancer therapeutic efficacy of IgE [41, 165, 13]. Here, employing a
chimeric (rat/mouse) antibody, rat MOv18-IgE, in a rat model showed significant differences when
compared to results in chapter 3 where a NOD/SCID mouse model with splenic engraftment of
human PBMC was used. It was shown that signal originated from indium-111 and associated with
the full antibodies or its degradation products was excreted much faster and in higher quantities
in NOD/SCID mice compared to the rat MOv18-IgE in the rat model. This resulted in a higher
excretion rate constant for the mouse model. One argument for this observation was the presence
of a natural and constantly renewed pool of FcεR expressing cells in rats to which the rat MOv18-
IgE antibody could bind and in the mouse model the cells available for binding to IgE via FcεR
receptors in the NOD/SCID mouse model were available in much smaller quantities. However,
the underlying catabolic processes and the way the majority of the injected anti-CSPG4- and rat
MOv18-IgE were metabolised and must be the same [212].
4.4.2 Biodistribution and SPECT imaging Liver/Spleen/Intestines/Blood
Results observed in NanoSPECT/CT imaging and biodistributions from rat MOv18-IgE showed a
massive accumulation of indium-111 signal (∼75% ID at 8h) in the liver. Rat MOv18-IgG showed
in contrast only ∼50% ID in the liver while ∼80% ID were found in blood circulation. This data is
inconclusive in regards to IgG because the % injected dose measured in the organs almost always
includes a fraction of blood that was measured. It was not possible to determine conclusively the
origin of the signal (organ or blood). Both antibodies, rat MOv18-IgE and -IgG, were radiolabelled
with the same method and targeted the same FRα epitope in the rat model. Since rat MOv18-IgE
and -IgG differed only in the Fc-part the reason for the biodistribution patterns must be dependent
on the Fc region of both antibodies [270, 60, 249]. It is now understood that the neonatal Fc receptor
(FcRn) is in large part responsible for the long serum half-life of IgG. IgG binds to the neonatal
121
4.4 Discussion
Fc receptor with high affinity at acidic pH, but with very low affinity at neutral (i.e., plasma, pH
4.5). This enables IgG to be bound by FcRn in the acidic environment of the sorting endosome
(pH ≤ 6.0) in endothelial cells and to be recycled back into circulation where dissociation occurs
under more alkaline (pH > 7) conditions [249]. However, since IgE does not bind to FcRn, in
the case of rat MOv18-IgE and IgE in general several other factors have been shown to influence
the distribution [51, 52, 242]. IgE when produced naturally in the mucosa is thought to bind to
its FcR receptor and circulates bound to the respective effector cell until this cell encounters a
cognate antigen. The high affinity FcεRI receptor is thought to promote binding to FcεR receptor
expressing cells [271]. This is hypothesised, with injected IgE as with the natively produced IgE, to
happen potentially before the antigen binding site has bound to its target receptor and would alter
the biodistribution compared to its rat MOv18-IgG counterpart in a way that FcεRI expressing
cells would instantly bind the IgE [13, 170]. Rather than showing target specific accumulation
at the tumour site, IgE signal would be observed further distributed in regards to the location
of immune cells. The FcεRII (CD23) receptor, also known as low affinity receptor, can bind to
several co-receptors like CD21 (complement protein) and different integrin (CD18/CD11b) among
others. CD21 is expressed on B cells, follicular dendritic cells (FDCs), activated T cells and
basophils. Adhesion pairing between these two molecules may have important consequences for,
not only the immune reaction, but also biodistribution and clearance of IgE. Especially, many
immune cells are not in free circulation in serum or tissue but concentrated in organs like liver
and spleen [272, 55, 71]. IgE biodistribution based on its FcεRI and FcεRII Fc-receptors would
show the location of FcεR receptor expression. That would explain not only the high accumulation
of signal seen with rat MOv18-IgE in liver but also spleen since both organs are known to host
a huge quantities of immune cell clusters. Another reason for the alternative biodistribution of
rat MOv18-IgE compared to rat MOv18-IgG was the glycosylation of IgE. Glycosylation in IgG
antibodies is known to be involved into the Fc-mediated effector cell binding; this is not known from
IgE antibody. However, there is significant glycosylation found on IgE (as described in chapter
3), many with terminal mannose residues which can bind to mannose binding lectin (MBL) and
complement proteins in circulation and in the liver [201, 253]. The function of IgE glycosylation is
not understood today [44]. Accumulation of rat MOv18-IgE in the spleen was 2.75% ID/g highest
with 0.73% ID at 24 h but did not show any significant reduction in signal over the time course
of 144 hours. The spleen is part of the lymphatic system and contains a high quantity of FcεR
expressing immune cells; it seems reasonable to assume that binding and accumulation seen in
spleen did not decline because of rMOv18-IgE was bound via one of its FcεR receptors to the FcεR
expressing immune cell fraction [273]. In contrast, most of the liver bound rat MOv18-IgE was
presumably degraded [211, 212, 274]. Additionally, the decline of indium-111 signal in liver seemed
to be associated with a rise in the signal from the intestines and, therefore, is thought to show
hepatobilary excretion of indium-111 and its associated rat MOv18-IgE degradation products or
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intact 111In-rat MOv18-IgE. Interesting here was also that IgG excretion and no metabolism was
not observed, although, IgG was found in liver.
4.4.3 Biodistribution blood and lung/tumour
The biodistribution analysis showed a rapid clearance of rat MOV18-IgE from blood pool. Since
the first biodistribution time point was at 8 hours it was not possible to assess the circulating
amounts of MOv18-IgE and their binding kinetics in the first 8 hours post injection. There are
a number of possible fates for MOv18-IgE in blood pool. MOv18-IgE is unbound in circulation
and could either bind over time to (a) free FcεR receptors on the surface of immune cells or (b)
it could be bound by MBL or complement proteins or on receptors on e.g. macrophages via the
free terminal mannose sugar residues in the blood pool or directly in liver. The third option (c)
would be the binding of free rat MOv18-IgE, similar to rat MOv18-IgG, to the tumour target
receptor FRα. To (a), FcεR expressing cells are not found in huge numbers in the blood pool but
more in lymph nodes or organs like spleen and liver [270, 275, 59]. The signal accumulation in
the spleen but also part of the liver binding of MOv18-IgE can be assumed to be a result of FcεR
binding. The terminal mannose sugar residues mentioned under point (b) might account for a
large part of the blood clearance, liver binding and subsequent hepatobilary excretion. Compared
to rat MOv18-IgG, rat MOv18-IgE shows a ∼100 fold lower tumour accumulation. This does not
exclude that the tumour accumulation observed with MOv18-IgE, although much lower than seen
with IgG, is originating from free circulating MOv18-IgE binding the FRα receptor via the variable
regions before binding to FcεR receptors on immune effector cells.
4.4.4 Biodistribution in kidneys
The biodistribution results showed a relatively high accumulation of rMOv18-IgE in the kidneys.
Compared to rMOv18-IgG the values observed are twice as high in rMOv18-IgE. In both biodistri-
bution studies MOv18-IgE and -IgG the observed kidney values are constant without any significant
de- or increase. It was also standing out that anti-CSPG4-IgE in the NOD/SCID mouse model did
not show any significant accumulation in the kidneys. In general, proteins and peptides lower in
size than ∼50kDa are excreted via kidneys. Degradation products of 111In-DTPA conjugated and
labelled antibodies are known from literature and change over the process to different size degrada-
tion products. 111In-DTPA and even more so 111In-CHX-A"<-DTPA metabolites are very stable.
The major metabolite known from literature from an IgG antibody labelled with indium-111 via
DTPA was found in urine and kidneys was 111In-DTPA-ε-lysine [212]. It is likely that all signals
from kidneys come from either degraded rat MOv18-IgE antibody fragments below the size of ∼50
kDa or from MOv18-IgE bound to its target receptor FRα which is expressed lightly in kidneys.
It could highlight the possibility that MOv18-IgE was released from liver after partial degradation
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or that a significant amount of MOv18-IgE bound to immune cells via the FcεR receptors was
cleared from the blood, internalised, and delivered to the lysosome for subsequent degradation and
excretion via the kidneys. The difference in a complete lack of the immune system in the mouse
model would be an explanation of low kidney measurements observed in the mouse model.
4.4.5 Conclusions
Overall, the experiments in rats might improve the translation of therapeutic IgE experiments
and the data output compared to other in vivo models. Here, the lack of unspecific antibody
isotype controls, the only small amount of rat antibody produced at the time and general time
constraints, build up to a situation where it was difficult to find a concluding outcome. However, a
consistent outcome for IgE is the high liver uptake and metabolism while the high blood retention
was consistent for IgG. The disseminated rat model, though mirroring more closely the clinical
set up, made it difficult to conclusively discuss tumour uptake. However, results in rats were in
line with observations from the NSG mouse model. IgE clears quickly from the circulation and is
metabolised by liver, whereas IgG stays in blood and slowly reaches tumour. The high liver uptake
and fast metabolism of MOv18-IgE and general difference of biodistribution in comparison to the
IgG counterpart are significant observations.
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5 Final remarks and future work
IgE class antibodies have shown promising results in (early) pre-clinical anti-tumour efficacy studies
[170, 35, 58]. In an attempt to better understand the mode of action of this novel type of anti-
tumour immunotherapy, this thesis aimed at development of a method to radiolabel IgE class
antibodies and for the first time deliver in vivo imaging data on biodistribution, targeting and
clearance of IgE and compare these findings to IgG in a clinical relevant in vivo model.
To date, nearly all monoclonal antibodies used in tumour immunotherapy are of the IgG iso-
type class and have for long time and almost exclusively been used in the treatment of some cancers
and improved prognosis for many patients [159]. Available antibodies for clinical applications are of
the IgG class. The reason for IgG being the most prevalent antibody class is historically grown as
IgG constitute the largest fraction of circulating antibodies found in human blood. Work in the late
1980s compared chimeric antibodies of the same specificity, each with Fc regions belonging to one of
the antibody classes, IgG1-4, IgM, IgA1-2, IgD, and IgE [190]. Antibodies were evaluated for their
ability to bind to complement factors and their potency to mediate haemolysis and cytotoxicity
of antigen-expressing target cells in the presence of complement. IgG in combination with human
peripheral blood mononuclear cells (PBMC) was the most effective antibody class in complement-
dependent cell killing in vitro, while the IgA and IgE antibodies were completely inert. Since this
pioneering work, antibody isotopes other than IgG have not been extensively considered and only
recent research brought other antibody classes into the focus of applied drug development [276].
While over half of IgG antibody treatments available are approved for haematological malignancies
where IgG class antibodies have the combined advantages of high specificity and affinity for their
target antigen and a long serum half-life, efficacious antibodies for solid tumours are still urgently
needed [27]. IgG antibodies showed only mediocre efficacy in tissue penetration and recruitment
of ADCP/ADCC or recruitment of Th2 directed immune response.
In contrast to IgG which acts by recruiting complement and FcγR expressing cells like
macrophages, neutrophils, eosinophils, dendritic cells, langerhans cells, B cells, mast cells, IgE
interacts with the same set of immune effector cells more efficiently by binding to one of its
two high affinity FcεR receptors. The high affinity and the different pathways triggered by two
receptors enable IgE to promote differential methods of cell killing. The degranulation of mast
cells and basophils with release of pro-inflammatory mediators and cytokines or ADCC, mediated
by the release of mediators such as NO, enzymes and cytokines results in target cell lysis or ADCP,
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mediated by the activation of macrophages and monocytes [170, 58, 50]. Native IgE antibodies
reside in tissues, bound to cell surface FcεR receptors, with only very low levels circulating in
blood. For this project it was hypothesised that these unique properties of IgE, i.e. effector cell
bound and tissue-resident, can be employed to trigger powerful immune responses against solid
tumours. It was further postulated that the properties of IgE commonly described in allergy and
protection from parasitic infections, if redirected against cancer cells, may translate to effective
targeting of solid tumours. In this context the aims of this thesis were:
• The development of an advanced conjugation and radiolabelling method. This method was
required to protect not only the antigen binding site but also the IgE Fc-receptors. The
method was needed to be the same for IgE and IgG class antibodies for the comparison
of imaging and biodistribution outcomes. Further, the method was needed to be straight
forward for the simple and reliant translation into later clinical application.
• A radiolabelled IgE was used in imaging studies as a powerful surveillance tool of targeting,
clearance and biodistribution kinetics in a single tumour bearing animal over time.
• Ex vivo biodistribution data was collected to observe and compare distribution, targeting
and clearance of IgE at specific time points.
• IgG radiolabelled by the same developed method and engineered as an IgE counterpart, was
compared to IgE in imaging and biodistribution studies in the same in vivo models.
• Imaging and biodistribution data of IgE and IgG antibodies with different target receptors
were collected in a humanised tumour xenograft model in NSG mice and a disseminated
lung metastases model in immunocompetent rats. The data was used with the aim to to
compare and assess, along with other research, the clinical relevance of the in vivo models in
the progress of drug development.
Various radiolabelling methods are available. Here, a suitable method was selected and
evaluated for this specific project. In chapter 2 a labelling strategy and method for IgE class
antibodies was developed. The conjugation and radiolabelling method used is based on a published
method of conjugation of chelating agents to antibodies and radiolabelling with trivalent metallic
isotopes [197]. IgE was radiolabelled with high specific activity and without the loss of affinity or
functionality. Further, the method allowed IgE and IgG class antibodies to be radiolabelled in the
same way to allow comparative assessment of biodistribution.
Chapter 3 describes the comparison of IgE vs. IgG biodistribution in a subcutaneous tumour
xenograft NSG mouse model with engrafted human PBMC’s [247, 238]. While IgG showed a long
serum half-life and good tumour targeting, IgE showed a greatly different distribution with rapid
liver uptake, fast clearance from blood and very little uptake in the tumour. This results cannot
directly support previous studies by Panos Karagiannis (NIHR Biomedical Research Centre at
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Guy’s and St. Thomas’s Hospitals and King’s College London, London, UK) that showed superior
efficacy of IgE over IgG in the same NSG mouse model and IgE dependent tumour infiltration of
monocytes and basophiles.
Imaging and biodistribution studies allowed assessing the differences between IgG and IgE.
The massive liver uptake was not predicted and no reports were found in literature.
It is based on the imaging and biodistribution data and the current knowledge of therapeutic
IgE difficult to explain antitumour effects only the very little tumour targeting seen. A possible
mechanism could be that IgE bound on its effector cells infiltrate the tumour and introduce with
high potency an immune response that is subsequently IgE independent [165, 37]. Another ex-
planation could be differences in the setup of the imaging study vs. the therapy study. In the
efficacy study of IgE a repeated dose of 10 mg/Kg antibody were used while a single dose of 3
mg/Kg were injected for the imaging and biodistribution studies. It is possible that the repeated
and higher dosage offers explanations that could not have been followed with the experimental
set up described in this thesis. IgE type antibodies are known to have high mannose type glyco-
sylation. The deglycosylation with PNGase F changed the biodistribution of anti-CSPG4-IgE by
lower liver uptake and higher tumour retention indicating that the biodistribution and clearance
is mostly dependant on the high mannose glycosylation on IgE. There is no evidence for the gly-
cosylation to interact with the binding of the FC receptors or interaction with the antigen binding
[201, 253, 200, 45]. The function of the high mannose glycosylation is unknown but results about
the influence of the mannose glycosylation on biodistribution in this thesis could suggest that IgE
antibodies are mannose glycosylated to filter any IgE out of serum. The IgE produced for the
efficacy and imaging/biodistribution studies resembled the high mannose glycosylation found in
native IgE antibodies. Naturally produced IgE, however, is not released into the blood circulation
in higher amounts but is released directly into tissues [44].
In addition to the mouse model described in chapter 3, IgE vs IgG biodistribution was
analysed in chapter 4 in a completely immune competent disseminated lung tumour rat model. Use
of the two different models gives a broader picture and allows drawing more general conclusions on
IgE biodistribution. The biodistribution seen in the rat model resembled the distribution pattern
of the mouse model. This was expected after the assessment of the mouse model because of the
high mannose glycosylation of IgE and its by then postulated impact on the biodistribution of IgE
in general.
The biodistribution and imaging studies were part of the pre-clinical analyses in an attempt
to translate the folate receptor alpha specific MOv18-IgE into a phase 0 or first-in-man study [151].
High radiation signal was observed in the liver, spleen, kidney and intestines and therefore these
organs in particular, were closely evaluated during the IHC toxicity study. Further studies have
shown that rat MOv18-IgE induced an anti-tumour effect in the tumour microenvironment (TME),
and indicated that the macrophages/monocytes activated in MOv18-IgE-treated animals may be
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involved in the observed antibody-mediated responses. Analysis of lung tumours demonstrated that
CD68+ macrophages infiltrated tumours, injected with rat MOv18-IgG or rat MOv18-IgE, but the
quantity of macrophages that penetrated deep into the tumour mass were significantly higher in
IgE treated animals. In addition, the IgE-treated cohort showed the population of macrophages
in necrotic areas where tumours were once present (Debra Josephs, unpublished).
The infiltration of macrophages, monocytes and other effector cells shown by Debra Josephs
in rats and in mice shown Panos Karagiannis (Data from the PhD thesis of Debra Josephs and
Panos Karagiannis, respectively) may explain the positive results for IgE in the efficacy studies.
Also, the analysis showed an infiltration of effector cells and IgE. This does not necessarily translate
into a high fraction of effector cells bound via FcεR to IgE being responsible for the whole extend
of the immune response. The high recruitment of effector cells could have been triggered by a
smaller fraction of IgE mediating a degranulation of effector cells that established a further IgE
independent recruitment of effector cells. However, the here presented imaging and biodistribution
studies did show only little infiltration of IgE.
5.1 Future work
One of the most promising additional research into IgE would be to follow up on the indication
that mannose glycosylation of IgE has a strong influence in IgE biodistribution. The process of
deglycosylation of IgE has to be standardised and stability and radiolabelling of the deglycosylated
IgE would need to be assessed. Alternatively, IgE without any sugar residues could be engineered
by mutating the IgE amino sequence at the location of glycosylation. This would avoid complex
enzymatic deglycosylation with further need of purification. A study to combine therapy and
imaging would allow investigating the effects of higher and/or repeated dosing into IgE biodis-
tribution. The SPECT/CT and PET/CT small animal scanner are by now set up to enable the
quantification of detected signal from the image. This would allow reducing or excluding the ex
vivo biodistribution study and relying on in vivo models being assessed over time non-invasively
by the small animal imaging.
Other research could be performed to look further into the mode of action of IgE. For exam-
ple, in the NSG mouse model human PBMC’s could be incubated with therapeutic radiolabelled
IgE and co-injected. IgE would be bound on the surface of effector cells and biodistribution, splenic
engraftment and targeting over time could be compared to biodistribution data from chapter 3.
The comparison of rat MOV18-IgE and -IgG in an immunocompetent rat model with dis-
seminated lung tumour were difficult to interpret because of the lack of non-specific IgG and IgE
controls. These control experiments have to be included in future work. This requires also more
research into the stability issues of the rat MOv18 antibodies. So far, rat MOv18-IgE and -IgG had
to be re-purified the day before used for injection in the treatment studies or before conjugation
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Biodistribution of IgE isotype control in % ID/g of all organs harvested. Data plotted including
SEM error bars (n=3).
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Comparison of biodistribution of anti-CSPG4-IgE, anti-CSPG4-IgG and IgE isotype control in %
ID/g at specific time points. Data plotted including SEM error bars (n=3).
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Comparison of biodistribution of anti-CSPG4-IgE, anti-CSPG4-IgG and IgE isotype control in %
ID/g at specific time points. Data plotted including SEM error bars (n=3).
166
6 Appendices
Rat MOv18-IgE full list of organs biodistribution in % ID/g
Rat MOv18-IgG full list of organs biodistribution in % ID/g
167
6 Appendices
Rat MOv18-IgG full list of organs biodistribution data at 8h for each individual rat
168
6 Appendices
Rat MOv18-IgG full list of organs biodistribution data at 8h for each individual rat
169
6 Appendices
Rat MOv18-IgG full list of organs biodistribution data at 24h for each individual rat
Rat MOv18-IgG full list of organs biodistribution data at 24h for each individual rat
170
6 Appendices
Rat MOv18-IgG full list of organs biodistribution data at 24h for each individual rat
171
6 Appendices
Rat MOv18-IgG full list of organs biodistribution data at 48h for each individual rat
Rat MOv18-IgG full list of organs biodistribution data at 48h for each individual rat
172
6 Appendices
Rat MOv18-IgG full list of organs biodistribution data at 48h for each individual rat
173
6 Appendices
Rat MOv18-IgG full list of organs biodistribution data at 144h for each individual rat
Rat MOv18-IgG full list of organs biodistribution data at 144h for each individual rat
174
6 Appendices
Rat MOv18-IgG full list of organs biodistribution data at 144h for each individual rat
175
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 8h for each individual rat
176
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 8h for each individual rat
177
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 8h for each individual rat
178
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 24h for each individual rat
179
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 24h for each individual rat
180
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 24h for each individual rat
181
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 48h for each individual rat
182
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 48h for each individual rat
183
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 48h for each individual rat
184
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 144h for each individual rat
185
6 Appendices
Rat MOv18-IgE full list of organs biodistribution data at 144h for each individual rat
186
6 Appendices

















































































Comparison of biodistribution of rat MOv18-IgE and rat MOv18-IgG in % ID/g at specific time
















































































Comparison of biodistribution of rat MOv18-IgE and rat MOv18-IgG in % ID/g at specific time
points. Data plotted including SEM error bars (n=3).
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